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Abstract 
Recruitment of neutrophils into the tissue during inflammation is a crucial 
component of the immune response. This study aimed to further understand the role 
of intercellular adhesion molecule-2 (ICAM-2) in this process. Endothelial cell (EC) 
ICAM-2 has been implicated in neutrophil extravasation however, its precise role in 
this process is largely unknown. To address this, the current investigation examined 
the expression and functional role of ICAM-2 in neutrophil-EC interactions in vivo.  
Analysis of EC ICAM-2 expression was performed in the mouse cremaster muscle 
using immunofluorescent staining and confocal microscopy. A high EC body 
expression of ICAM-2 relative to that of EC junctions in post-capillary venules was 
observed. It was therefore hypothesised that ICAM-2 could potentially be involved 
in both luminal neutrophil-EC and junctional interactions. This hypothesis was 
analysed using confocal intravital microscopy (IVM) of cremaster muscles from WT 
or ICAM-2 KO Lys-eGFP-ki mice (express fluorescent neutrophils) in conjunction 
with fluorescent labelling of ECs. Neutrophil crawling and transendothelial 
migration (TEM) dynamics in IL-1β-stimulated post-capillary venules was analysed. 
A role for ICAM-2 in supporting speed and continuity of crawling and the initiation 
of TEM was demonstrated. Using functional blocking mAb to MAC-1 in WT and 
ICAM-2 KOs, the role of ICAM-2 in neutrophil crawling was demonstrated to be 
governed through a potential interaction with neutrophil MAC-1.  
It is therefore possible that non-junctional EC ICAM-2 has important roles in 
regulating neutrophil polarisation during crawling whilst junctional ICAM-2 
mediates the opening of EC junctions and/or influencing the site of ‘preferred’ TEM. 
This study provides the first in vivo evidence for the ability of ICAM-2 to support 
neutrophil crawling and the initiation of TEM in IL-1β-induced neutrophil 
extravasation.  
To extend the above findings in a complex vascular injury model, a cremasteric 
Shwartzman Reaction, amenable to IVM analysis, was also developed as part of this 
project. 
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 CHAPTER 1: General introduction 
 
1.1  Inflammation 
 
Inflammation is a physiological process crucial for the body’s immune response to 
harmful stimuli, such as pathogens (e.g. viruses, bacteria, fungi or parasites), 
damaged cells or other irritants. It serves to eliminate the initial cause of tissue injury 
and remove necrotic cells and debris which have formed as a result. The host 
immune response is mediated by the innate and the adaptive systems. The innate 
system is the first line of defence and has a vital role in initiating subsequent adaptive 
immune response by distinguishing between self and harmful foreign material. The 
innate immune response consists of neutrophils and macrophages which have the 
ability to kill and engulf bacteria. The adapted immune response processes the 
pathogen through highly specialised T and B lymphocytes. This latter phase 
ultimately stimulates cell death and the development of memory to specific 
pathogens. Upon complete removal of the pathogen and the immune cells involved 
the inflammatory response comes to an end (Serhan et al., 2008). In some cases when 
this response becomes uncontrollable and/or is inappropriately triggered it can harm 
the host and develop into pathological inflammation. This uncontrolled immune 
response is an underlying cause and/or effect of numerous diseases such as vasculitis, 
atherosclerosis, arthritis, sepsis, ischemia-reperfusion injury and is also a component 
of cancers. Inflammation can therefore occur throughout the body and is exhibited in 
and/or is a cause of a wide range of different pathological conditions. The 
fundamental mechanisms of this response are however consistent in all inflammatory 
reactions and remain of immense interest to researchers seeking to unravel the 
associated mechanisms.  
 
An inflammatory response is characterised by swelling/odema (tumour) caused by 
the increase in vascular permeability, vasodilatation and leukocyte migration, redness 
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(rubor) as a result of increased blow flow, pain (dolor) due to the increased 
sensitivity of neurones and release of neuropeptides in addition to the pressure 
exerted by edema, heat (calor) caused by the increase in blood flow and an increase 
in the metabolic rate and lastly can be associated with loss of function (function 
laesa). These effects are caused by the co-ordinated response of local inflammatory 
mediators on blood vessels, leukocytes and plasma components and the activation of 
several pathways including the complement system, coagulation, fibrinolysis, 
arachidonic acid pathway, kinin metabolism and the generation of free radicals.   
 
1.1.1  Innate immunity 
Upon initial encounter of foreign antigens the innate immune response primes or 
prepares the adaptive immune response. Neutrophils and classical monocytes 
(Geissmann et al., 2008) are the first cells to be recruited to the tissue. In humans 
they form the most abundant subsets of leukocytes in the blood circulation and hence 
are readily available to be activated and recruited. Tissue resident leukocytes such as 
macrophages differentiated from non-classical monocytes, and dendritic cells 
differentiated from classical monocytes exist at sites underlying the epithelial barrier 
(Geissmann et al., 2008) where they engulf pathogens and have the ability to 
generate inflammatory mediators such as cytokines, chemokines and 
chemoattractants which act to recruit other immune cells to the specific site of 
infection. Identification of the two monocytes subets is now well accepted and are 
defined by the different levels of surface protein they express, divergent differiation 
pathways and their fate (Geissmann et al., 2008).  
 
Key cytokines involved in innate immunity include tumour necrosis factor-α (TNF-
α) and interleukin-1β (IL-1β) which act predominately on leukocytes and endothelial 
cells (ECs) respectively. Chemokines such as CCL2/monocyte chemoattractant 
protein-1 (MCP-1) and CXCL8/interleukin 8 (IL-8) and lipid chemoattractants 
including leukotriene B4 (LTB4) and platelet-activating factor (PAF) are in general 
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thought to guide and attract leukocytes to specific sites of inflammation (Ley et al., 
2007; Mantovani et al., 2011). These inflammatory mediators together with the 
changes that occur in the blood flow in turn upregulate and/or redistribute EC 
adhesion molecules e.g. E-selectin, intercellular adhesion molecule-1 (ICAM-1), 
junctional adhesion molecule-C (JAM-C) as well as activating various integrins that 
are expressed on leukocytes. Collectively, these events promote leukocyte adhesion 
to the vascular wall and initiate leukocyte extravasation into the tissue.  
 
Once neutrophils are recruited to the site of inflammation they degranulate specific 
peptides such as lytic enzymes, potent anti-microbial and cytotoxic mediators. 
Reactive oxygen species (ROS) which are present in cytoplasmic granules also help 
kill the pathogen. In addition to this, neutrophils have the ability to produce various 
cytokines, chemokines and chemoattractants which stimulate the activation of ECs 
and the recruitment of more cells. Neutrophils interact with pathogens via pattern 
recognition receptors (PRRs). The PRRs (e.g. toll-like receptors (TLR) and formyl 
methionine peptide receptors) are expressed on the surface of neutrophils, monocytes 
and macrophages, component of the innate immune response that can engulf and kill 
pathogens (Figure 1.1) (Geissmann et al., 2008). The complement system consisting 
of several serum proteins can also recognise pathogens. This pathway can therefore 
assist in combating the pathogen and can relay information to the adaptive immune 
system. Neutrophils are also known to form neutrophil extracellular traps (NETs) 
which help localise, engulf and destroy the pathogen through respiratory burst 
induced by rapid ROS production (Figure 1) (Brinkmann et al., 2004). Once 
components of the innate system cells are recruited and the pathogen is localised and 
engulfed the adaptive system is activated. 
 
1.1.2  Adaptive immunity 
The adaptive immune system consisting of T and B cells (also known as T and B 
lymphocytes) process the pathogen resulting in the elimination of the harmful 
stimuli. Lymphocytes develop memory to the pathogen in order to generate more 
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efficient response upon subsequent exposure to that particular pathogen. 
Macrophages together with dendritic cells initially present antigens to cells of the 
adaptive immune system (T and B cells). For this to take place antigen presenting 
cells (APCs) must migrate to lymphoid tissues to encounter T and B cells, and this 
occurs via the active and dynamic movement of cells from the extravascular tissue 
(site of injury) into local lymph vessels. Once the cells are in the lymphoid tissue 
they can encounter and activate T or B cells initiating a slower but highly specific 
adaptive immune response (Figure 1.1). Initially the APC presents the antigen to T 
cells where the antigen is processed through the formation of an immunological 
synapse which induces intracellular signalling leading to immune priming and 
apoptosis, a process usually termed cellular immunity. Alternatively macromolecular 
antigens are recognised by immunological antibodies which are mediated by B cells 
and referred to as humoural immunity. The development of highly specialised T and 
B cells takes several days to occur and the feature of pathogen memory by 
lymphocytes allows a quicker and more efficient response upon subsequent exposure 
to the same pathogen. More importantly it also allows the body to recognise 
significantly more pathogens through the highly complex process of genetic 
recombination. 
 
A high concentration of toxic mediators are released during both innate and adaptive 
immunity therefore this process has to be effectively controlled to ensure elimination 
of the pathogen with minimal damage to the host. When these responses are 
excessive and/or inappropriately triggered it can lead to and/or exacerbate numerous 
pathological conditions. For this reason there is now much interest in the resolution 
phase of inflammation, the series of responses that promote tissue healing through 
the action of numerous endogenous anti-inflammatory mediators (e.g. resolvins) that 
assist in controlling inflammation (Serhan et al., 2007). Inflammation can be 
classified into an acute or chronic response. An acute inflammatory response usually 
occurs immediately after an encounter with a pathogen or tissue injury and lasts for a 
short time period (minutes to days) and is generally characterised by neutrophil 
infiltration and plasma exudation. Chronic inflammation is longer lasting (days to 
years) and primarily involves macrophages, monocytes and lymphocytes and this 
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response can typically occur during autoimmune diseases. This type of inflammation 
is associated with a significant amount of pain due to sustained inflammation over 
longer time periods and the release of neuropeptides which increases the sensitivity 
of sensory nerves (Brain, 1997). As uncontrolled inflammation is the underlying 
cause and/or effect of many diseases, it is important to understand this process in 
more detail. Investigating the early stages of leukocyte recruitment from the blood 
into the tissue, which initiates this whole process, can help enhance our 
understanding of inflammatory reactions and potentially identify targets for novel 
anti-inflammatory drugs. 
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Figure 1.1: Key vascular processes that occur during inflammation.  
During an inflammatory response an increase in neutrophil and monocyte 
recruitment, vasodilatation, increased blood flow and vascular permeability are seen. 
The pathogen (e.g. bacteria shown in green) is engulfed and killed using toxic 
granules present inside the cytoplasm. Macrophages phagocytose the apoptotic 
neutrophil and promote phagocyte exit from the tissue via the lymphatics where it 
presents the antigen to lymphocytes in lymphatic tissues. Diagram adapted from 
Serhan et al., 2008. 
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1.2  Leukocyte extravasation 
 
Leukocyte extravasation is a multistep process by which leukocytes are recruited 
from the blood circulation to the extravascular space where they accumulate, identify 
and engulf the invading pathogen. For this to occur leukocytes free flowing in blood 
at high shear rates must be effectively slowed down in order to establish strong 
interactions with ECs lining the vascular lumen (Ley et al., 2007). This process is 
required to enable leukocytes to breach the barriers of the vessel wall and is largely 
dependent on a series of specific, dynamic and overlapping adhesive interactions 
between activated leukocytes and components of the vessel wall.  
 
1.2.1  Vessel wall barrier 
ECs line the lumen of the vessel wall and are the first barrier through which 
leukocytes must penetrate to reach the extravascular tissue. This monolayer is in 
direct contact with the blood. ECs can be continuous and non-fenestrated (e.g. brain, 
skin, heart and lung vasculature), fenestrated (e.g. in capillaries of endocrine glands 
and kidney glomeruli) or alternatively can have a discontinuous pattern as found in 
the liver. ECs have a role in mediating blood pressure through regulating vascular 
tone although these processes are largely mediated by vascular smooth muscle cells. 
The contacts between two ECs determines the degree of tightness and hence this 
layer also controls vascular permeability and leukocyte TEM.  
 
Each EC is connected to adjacent cells through interendothelial junctions (Figure 
1.2) forming structures known as tight junctions consisting of JAMs, occludin, and 
claudins and adherens junctions consisting of VE-cadherin and catenins (Dejana, 
2004). Tight junctions reduce vascular leakage and are closely associated with the 
actin cytoskeleton and hence also involved in cell polarity. Adherens junctions are 
important for the regulation of structural integrity, and also interact with the actin 
cytoskeleton. There are also gap junctions formed by the connexin family, which are 
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essential for communication and the formation of molecular pores, although they are 
not considered to be involved in leukocyte migration (Dejana, 2004). 
  
Molecules well known to be involved in leukocyte migration directly are also part of 
tight/adherens junctions. These molecules include platelet endothelial cell adhesion 
molecule (PECAM-1), ICAM-2, CD99, CD99L2 and endothelial cell-selective 
adhesion molecule (ESAM) (Figure 1.2). These protein-protein interactions 
collectively maintain vascular integrity, regulate permeability and also enable inter-
endothelial communication (Dejana, 2004). For leukocytes to transmigrate through 
this barrier the junctional cell-cell contacts must be overcome in a highly regulated 
manner through the sequential interaction of activated leukocyte and ECs. These 
interactions are collectively known as the leukocyte adhesion cascade. 
 
Figure 1.2: Junctional contacts between two endothelial cells.  
Endothelial cell-cell junctional interactions are formed of tight junctions composed 
of junctional adhesion molecules (JAMs), occludin, and claudins, and adherens 
junctions composed of VE-cadherin and catenins. Diagram adapted from Dejana, 
2004. 
30 
 
1.3  Leukocyte adhesion cascade 
 
The initial model of the leukocyte adhesion cascade consisted of three stages; 
leukocyte rolling, activation and firm adhesion. In more recent years extra steps have 
been defined and the full cascade currently consists of the following; leukocyte 
tethering (capture), rolling, slow rolling, firm adhesion (arrest), spreading 
(polarisation), crawling, transendothelial migration (TEM) (transcellular or 
paracellular) and transmigration through the pericyte sheath and basement membrane 
(Figure 1.3) (Ley et al., 2007). Each stage is mediated by several adhesion molecules 
which are described in Figure 1.3. The key stages involved in this process are 
described in more detail below. 
 
Figure 1.3: Leukocyte adhesion cascade.  
Key endothelial adhesion molecules and the leukocyte ligands that are involved at 
each distinct stage are shown. These include selectin and integrin mediated rolling, 
integrin mediated firm adhesion, spreading involving various signalling moclules 
such as VAV PI3K and SRC, ICAM-1 mediated intravascular crawling, PECAM-1, 
JAMs, CD99 and ESAM mediated transendothelial migration and finally ICAM-1 
and integrin mediated transmigration through the pericyte sheath and basement 
membrane. Diagram adapted from Ley et al., 2007. 
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1.3.1  Leukocyte tethering and rolling 
Leukocyte tethering and rolling describes the transient adhesive interactions between 
leukocytes and ECs lining blood vessels. This process brings the fast flowing 
circulating leukocytes in direct contact with ECs which only occurs in response to 
inflammatory stimuli. During an inflammatory response EC activation by 
inflammatory mediators (e.g. endotoxins, cytokines) results in an increase in the 
expression of selectins such as P-selectin (CD62P) and E-selectin (CD62E), and 
CAMs such as intercellular adhesion molecules-1 (ICAM-1) and vascular cell 
adhesion molecule-1 (VCAM-1) on the intravascular EC surface. There are in fact 3 
different types of selectins and are all important for leukocyte tethering and rolling. 
L-selectin (CD62L) which is constitutively expressed on circulating leukocytes, P-
selectin which is stored in granules of platelets and ECs and are rapidly mobilised 
when activated and E-selectin which is expressed on activated ECs.  
 
Selectins are type 1 transmembrane glycoproteins with a N-terminal C-type lectin 
domain which is more than 60% identical across all three subtypes, an epidermal 
growth factor (EGF) -like domain followed by a variable series of short consensus 
repeats composed of complementary regulatory-like modules (Bevilacqua and 
Nelson, 1993; Ridger et al., 2008). Selectins have a transmembrane domain and a 
short cytoplasmic tail linking to the cytoskeleton. The number of consensus repeats 
in each selectin is different. The lectin domain is a carbohydrate portion considered 
to be the site which binds to several ligands such as P-selectin glycoprotein ligand-1 
(PSGL-1), glycosylation-dependent cell adhesion molecule (GlyCAM-1), mucosal 
addressin cell adhesion molecule (MAdCAM-1), E-selectin ligand-1 (ESL-1) and 
CD44. All selectin ligands are fucosylated carbohydrate structures containing 
sulfated-sialyl-Lewis
x
, which is a tetrasaccharide carbohydrate recognised by the 
lectin domain of selectin (Bevilacqua and Nelson, 1993; Zarbock et al., 2011). 
Among these ligands PSGL-1 expressed on leukocytes and ECs is the major ligand 
of all three selectins (Figure 1.3). 
 
32 
 
A key feature of selectins is their unique ability to transiently bind to their ligands 
under high shear rate. This feature is required for leukocyte capture, and enables 
subsequent strengthening of leukocyte-EC interactions (Ley et al., 2007; Ridger et 
al., 2008). These bonds are initially relatively weak and involve rapid dissociation 
followed by the formation of new bonds. L-selectin is considered to be involved in 
the very early stages, and unlike P-selectin and E-selectin expression which increases 
during inflammation, L-selectin is shed from leukocytes following their activation by 
chemoattractants (e.g. IL-8, C5a and PAF). L-selectin interaction with PSGL-1 is 
also involved in leukocyte-leukocyte interaction and enforces secondary leukocyte 
recruitment (Ley et al., 2007). P-selectin is preformed and rapidly mobilised (5-10 
minutes) from Weibel-Palade bodies during EC activation and it is crucial for 
tethering as well as rolling. Of interest the role of platelet P-selectin has also been 
shown to support platelet-leukocyte interactions (Gawaz et al., 2005). E-selectin 
requires de novo synthesis via transcriptional up-regulation and hence peaks around 
4-6 hours and is important for rolling although more recently its sequential 
interactions with PSGL-1, ESL-1 and CD44 has been shown to be involved in 
tethering, rolling and slow rolling respectively (Hidalgo et al., 2007) (Figure 1.4). It 
should be noted, however, that rolling can still occur in the absence of P-
selectin/PSGL-1 (Ridger et al., 2005) and that the molecules involved in tethering, 
rolling and slow rolling are likely to have overlapping and redundant roles.  
 
Ligand bound selectins and EC bound chemokines trigger downstream signalling 
pathways within leukocytes which results in the activation, clustering and the 
conformational change of key leukocyte surface proteins called integrins which are 
discussed in more detail in Section 1.3.2. Up-regulating and activating integrins 
promotes interactions with their key ligand ICAM-1 on activated ECs. This process 
leads to slow rolling and hence increases leukocyte proximity to ECs inducing 
further up-regulation and activation of integrins. In addition to the selectins, VCAM-
1 interaction with the integrin very late antigen-4 (VLA-4, α4β1, CD49d/CD29) also 
supports this process and could be involved in selectin independent rolling. 
Eventually leukocyte motility slows down considerably, and stronger interactions 
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form resulting in greater exposure of leukocytes to chemokines (e.g. MCP-1, IL-8, 
RANTES and MIP-1α/β) that eventually results in leukocyte adhesion.  
 
 
 
Figure 1.4: Selectin mediated leukocyte tethering, rolling, slow rolling and 
activation.  
PSGL-1 is a key ligand for P-selectin and E-selectin. More recently E-selectins has 
been shown to exhibit a sequential interaction with PSGL-1, ESL-1 and CD44, 
mediating tethering, rolling and slow rolling, respectively. Diagram from Hidalgo et 
al., 2007. 
 
1.3.2  Leukocyte adhesion 
 Leukocyte adhesion is a rapid process mediated by EC associated chemokines and 
chemoattractants, and marks the point at which the leukocyte has strong interactions 
with the EC layer. Whilst tethering and rolling is mediated in general by selectins, 
adhesion is predominately mediated by chemokines which activate key integrins on 
the surface of leukocytes which in turn bind to EC proteins such as ICAM-1 and 
VCAM-1 (Ley et al., 2007).  
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Integrins are a large group of type 1 transmembrane polypeptide receptors. Each 
integrin consists of one α and β chain that are non-covalently bound with a large 
glycosylated extracellular domain, a hydrophobic transmembrane portion and a small 
cytoplasmic tail (Figure 1.5) (Shattil et al., 2010). There are currently at least 24 
different subtypes of integrins that exist (formed from 18 different α and 8 β 
subunits) however three particular subtypes are most widely implicated in leukocyte-
EC interactions. These are, β1-integrin VLA-4, and β2-integrins lymphocyte function-
associated antigen-1 (LFA-1, αLβ2, CD11a/CD18) and macrophage receptor 1 
(MAC-1, αMβ2, CD11b/CD18). These integrins are commonly found on most 
leukocytes (Hogg et al., 2011; Huttenlocher and Horwitz, 2011). Whilst LFA-1 and 
MAC-1 are well known to bind to ICAM-1 and ICAM-2, VLA-4 is known to bind to 
VCAM-1 during leukocyte recruitment.  
 
The α and β domains of integrins contain seven and four repeated homologous 
domains on the N terminus respectively (Figure 1.5). The α subunit is a C2-type Ig-
like domain, which contains an ‘I’ or ‘A’ domains (~200 amino acids located 
between the second and third domain) in the extracellular portion which forms the 
metal ion-dependent ligand binding domain (Hogg et al., 2011; Ley et al., 2007). The 
β subunit consists of a similar ‘I’-like domain, PSI (for plexins, semaphorins and 
integrins) domain followed by four tandem EGF-like repeats (Figure 1.5). The 
cytoplasmic portions for both subunits are small, however the β unit is slightly longer 
and is generally considered to be essential for focal adhesion and cell spreading 
through inside-out signalling via proteins such as talin (Kinashi, 2005; Shattil et al., 
2010). Alterations in their structural conformation and clustering of heterodimers 
into oligomers regulate their binding and activation properties which are also 
generally induced by inside-out signalling. These events are highly complex whereby 
the affinity and avidity of integrins for their ligands are altered. Whilst low affinity 
integrins have a more folded extracellular portion, high affinity integrins have an 
extended extracellular domain (Figure 1.5) (Hogg et al., 2011; Ley et al., 2007). 
Conformational change in the large extracellular domain exposes the ligand binding 
site and thus stimulates outside-in signalling. Integrin membrane clustering also 
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occurs and facilitates protein interactions between the cytoplasmic domains (Kinashi, 
2005; Shattil et al., 2010). The bi-directional integrin signalling is key to numerous 
cellular process such as cell polarity, cytoskeletal structure, gene expression, cell 
survival and proliferation (Kinashi, 2005; Shattil et al., 2010). After such functions 
integrins are known to be recycled.  
 
Upon ligand interaction of integrins, leukocyte-EC interactions become stronger, and 
hence can be further activated by chemokines and chemoattractants that are 
immobilized and presented on luminal surface of ECs by GAGs which bind to G-
protein coupled receptors (GPCRs) on leukocyte (Ley et al., 2007). This also induces 
inside-out signalling which can subsequently lead to the conformational change and 
clustering of integrins (Ridger et al., 2008). Of interest, platelets are also known to 
adhere to ECs and leukocytes during this cascade and may also be involved in 
recruiting and/or stabilizing leukocyte adhesion. Once leukocytes have firmly 
adhered, the interaction is further strengthened through integrin mediated outside-in 
signalling and consequently further phenotypic and physiological changes within 
leukocytes occur leading to leukocyte spreading or polarization and crawling (Ley et 
al., 2007). 
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Figure 1.5: The structure and conformational changes of integrins.  
As an example the structure of lymphocyte function-associated antigen-1 (LFA-1, 
αLβ2) is shown. Integrins are composed of an α and β subunit. The α unit is slightly 
longer in the extracellular portion and the β unit is slightly longer in the cytoplasm 
portion. In low affinity forms, extracellular regions of the α- and β-subunits are 
folded whereas in the higher affinity forms this region is extended. The α subunit 
contains an I domain where extracellular ligands such as the CAMs interact, inducing 
outside-in signalling. The β subunit contains an I-like domain, however its functions 
are not fully understood. Inside-out signalling generally occurs through proteins such 
as talin interacting with the cytoplasmic portion of the β unit. Diagram adapted from 
Hogg et al., 2011.  
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1.4  Leukocyte polarization and crawling 
 
Leukocyte polarisation and crawling describes the shape change that occurs within 
leukocytes and the motion by which leukocytes move to a specific site on the EC 
layer to undergo TEM. Although leukocyte polarisation is likely to occur during 
leukocyte rolling, it is more commonly associated with the crawling stage. 
Polarisation describes the rearrangement of proteins within the cell creating a leading 
(front) end and trailing (back) end. Almost all leukocytes undergo crawling which 
suggests that the initial site of adhesion is not ideal to support TEM and may require 
further activation of EC and/or leukocytes. Furthermore as crawling has been shown 
to occur perpendicular and against the direction of blood flow (Phillipson et al., 
2009), it is well accepted that this is an active process rather than due to passive 
movements as a result of the high shear rates of blood flow. In order for leukocytes 
to crawl the cell must undergo spreading or polarisation. This includes extension of 
leukocyte protrusions via active reorganization of actin cytoskeleton, forming a 
protrusive leading edge called pseudopodia (Figure 1.6). These can be large and 
broad (lamellipodia) or thin (filopodia) and these structures are formed on the closest 
side to the chemoattractant (Huttenlocher and Horwitz, 2011) (Figure 1.6). The 
lamellipodia has ‘dendritic’ like filamentous actin (F-actin) which extend based on 
directional cues, in contrast filopodia display long parallel bundles and are sensors to 
the local environment and hence may not be essential for chemotaxis (Ridley, 2003). 
On the opposite side of the leading edge a contracting trailing end called the uropod 
is formed. These distinct structures have been characterised as having different 
intracellular protein localisation however there is very little information with regards 
to the mechanism that determains the type of protrusions formed and whether these 
different types of protrusions can form simultaneously. It is also unknown whether 
different types of potrusions are dependent on the type of stimuli.  
 
The crawling process involves key molecular actin machinery. Actin is regulated 
through co-ordinated signalling events which cause cell polarisation, protrusion, 
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adhesion formation, rear retraction and de-adhesion (Figure 1.6). Local activation of 
signalling proteins at the leading edge, for example Cdc42-Par6-atypical protein 
kinase C (aPKC) pathway, Rac and PIP3 polarizes cellular structures such as the 
microtubule organizing centre (MTOC), Golgi complex and nucleus (Figure 1.6). 
Rac/Cdc42 and WASP/WAVE signalling together with actin-binding proteins 
underlie the mechanisms associated with the organisation and polymerisation of the 
actin (Ridley, 2003). The interaction of Rho and Rac ensures that whilst Rac activity 
increases at the leading edge, Rho activity is inhibited at that site. In this situation, 
Rho activity is stimulated at the sides and uropod, whereas Rac-induced protrusions 
are inhibited in these areas. De-adhesion at the rear has also been suggested to 
involve Rac (Ridley, 2003) therefore indicating that Rho and Rac activity and 
regulation is far more complex. After cell protrusions are established they are further 
strengthened via molecules such as talin, which bind to integrins as described 
previously (Section 1.3.2) and stimulates inside-out signalling involving 
phosphatidylinositol 3-kinase (PI3K) (Figure 1.5). These adhesive interactions are 
transient and are followed by de-adhesion which in turn are followed by new 
adhesions at the leading edge, responses associated with focal adhesions and focal 
adhesion kinases (FAKs).  
 
Different types of focal adhesions exist, nascent adhesions, focal complexes and 
focal adhesions (Huttenlocher and Horwitz, 2011). Nascent adhesions and focal 
complexes are small dot-like adhesions located on leading edge protrusions and are 
known to support actin polymerisation (Huttenlocher and Horwitz, 2011). Focal 
adhesions are more well known and are composed of integrin clusters located in the 
middle part of the cell and on actin filament bundles (Huttenlocher and Horwitz, 
2011). Focal adhesions in particular, regulate the turnover of adhesion and de-
adhesions (Ridley, 2003). This also occurs at the trailing edge and involves 
weakening of the integrin/cytoskeletal linkage possibly through the cleavage of talin 
and a deactivation of integrins via conformational changes to a low affinity state. 
Relative to the leading edge, the events that occur at the trailing edge are less well 
understood however it is known that mechanisms that occur in the latter region are 
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often linked to Rho/ROCK signalling whilst myosin II sustains cell polarity during 
rear retraction (Huttenlocher and Horwitz, 2011; Ridley, 2003; Rottner and Stradal, 
2011). Rear retraction and de-adhesion is associated with Rho family of proteins as 
well as FAK, Src, ERK and Ca
2+
 influx.  
 
The mechanisms that occur at the leading and trailing edge take place in a highly 
regulated manner causing leukocytes to migrate in response to directional cues (e.g. 
gradients of chemokines) and adhesion molecules (Phillipson et al., 2006; Sumagin 
et al., 2010). The leading and trailing edges are formed to assist leukocyte 
locomotion/crawling towards preferential EC sites which can support TEM. As the 
leading edge extends forward the uropod de-adheres, creating a millipede-like 
movement. Integrins have key roles in the crosstalk between the cell membrane and 
the cytoskeleton and these interactions are crucial to this process. Key linkage 
molecules that exist between the actin cytoskeleton with cell surface integrins are 
talin, vinculin and α-actinin, although the precise ligand interactions are unclear as 
these linkage proteins can all also bind to actin directly, as well as to integrins. The 
short transient occurrence of protrusions, adhesions, and de-adhesions in a 
coordinated fashion, sustains cell polarity which is the key to efficient leukocyte 
crawling. 
 
In neutrophils, cellular polarisation and crawling has been linked to MAC-1/ICAM-1 
interactions whereas adhesion is considered to be mediated by LFA-1/ICAM-1 
interactions (Ley et al., 2007; Phillipson et al., 2006; Sumagin et al., 2010). MAC-1 
is stored in secretory secondary and tertiary granules and is readily mobilised 
following neutrophil activation (Zarbock and Ley, 2008). There is also some data 
that suggests that LFA-1 engagement results in MAC-1 up-regulation and is involved 
in stages following LFA-1-mediated adhesion. Further studies using confocal 
microscopy have shown although MAC-1 expression is homogenous on the cell 
surface, its activity is more pronounced at the leading edge of the cell (Hidalgo et al., 
2009), and could therefore mediate dynamic adhesions and de-adhesions between 
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leukocytes and ECs during leukocyte crawling. This could be regulated by 
conformational changes in the structure of MAC-1, which alters ligand affinity 
states, and has been linked to inside-out signalling via linkage proteins such as talin 
(Figure 1.5) (Ridley, 2003). These linkage molecules provide communication 
between the cell membrane and the cytoskeleton, hence inducing focal adhesions 
(integrin clustering), and thereby supports neutrophil crawling. 
 
The crawling of different leukocyte subsets has been shown to be dependent on 
slightly different molecules. For example LFA-1 is known to be crucial in 
lymphocyte crawling (Shulman et al., 2009) whereas MAC-1 is known to be 
important in neutrophil crawling (Ley et al., 2007; Phillipson et al., 2006; Sumagin et 
al., 2010). Interestingly monocyte and T cell crawling have also been linked to 
ICAM-2 which is discussed in more detail in Section 1.8. Recent data highlights the 
involvement of ICAM-1 clustering (Sumagin and Sarelius, 2010), VAV-1 (Rho 
family guanine exchange factor) (Phillipson et al., 2009) and JAM-A (Weber et al., 
2007) although very little is known about the mechanisms by which these molecules 
are involved in leukocyte polarisation and/or crawling. Whether this is a random 
process or an inherent response remains unclear and whether crawling is 
chemotactic, chemokinetic, haptotactic or mechanotactic (driven by mechanical 
forces) is still poorly understood. The redundant, co-operative and multiple 
overlapping functions of several proteins that regulate leukocyte polarisation and 
crawling clearly demonstrate that these events are highly complex and the 
mechanisms and pathways involved are only just being identified. 
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Figure 1.6: Leukocyte polarisation and crawling.  
(A) Cell polarity involves the rearrangement of proteins at the front (leading edge), 
the back (trailing edge) or the sides of the cell in response to chemotactic agents. 
Cdc42 along with PKC reorganises specific proteins toward the leading edge, 
controls the organization of microtubules and regulates the localization of 
microtubule organising centre (MTOC) and golgi apparatus. (B) Protrusions and 
adhesion formation is required for the movement of the cell. This requires 
WASP/WAVE proteins (targets of Rac and Cdc42 and other signalling pathways) 
which regulates the formation of actin branches through actin polymerisation. 
Protrusions are stabilized by the formation of integrin dependent adhesions. Integrins 
are activated by talin binding and through PKC-, Rap1-, and PI3K-mediated 
pathways. (C) Rear retraction occurs though de-adhesion which is mediated by 
several signalling pathways such as Src/FAK/ERK, Rho and myosin II. Collectively 
these events induce a millipede-like cell movement on activated ECs. Diagram from 
Ridley, 2003. 
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1.5  Leukocyte transendothelial migration 
 
Intravascular crawling is followed by leukocyte interactions with the site of TEM. 
Leukocyte interactions with ECs during crawling trigger the expression of various 
inflammatory adhesion molecules, mediators and intracellular signalling events that 
initiate and/or facilitate leukocyte passage through the endothelium. This is an active 
process where in vitro studies based on clustering of adhesion molecules generates 
endothelial proadhesive platforms (EAPs), docking structures or transmigratory cups 
(Carman and Springer, 2004), regions that are considered to be ‘equipped’ for TEM 
(Figure 1.7). The existence of locations particularly permissive to TEM, or 
‘transmigratory portals’, have variously been suggested to be at tricellular EC 
junctions which are most abundant at the convergence of two vessels (Burns et al., 
1997; Sumagin and Sarelius, 2010), ICAM-1 enriched regions (Sumagin and 
Sarelius, 2010), or identified by chemotactic gradients (Burns et al., 1997; Massena 
et al., 2010; Sumagin and Sarelius, 2010). It is also known that invasive leukocyte 
protrusions may seek out permissive areas and actively force leukocytes to squeeze 
through the distinct barriers of the vascular wall (Figure 1.7). Leukocyte TEM occurs 
via paracellular (between two EC junctions) or transcellular (through the body of an 
EC) migration (Figure 1.7 and 1.8) and two distinct mechanisms have been proposed 
(Nourshargh et al., 2010).  
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Figure 1.7: Leukocyte crawling and transmigration through the vessel wall.  
Intraluminal leukocyte crawling mediated via MAC-1/ICAM-1 allows the cell to 
reach a specific region of the vessel wall usually between two adjacent ECs 
(paracellular). The formation of docking structures (DS) and endothelial adhesive 
platforms (EAPs) is known to influence the site at which leukocytes begin to 
transmigrate through. Once the leukocyte has penetrated the EC layer it migrates 
through the gaps between pericytes and areas which have low expression regions 
(LERs) of proteins in the basement membrane. Diagram from Woodfin et al., 2010. 
 
1.5.1  Paracellular TEM 
Paracellular TEM described the movement of leukocyte between adjacent ECs. In 
order for paracellular TEM to occur protein-protein interactions between two ECs 
need to be overcome. Adherens junctional interactions involving VE-cadherins are 
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crucial to this process, due to their fundamental role in maintaining EC-EC contacts 
as previously discussed (Section 1.2.1). During paracellular TEM, this interaction is 
breached through cytoskeletal contraction with ECs induced by intracellular Ca
2+
 
flux which activates myosin light chain kinase leading to the phosphorylation of 
numerous signalling molecules (Nourshargh et al., 2010). This results in a reduction 
in EC-EC interactions allowing leukocyte protrusions to access areas between two 
adjacent ECs. Consequently this permits endothelial junctional molecules to interact 
with their leukocyte ligands. Other junctionally expressed proteins (e.g. JAM-A, 
JAM-C) can be cleaved and/or undergo resdistribution away from junctions, events 
that also reduce the barrier function of EC-EC contacts. More recently a distinct 
vesicle-like interconnected membrane compartment called the lateral border 
recycling compartment (LBRC) situated beneath EC borders has been shown to be 
involved in the recycling of EC membranes which facilitates leukocyte TEM 
(Mamdouh et al., 2003; Mamdouh et al., 2008). This compartment contains PECAM-
1, CD99 and JAM-A which is trafficked to the site of TEM by kinesin (Mamdouh et 
al., 2008). These events occur in a highly regulated and selective manner ensuring 
that a tight seal of the EC membrane around the leukocyte is maintained.  
 
ICAM-2, JAMs and PECAM-1 are heavily implicated in TEM. Each of these 
molecules display a distinct and sequential role at specifics stages (Woodfin et al., 
2009). ICAM-2 expressed on ECs has been demonstrated to mediate luminal stages 
of TEM, supporting the movement of cells from the vascular lumen to junctional 
regions (Figure 1.7). JAM-A interaction appears to support the migration of 
leukocytes between two ECs (Figure 1.8). Other JAM members such as JAM-B and 
JAM-C are also concentrated at tight junctions and are appear to support this process 
(Figure 1.8). EC JAMs can interact in a homophilic manner with adjacent ECs or in a 
heterophilic manor with various integrins such LFA-1 for JAM-A, VLA-4 for JAM-
B and MAC-1 for JAM-C. Furthermore some JAMs also interact with each other 
such as JAM-B and JAM-C (Weber et al., 2007). The role of JAMs in regulation of 
TEM is highly complex and has been reviewed by Weber et al., (2007). After JAM-
A interactions, EC PECAM-1 interacts with PECAM-1 expressed on leukocytes 
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resulting in induced expression and activation of leukocyte laminin receptors 
(integrin α6β1) (Dangerfield et al., 2002). This allows leukocytes to transmigrate 
through the pericyte sheath and the vascular basement membrane (Nourshargh et al., 
2010). The involvement of ICAM-2, JAM-A and PECAM-1 in transmigration has 
been demonstrated to occur only if the EC is directly activated whereas direct 
stimulation of leukocytes overrides the requirements for these proteins in some 
models (Woodfin et al., 2009).  
 
Leukocyte TEM can also occur independently of ICAM-2, JAM-A and PECAM-1 as 
induced by different stimuli or in the context of recruitment of different leukocyte 
subsets. Other molecules implicated in TEM include CD99 and CD99L2 (Bixel et 
al., 2010). The mechanisms through which thee molecule mediates TEM are not fully 
understood although CD99 and CD99L2 have been demonstrated to have roles at a 
later stage to PECAM-1 (Bixel et al., 2010). Other endothelial junctional molecules 
implicated in TEM include ESAM found on ECs and platelets but again full details 
of how this molecule regulates TEM remains to be elucidated. The involvement of 
these EC proteins are considered to be a dynamic process, some involving the LBRC 
which has been shown to express PECAM-1, JAM-A and CD99. Several forms of 
paracellular migration have also been reported; normal TEM (i.e. luminal to 
abluminal), hesitant TEM (i.e. luminal to abluminal but also showing several back 
and forward oscillations within the junction) and reverse TEM (i.e. abluminal to 
luminal) which has been linked to the loss of EC JAM-C (Woodfin et al., 2011). 
These multiple forms of TEM add further layer of complexity to this field.   
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1.5.2  Transcellular TEM 
Although paracellular migration occurs more frequently, it is now known that 
transcellular migration can also take place (Feng et al., 1998; Feng et al., 2002). 
Transcellular TEM describes the movement of leukocytes directly through the body 
of thin EC layers (Figure 1.8). In most models studied this represents approximately 
10-30% of all transmigration events (Ley et al., 2007). One study has demonstrated 
that inhibiting the ability of leukocytes to crawl to the site of ‘preferred’ TEM 
enhanced transcellular TEM (Phillipson et al., 2006). Other studies have seen an 
increase in transcellular event following N-formyl-methionyl-leucyl-phenylalanine 
(FMLP) stimulation (Feng et al., 1998). However, the concept of transcellular TEM 
is still novel and there are various discrepancies in the literature regarding the 
associated mechanisms.  
 
 
Figure 1.8: Molecules supporting leukocyte paracellular and transcellular TEM.  
Proposed molecular pathways involved in TEM between adjacent ECs (paracellular) 
and through cell body of EC (transcellular). Diagram from Ley et al., 2007. 
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It is generally considered that transcellular TEM involves many of the proteins 
implicated in paracellular TEM as some of these are also expressed in non-junctional 
areas (e.g. PECAM-1). Transcellular TEM is initiated by insertion of leukocyte 
membrane protrusions into ECs (Carman and Springer, 2008). Leukocyte protrusive 
structures can bind to ICAM-1 clusters which form EC transmigratory cups that 
embrace the leukocyte and encapsulates it with EC membrane (Carman and Springer, 
2008). As well as ICAM-1, these structure have been demonstrated to also involve 
VCAM-1 and is thought to be dependent on LFA-1 and VLA-4 (Carman and 
Springer, 2004) however it should be noted that the mechanism and the existence of 
transmigratory cups in vivo still remains to be established. During transcellular TEM 
VCAM-1, ICAM-1 and CD99 concentrate at sites called the vesicular vacuolar 
organelles (VVOs) (Ley et al., 2007). VVOs are located in close proximity to 
intercellular junctions and consist of continuous membrane layers at the site of EC 
pore formation, which connects to F-actin providing additional membrane during 
leukocyte TEM (Figure 1.8) (Nourshargh et al., 2010). Similarly, other studies have 
suggested that PECAM-1 within the LBRC is involved in this process, again by 
providing additional membrane which is enriched with JAM-A, PECAM-1 and 
CD99 (Mamdouh et al., 2003; Mamdouh et al., 2008). As this route of TEM very 
rarely occurs and given that there are some reports that have suggested that this route 
takes slightly longer, this mechanism of TEM may therefore be a ‘back up’ response 
which occurs more frequently when paracellular events are restricted (e.g. the ECs of 
the blood brain barrier due to tight EC-EC interactions) (Phillipson et al., 2006). 
 
 
1.6  Transmigration through the pericyte sheath and the basement 
membrane  
 
Once leukocytes have penetrated the EC layer, they must overcome the next barrier 
which is the pericyte sheath and the basement membrane (Figure 1.3). Pericytes are 
elongated cells which have many protrusions that are directly in contact with ECs. 
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They are situated around the endothelium and are embedded within the basement 
membrane. The basement membrane is predominately composed of collagen type IV 
and laminin interconnected to other extracellular matrix protein components. 
Transmigration through this layer appears to take much longer (>5-15 minutes) than 
the time taken to breach the EC layer (~6 minutes) (Ley et al., 2007). This reflects 
the relative difference in barrier strength and/or how dynamically the barrier can 
respond to the migration of leukocytes in comparison to that of ECs and more 
importantly highlights the fact that different mechanisms and interactions are 
mediating these events. A limited number of studies have investigated the profile and 
mechanism, of leukocyte migration through the pericyte and basement membrane, 
partially due to current experimental limitations in isolating and culturing pericytes, 
and therefore it is poorly understood. A recent development in this area has been the 
identification of regions within the basement membrane that contain a lower 
expression of various basement membrane components such as, laminin-8, laminin-
10 and collagen IV (Voisin et al., 2010). These sites have been termed low 
expression regions (LERs) and appear to be regions preferentially used by migrating 
leukocytes to exit venular walls (Voisin et al., 2010) (Figure 1.7). The pericyte layer 
contains gaps between adjacent cells that are aligned with LERs, providing a more 
permissive route for migrating leukocytes (Voisin et al., 2010). Recent studies in our 
group have indicated that pericyte gaps enlarge during TEM, a response that may 
additionally facilitate leukocyte transmigration (Proebstl et al., 2012). It was also 
found that leukocytes exhibit abluminal crawling on the pericyte sheath within the 
vessel wall, a process that was demonstrated to be mediate via ICAM-1 (Proebstl et 
al., 2012).  
 
In conjunction with the morphological changes within this layer, specific adhesive 
interactions also appear to occur. As mentioned previously homophilic PECAM-1 
interactions can lead to the up-regulation of β1-integrins (e.g. α6β1) which bind to 
laminin and thereby facilitate migration of leukocytes through this layer (Dangerfield 
et al., 2002). Together the LERs, pericyte gaps and various integrin interactions 
provide a mechanism by which leukocytes can pass through the pericyte layer and 
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basement membrane, and enter the extravascular tissue as guided by chemokines and 
chemoattractant gradients formed at the core of the inflammatory site. 
 
1.7  Key endothelial cell proteins involved in leukocyte extravasation 
 
1.7.1  PECAM-1 
PECAM-1 is widely expressed on immune cells which originate from hematopoietic 
stem cells, such as neutrophils, monocytes, platelets and lymphocytes (DeLisser et 
al., 1997). It is also highly expressed on vascular ECs with pronounced expression at 
EC junctions. It is commonly associated with leukocyte TEM, angiogenesis, 
thrombosis, permeability and exhibits key signalling properties (Privratsky et al., 
2010). PECAM-1 has been demonstrated to bind to PECAM-1, αvβ3-integrin, GAGs, 
CD38 and CD117. This molecule can also undergo inside-out signalling whereby 
shear stress, inflammatory mediators and ligation of various immune receptors can 
result in multiple functions governed by changes in its expression and/or 
phosphorylation status (Privratsky et al., 2010). As a result of intense research there 
is currently a significant body of information regarding the structure and function of 
PECAM-1 in inflammation (Privratsky et al., 2010). 
 
PECAM-1 (CD31) is a 130 kDa type 1 transmembrane protein part of the 
immunoglobulin (Ig)-like superfamily and is well known for its role in leukocyte 
TEM. It is composed of a large extracellular domain containing six N-terminal Ig-
like domains encoded by single exon, a transmembrane domain and a large 
cytoplasmic tail (Figure 1.9) (DeLisser et al., 1997; Privratsky et al., 2010). The first 
Ig-like domain is crucial for homophilic ligand interaction whereas domain 5 and 6 
are implicated in heterophilic binding (Woodfin et al., 2007). The cytoplasmic 
domain contains residues that are important in cell signalling such as palmitoylation 
sites (important for apoptosis), docking structures and phosphorylation sites 
including immunoreceptor tyrosine based inhibitory motifs (ITIMs) (Figure 1.9). The 
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two cytoplasmic ITIMs are known to contain 2 tyrosine residues at position 663 and 
686 (Figure 1.9). Upon ligand interaction these residues are phosphorylated and 
undergo downstream signalling events involving proteins containing Src homology 2 
(SH-2). Downstream signalling results in various cellular responses such as up-
regulation and activation of integrins, increase in permeability, PECAM-1 recycling 
(Mamdouh et al., 2008), cell motility and contractility and cell survival (Woodfin et 
al., 2007).  
 
 
 
Figure 1.9: Structure of PECAM-1.  
PECAM-1 is a 130 kDa transmembrane glycoprotein protein belonging to the Ig-like 
super family of adhesion molecules. It consists of extracellular domain containing 6 
Ig-like domains, a transmembrane domain and a cytoplasmic tail. Key components of 
PECAM-1 have been shown; S-S disulfide bridges, * heparin binding sequence, • N-
linked glycosylation sites, $ heterophilic binding, # homophillic binding, @ 
important residues for localisation and ^ ITIMs. Diagram adapted from DeLisser et 
al., 1997. 
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1.7.2  PECAM-1 in leukocyte transmigration 
Using in vitro migration assays through endothelial monolayers, Muller et al., (1993) 
were the first to show a function for PECAM-1 in leukocyte transmigration. This role 
was further confirmed using various in vivo models such as the rat peritonitis model 
(Vaporciyan et al., 1993). The first direct evidence for the involvement of PECAM-1 
in the leukocyte adhesion cascade came from intravital microscopy (IVM) studies 
where its role in leukocyte migration was demonstrated (Wakelin et al., 1996). Since 
these initial studies research has focused on understanding the regulation and 
mechanisms behind the functions of PECAM-1 in more depth. It is well accepted 
that PECAM-1 exerts its role in this context in a homophilic manner where EC 
PECAM-1 interacts with leukocyte PECAM-1. However, heterophilic interactions 
have also been reported such as interactions with CD177, a molecule detected on a 
subset of neutrophils (Sachs et al., 2007). Other more controversial heterotypic 
ligands are αvβ3-integrin, GAGs and CD38 present on lymphocytes although the 
precise function of these interactions are largely unknown. Studies by Mamdouh et 
al., (2003) have suggested a novel mechanism of PECAM-1 mediated leukocyte 
TEM involving the LBRC which provides a means of recycling proteins between the 
vesicle and the EC border (Mamdouh et al., 2003; Mamdouh et al., 2008). During 
leukocyte TEM the recycled PECAM-1 is directed to EC junctional areas where 
leukocytes are transmigrating. This source of PECAM-1 has been shown to support 
both paracellular and transcellular TEM (Mamdouh et al., 2009; Mamdouh et al., 
2003) and provides novel insights into the regulation of PECAM-1 expression. 
Whilst of great interest, this mechanism has been based on in vitro assays and the 
existence of LBRCs in vivo is yet to be defined. 
 
Other in vivo studies have demonstrated that the functional role of PECAM-1 during 
leukocyte TEM is dependent on the inflammatory stimulus, as IL-1β but not TNF-α-
induced leukocyte transmigration is reduced in PECAM-1 KO mice (Thompson et 
al., 2001). This study also indicated that PECAM-1 has a transient role in mediating 
transmigration. Furthermore, the site of leukocyte arrest in PECAM-1 deficient mice 
(as shown by electron microscopy) was found to be between ECs and the 
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perivascular basement membrane (Figure 1.3) suggesting a key role for PECAM-1 at 
this stage. As mentioned previously, subsequent studies have suggested that 
leukocyte and EC PECAM-1 interaction upregulates key laminin receptors such as 
β1-integrins (e.g. α6β1), required for neutrophil transmigration through the 
perivascular basement membrane (Dangerfield et al., 2002).  
 
1.7.3  JAM family 
The JAMs are type 1 transmembrane proteins and are part of the Ig-like superfamily. 
JAMs consist of two groups, the classical members JAM-A, -B and –C and the other 
subgroup consists of ESAM, coxsackie adenovirus receptor (CAR), JAM-4 and 
JAM-like (JAM-L) protein (Dejana, 2004; Ebnet et al., 2004; Weber et al., 2007). 
Although these molecules (apart from JAM-4) have been reported to be involved in 
leukocyte migration, the classical JAMs have received most attention in recent years.  
 
The classical JAMs are members of the Cortical Thymocyte markers for Xenopu 
(CTX) family, and are well known to be constitutively expressed at EC junctions 
(Ebnet et al., 2004; Weber et al., 2007). They are composed of an extracellular 
portion containing two N-terminal Ig domains incorporating disulphide bonds 
through conserved cysteine residues, a single transmembrane segment and a 40 
amino acid cytoplasmic tail which has PDZ domain binding motifs (Figure 1.10). 
JAMs are known to exhibit homophilic and heterophilic binding to various integrins 
as well as other JAM family members. In addition to their EC junctional expression, 
JAM-A and JAM-C are known to be expressed on different leukocyte subsets and 
JAM-A is also found on platelets. During leukocyte migration some JAM members 
(e.g. JAM-A and JAM-C) have been shown to redistribute away from EC junctions 
(Weber et al., 2007) and thereby support leukocyte adhesion as well as TEM, 
although the mechanism by which this occurs is yet to be established.  
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1.7.4  JAMs in leukocyte transmigration    
JAM-A binds to leukocyte LFA-1 and is expressed on ECs, leukocytes and platelets. 
Its expression on ECs is known to be redistributed, cleaved or upregulated upon 
inflammation in some in vitro models (Weber et al., 2007). It has also been 
specifically implicated in leukocyte extravasation at the level of the EC, proximal to 
that of PECAM-1 (which is at the level of the basement membrane) (Woodfin et al., 
2009). Like PECAM-1 its role is dependent on the direct activation of ECs (Woodfin 
  
Figure 1.10: Structure of classical JAMs.  
JAMs are transmembrane glycoprotein proteins belonging to the Ig-like super family 
of adhesion molecules. They consist of extracellular domain containing 2 Ig-like 
domains, a transmembrane domain and a cytoplasmic tail. JAM-A, B and C are sub 
grouped into the CTX family and are strongly implicated in leukocyte migration.  
Key components of JAMs have been shown; S-S disulfide bridges and • N-linked 
glycosylation sites. Diagram adapted from Ebnet et al., 2004. 
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et al., 2009). Leukocyte JAM-A has also been implicated in leukocyte directional 
motility through regulating the activity of the actin cytoskeleton (Dejana, 2004).  
 
JAM-B binds to VLA-4 on leukocytes, JAM-C on leukocytes and ECs and JAM-B 
on ECs. Interestingly it has a higher affinity for JAM-C than JAM-B. JAM-B 
expression is confined to ECs and has been detected in Peyer’s Patches, lymph 
nodes, heart, brain and testes. It has been shown to have a role in leukocyte 
recruitment in various inflammatory models (Cunningham et al., 2002; Lamagna et 
al., 2005; Ludwig et al., 2005; Ludwig et al., 2009). Direct evidence for the role of 
JAM-B at specific stages of leukocyte extravasation comes from the use of a murine 
cutaneous IVM model where fluorescently labelled lymphocytes were injected in 
mice along with an anti-JAM-B antibody (mAb) (Ludwig et al., 2009). This study 
reported that anti-JAM-B treatment reduces T-lymphocyte rolling however, the 
authors also found that JAM-B had tissue-specific roles. The function of JAM-B in 
leukocyte recruitment is also found to be independent of JAM-C (Ludwig et al., 
2005), however the mechanisms through which this protein regulates leukocyte 
migration are only just emerging and require further investigation.  
 
Lastly JAM-C has roles independent to that of JAM-B as it can also bind to 
leukocyte MAC-1 and EC JAM-C. JAM-C is expressed on ECs, smooth muscle 
cells, fibroblast, nerves and testis. Its expression on ECs is known to be redistributed 
away from junctions upon inflammation and has been implicated in leukocyte 
extravasation using several models. More recently it has been directly linked to 
polarised neutrophil migration during paracellular TEM (Woodfin et al., 2011) 
although further studies are required to fully understand its role in this process.  
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1.7.5  ICAMs family 
The ICAMs are type 1 transmembrane proteins part of the Ig-like superfamily, and 
are well known for their ability to bind to integrins. There are currently five members 
of this family: ICAM-1, -2, -3, -4 and -5. ICAM-1 has been most widely studied and 
has key roles in leukocyte extravasation along with ICAM-2. ICAM-3 is known to be 
involved specifically in dendritic cell migration where as ICAM-4 is implicated in 
some erythrocyte functions (e.g. in sickle cell anaemia) and ICAM-5 has been shown 
to have key roles in the development of neurones (Hayflick et al., 1998; Heping 
Yang, 2012; Toivanen et al., 2008). Each protein consists of 2-9 C-type Ig-like 
domains and is capable of binding to integrins and inducing numerous cellular 
events. As the current investigation focuses on leukocyte migration and very little is 
known about ICAM-3 only ICAM-1 and ICAM-2 will be discussed in detail below.  
 
1.7.6  ICAM-1 
ICAM-1 is constitutively expressed on ECs at low levels and is highly upregulated 
upon inflammation peaking at around 4-6 hours. ICAM-1 is also expressed on 
various leukocyte subsets and can be found in a soluble form in plasma of patients 
with cardiovascular disorders (Lawson and Wolf, 2009). ICAM-1 is known to be 
involved in APC/T cell interactions and signalling and is a key protein involved in 
leukocyte transmigration (Albelda et al., 1994; Hayflick et al., 1998).  
 
ICAM-1 (CD54) is a 90-110 kDa protein (depending on its glycosylation status) and 
is well known for its ability to bind to key integrins. It is composed of an 
extracellular domain containing five N-terminal Ig-like domains, a transmembrane 
domain and a cytoplasmic tail (Figure 1.11) (Toivanen et al., 2008). The three Ig-like 
domains are crucial for heterophilic ligand interaction, whereas the cytoplasmic 
domain contains residues that are important in cell signalling which enables it to 
have a close interaction with the cytoskeleton (Figure 1.11). ICAM-1 has binding 
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affinity for the β2-integrins LFA-1 and MAC-1 on leukocytes, fibrinogen, 
rhinoviruses and Plasmodium falciparum-infected erythrocytes. ICAM-1 also 
undergoes inside-out signalling where it can bind to adaptor proteins such as ERM, 
talins and kindlins to regulate its affinity and avidity for its ligand.  
 
 
Figure 1.11: Structure of ICAM-1 and ICAM-2.  
ICAMs are transmembrane glycoproteins belonging to the Ig-like super family of 
adhesion molecules. ICAM-1 and ICAM-2 are strongly implicated in leukocyte 
migration. They consist of extracellular domain containing 5 or 2 Ig-like domains, a 
transmembrane domain and a cytoplasmic tail. Key components of ICAM-1 and 
ICAM-2 have been shown; S-S disulfide bridges, • N-linked glycosylation sites, $ 
LFA-1 binding, & MAC-1 binding and # fibrin(ogen) binding. Diagram adapted 
from Toivanen et al., 2008. 
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1.7.7  ICAM-1 in leukocyte transmigration 
The role of ICAM-1 at specific stages of the leukocyte adhesion cascade has been 
studied for many years and it has been implicated in all key stages of this process. It 
has been described as a molecule that supports slow rolling (Ley et al., 2007) or the 
transition between rolling and adhesion however it is most well known to mediate 
adhesion. Almost no leukocyte transmigration occurs if the function of this molecule 
is inhibited in a wide range of in vitro and in vivo models, confirming its key role in 
this process. It is now becoming clear that ICAM-1/LFA-1 interactions are involved 
in adhesion where as ICAM-1/MAC-1 interactions are involved in leukocyte 
crawling (Phillipson et al., 2006; Sumagin et al., 2010). Heterogeneous ICAM-1 
expression on ECs during inflammation has been linked to leukocyte crawling and 
ICAM-1 clustering is deemed to influence the ‘preferred’ sites of leukocyte TEM 
(Sumagin and Sarelius, 2010). Furthermore transmigratory cups containing F-actin 
surrounded by various integrin and adaptor proteins are also enriched with ICAM-1 
(Carman and Springer, 2004). This occurs through the activation of ICAM-1 which 
induces Ca
2+ 
influx activating signalling pathways such as p38, Rho and MECS. 
These signalling pathways regulate cell polarisation and facilitate migration of 
leukocytes through ECs by destabilising endothelial junctional bonds (Ridley, 2003). 
Recently ICAM-1 has been found on pericytes and was demonstrated to be involved 
in abluminal neutrophil crawling between ECs and the pericyte sheath (Proebstl et 
al., 2012).  
 
Another key area of research focuses on the co-operative and redundant roles of 
ICAM-1 relative to that of ICAM-2. At present the results from the literature imply 
that these molecules have distinct and overlapping functions that can be co-operative 
or redundant in some cases depending on the inflammatory model and the subset of 
leukocyte. There is data to suggest that only in the absence of functional ICAM-1, 
ICAM-2 is involved in TEM of T cells (Reiss et al., 1998). In support of this study a 
different group has also shown that ICAM-1 has a co-operative role with ICAM-2 in 
lymphocyte migration across lymph nodes however this study also demonstrated that 
ICAM-1 has ICAM-2-independent roles in lymphocyte migration to inflamed tissues 
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(Lehmann et al., 2003). A more recent study showed that T cell polarization and 
crawling under physiological shear flow is supported by EC ICAM-1 and in its 
absence, by EC ICAM-2 (Steiner et al., 2010) although ICAM-2 can only partially 
compensate for the lack of ICAM-1 in these early stages (Boscacci et al., 2010). 
Studies by Issekutz et al (1999) showed an additive reduction of neutrophil 
extravasation when ICAM-1 and ICAM-2 were both blocked however they found no 
effect when ICAM-2 alone was inhibited. Collectively these studies demonstrate that 
ICAM-1 and ICAM-2 exhibit some co-operative roles which seem to be largely 
dependent on the experimental model and/or the subtype of leukocyte being 
investigated.  
 
 
1.8  ICAM-2 
 
ICAM-2 (CD102) is a 55 kDa protein and is well known for its role in leukocyte 
recruitment through binding to key leukocyte integrins. More specifically it has been 
shown to have extracellular binding affinity to the integrins LFA-1 (Li et al., 1993; 
Staunton et al., 1989) and MAC-1 (Xie et al., 1995), VLA-4 (Seth et al., 1991) and 
DC-SIGN (Geijtenbeek et al., 2000). ICAM-2 is composed of an extracellular 
domain containing two N-terminal Ig-like domains, a transmembrane domain and a 
short 28 amino acid cytoplasmic tail (Figure 1.11) (Staunton et al., 1989). Domain 1 
consists of 85 amino acid residues, and has a disulphide bond creating a compact, flat 
structure. It has a highly conserved glutamine residue at position 37 which is crucial 
for interacting with LFA-1 (Casasnovas et al., 1997). Domain 2 is much larger and is 
positioned so that the functional N-terminal faces away from the cell membrane 
(Casasnovas et al., 1997). ICAM-2 has many structural similarities to ICAM-1 
specifically, the two Ig domains of ICAM-2 have a 35% homology to that of ICAM-
1. However as ICAM-2 has a smaller N-terminal relative to ICAM-1 it is believed to 
have restricted accessibility for ligands. For this reason LFA-1 is thought to have a 
much lower affinity for ICAM-2 relative to that of ICAM-1. Like most Ig-like 
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proteins it is secured by disulphide bridges and consists of numerous glycosalytion 
sites (Figure 1.11). LFA-1 and MAC-1 bind to the first Ig domain and precise site of 
DC-SIGN binding to ICAM-2 is currently unknown, although this is thought to be 
the primary ligand for ICAM-2 due to its high affinity for ICAM-2 (Geijtenbeek et 
al., 2000). It has also been demonstrated to bind in trans in a homophilic manner 
(Huang et al., 2005). ICAM-2 can form intracellular interactions with ezrin (Heiska 
et al., 1996; Yonemura et al., 1998) and α-actinin (Heiska et al., 1996) which implies 
it has a key role in intiating intracellular signalling. 
 
Based on the high basal expression of ICAM-2 and the fact that this protein remains 
unchanged during inflammation, ICAM-2 was initially deemed more relevant in 
lymphocyte recirculation. There is now however strong evidence for a role of ICAM-
2 in leukocyte transmigration (Huang et al., 2006; Woodfin et al., 2009). There are 
also some studies that have indicated that ICAM-2 could be involved in other cellular 
processes such as apoptosis (Helander et al., 1996; Perez et al., 2002), angiogenesis 
(Huang et al., 2005), immune cell activation (Carpenito et al., 1997)(Carpenito et al., 
1997; Carpenito.C et al., 1997), signalling (Perez et al., 2002; Yonemura et al., 
1998), osteoclastogensis (Li et al., 2012), transepithelial migration (Gerwin et al., 
1999; Porter and Hall, 2009) and surveillance in pancreatic carcinogenesis (Hiraoka 
et al., 2011) although these areas are poorly understood. Exciting data demonstrating 
ICAM-2 transfection using adenovirus vector might be an effective form of gene 
therapy(Carpenito.C et al., 1997) for peritoneal metastasis of gastric cancer due to its 
involvement in recruiting immune cells to the site (Tanaka et al., 2004) has been 
shown. Additionally high gene expression of ICAM-2 in patients with acute conary 
syndrome has also been reported (Glogowska-Ligus et al., 2012) and a suppression 
of metasis potential in ICAM-2 expressing neuroblastoma cells in vivo (Feduska et 
al., 2013). These studies provide further indications that the specific functions of 
ICAM-2 are poorly understood and require further investigations.   
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1.8.1  ICAM-2 expression 
ICAM-2 is constitutively expressed on ECs and is not generally thought to be 
regulated during inflammatory responses (de Fougerolles et al., 1991), although there 
are some reports of a down regulation in expression (Godwin et al., 2004; 
McLaughlin et al., 1999; McLaughlin et al., 1998). In more clinical models there 
appears to be an up-regulation of ICAM-2 (Alizadeh et al., 2000; Bernstein et al., 
1998; Gerwin et al., 1999; Hiraoka et al., 2011; Renkonen et al., 1992) although this 
could be linked to its expression on epithelial cells (Porter and Hall, 2009) rather 
than ECs. It is also known to be expressed on neutrophils (Sundd et al., 2012), 
monocytes (de Fougerolles et al., 1991), T cells (de Fougerolles et al., 1991), 
eosinophils (Gerwin et al., 1999), natural killer cells (Helander et al., 1996; 
Somersalo et al., 1995), platelets (Diacovo et al., 1994; Kuijper et al., 1998) and 
synovial cells (Singh et al., 2006). ICAM-2 is constitutively expressed at much 
higher levels than ICAM-1 (15-fold) on ECs under basal conditions and unlike 
ICAM-1 which is well known to be highly inducible by various inflammatory stimuli 
(e.g. IL-1β and TNF-α) ICAM-2 is not. Although ICAM-2 is highly conserved, its 
expression is found to be variable across species and therefore it’s function may also 
vary in this respect (Godwin et al., 2004). 
 
1.8.2  ICAM-2 in leukocyte transmigration 
Despite the fact that both ICAM-1 and ICAM-2 were cloned just over 20 years ago 
(Horley et al., 1989; Staunton et al., 1989), relative to ICAM-1 very little is known 
about the functions of ICAM-2. ICAM-2 was initially heavily implicated in the 
recruitment of lymphocytes (Boscacci et al., 2010; Lehmann et al., 2003; Steiner et 
al., 2010; Reiss et al., 1998) however to date it has now been linked to the 
recruitment of neutrophils  (Hobden, 2003; Huang et al., 2006; Issekutz et al., 1999; 
Sundd et al., 2012; Woodfin et al., 2009), monocytes (Schenkel et al., 2004), 
eosinophils (Gerwin et al., 1999), natural killer cells (Somersalo et al., 1995) and 
dendritic cells (Geijtenbeek et al., 2000). Very few studies have however have 
attempted to elucidate the mechanisms through which ICAM-2 supports leukocyte 
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extravasation. Those studies which have addressed this question have shown that 
ICAM-2 is implicated in natural killer cell polarisation during crawling, a process 
which maybe regulated by F-actin polymerisation at the leading edge (Somersalo et 
al., 1995). Other studies have demonstrated a role for EC ICAM-2 in monocyte 
‘locomotion’ on human umbilical vein endothelial cells (HUVECs) through its 
interaction with β2-integrins (Schenkel et al., 2004) and in lymphocyte polarisation 
and crawling in a blood brain barrier model in vitro (Steiner et al., 2010). The latter 
role was suggested to occur co-operatively with that of ICAM-1 and this property has 
been confirmed in numerous other studies (Boscacci et al., 2010; Huang et al., 2006; 
Lyck et al., 2003; Steiner et al., 2010). A recent report has identified a role for 
neutrophil ICAM-2 in stabilising rolling through interactions with neutrophil LFA-1 
(Sundd et al., 2012). However the majority of reports that have linked ICAM-2 to 
leukocyte extravasation consider this phenomenon to be mediated by EC ICAM-2 
(Boscacci et al., 2010; Schenkel et al., 2004; Steiner et al., 2010; Woodfin et al., 
2009). ICAM-2 is specifically considered to be involved in regulating neutrophil 
transmigration into the tissue, but not adhesion in vivo (Huang et al., 2006; Woodfin 
et al., 2009) however the ligand and the precise mechanisms by which it contributes 
to neutrophil extravasation are largely unknown, and these questions form the focus 
of the present investigation. 
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1.9  Aims and hypothesis 
 
At present little is known about the functional role of ICAM-2 in acute inflammation 
and this was further investigated in the current study. It was hypothesised that 
ICAM-2 supports neutrophil extravasation via mechanisms occurring prior to the 
completion of TEM. The overall aim of this study was therefore to investigate the 
involvement of ICAM-2 in regulating neutrophil extravasation in vivo by addressing 
the following key objectives:  
1.9.1  Investigate the cellular distribution of ICAM-2 expression 
To date no study has investigated the possibility of EC ICAM-2 redistribution during 
inflammation. Therefore post-capillary venules of the mouse cremaster muscle and 
the ear dermal vasculature were analysed for the precise sub-cellular location of 
ICAM-2 within individual ECs. Using the cremasteric tissues a more detailed 
analysis of the expression of ICAM-2 was carried out under control and inflamed 
conditions to examine potential changes in expression of ICAM-2. ICAM-2 
expression on different blood leukocyte subsets was also studied. 
1.9.2  Anaylse the functional role of endothelial ICAM-2 in neutrophil-EC 
interactions during neutrophil extravasation   
To elucidate the specific function of ICAM-2 during inflammatory conditions in 
vivo, neutrophil-EC interactions were investigated in IL-1β-stimulated mouse 
cremaster muscles. Using confocal IVM of mice expressing eGFP in neutrophils 
(Lys-eGFP-ki mice), and in vivo EC labelling, neutrophil crawling and TEM 
dynamics were quantified in both WT and ICAM-2 deficient mice. 
1.9.3  Examine the potential neutrophil ligand for ICAM-2 that supports 
neutrophil-EC interactions 
ICAM-2 is well known to interact with β2-integrins. The function of ICAM-1, MAC-
1 and ICAM-2 in IL-1β-stimulated neutrophil-EC interactions were analysed using 
confocal IVM. Using this approach, the potential interaction of EC ICAM-2 with 
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neutrophil MAC-1 was investigated. The contribution of ICAM-1 in this model was 
examined to account for any ICAM-1 dependent MAC-1 functions. 
1.9.4  Develop a cremasteric Shwartzman reaction model.  
To enable the possibility of extending the above investigations of IL-1β-induced 
inflammation to a more complex, pathologically relevant model, a cremasteric 
Shwartzman reaction IVM model was developed as part of this work. This response 
shows neutrophil recruitment, formation of microthrombi and haemorrhage, and can 
be used in future work for investigating the role of ICAM-2 as well as other adhesion 
molecules in these responses by IVM.   
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CHAPTER 2: Materials and methods 
 
2.1  Animals and reagents 
 
2.1.1  Animals  
Male mice (20–25g) of several different genotypes were used in this study. All mice, 
including genetically modified animals, were on a C57BL6 background. Wild-type 
(WT) C57BL/6 mice were purchased from Charles River Laboratories (Margate, 
United Kingdom), and ICAM-2 KO mice (Gerwin et al., 1999) were a gift from Prof. 
Britta Engelhardt (Theodor Kocher Institute, University of Bern, Switzerland). For 
live imaging WT or ICAM-2 KO mice with eGFP gene knocked-in (ki) to the 
lysozyme M (Lys) locus (Lys-eGFP-ki) resulting in exhibition of eGFP in 
myelomonocytic cells (Faust et al., 2000) were used. This genotype of mouse 
expresses high levels of eGFP in neutrophils and a lower level in monocytes. No 
differences in neutrophil responses have been reported using either the homozygous 
or heterozygous Lys-eGFP-ki mice in our model, however only mice heterozygous 
for Lys-eGFP-ki were used in the present study. ICAM-2 KO x Lys-eGFP-ki mice 
were generated in-house for this study by interbreeding the ICAM-2 KO mice with 
Lys-eGFP-ki mice, yielding animals deficient in ICAM-2 (homozygous) with eGFP 
positive neutrophils and monocytes (heterozygous). C57BL/6 mice in which the gene 
for eGFP has been knocked-in to the CX3CR1 locus (CX3CR1-eGFP-ki), resulting 
in the expression of eGFP in all monocytes (as well as in natural killer cells and 
some T cells) but not in neutrophils obtained from the European Mutant Mouse 
Archive (Orleans, France) were also used. No differences in leukocyte 
transmigration using heterozygous CX3CR1-eGFP-ki mice compared to WT have 
been reported. However, homozygous mice CX3CR1-eGFP-ki mice have shown 
some differences in leukocyte migration compared with WT, therefore only mice 
heterozygote for CX3CR1-eGFP-ki were used during the course of this study. All 
animals were housed in individually ventilated cages and animal facilities were 
regularly monitored for health status and infections. All in vivo experiments were 
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performed under the UK legislation for the protection of animals, and animals were 
humanely killed by cervical dislocation in accordance with UK Home Office 
regulations.  
 
2.1.2  Antibodies  
All monoclonal antibodies (mAbs) used during the course of this study were raised 
against mouse proteins. Anti-ICAM-2 mAb (3C4; rat IgG2a), isotype control mAbs 
(rat IgG2a and rat IgG2b) were obtained from Serotec (Kidlington, United 
Kingdom). Anti-ICAM-1 mAb (YN-1; rat IgG2b), anti-PECAM-1 mAb (C390; rat 
IgG2a), APC-labelled anti-CD115 (AF598; rat IgG2a), Alexa Fluor 647-labelled 
anti-CD3 (17A2; rat IgG2B), anti-VE-cadherin (BV14; IgG2b) and anti-integrin 
alpha IIb (CD41)-phycoerythrin (PE) (MWReg30; rat IgG1) was from eBiosciences 
(Hatfield, United Kingdom). Anti-MAC-1 (M1/70; rat IgG2b), Alexa Fluor 488-
labelled anti-ICAM-2 (3C4; rat IgG2a), PE-labelled anti-GR1 (Ly-6 G/Ly-6 C) 
(RB6-8C5; rat IgG2b) and PE-Cy7-labelled anti-B220 (RA3-6B2; rat IgG2a) was 
purchased from Biolegend (Cambridge, United Kingdom). Anti-CD16/CD32 (2.4G2, 
rat IgG2b) was from BD Pharmingen (Oxford, United Kingdom). Anti-α-smooth 
muscle actin (α-SMA)-Cy3 (1A4; mouse) was from Sigma (Saint Louis, USA). 
Monoclonal antibody Alexa Fluor conjugation kits were from Invitrogen (Paisley, 
United Kingdom). The following antibodies were conjugated in-house; anti-
PECAM-1 (CD31) mAb, anti-ICAM-2 mAb, anti-ICAM-1, anti-VE-cadherin and 
appropriate isotype controls. All mAb given in vivo had low endotoxin levels based 
on the manufactures data sheets.  
 
2.1.3  Inflammatory stimuli  
Recombinant mouse interleukin-1β (IL-1β) was purchased from R&D systems 
(Abingdon, United Kingdom). Lipopolysaccharide (LPS) from E.coil 011:B4 was 
obtained from Sigma-Aldrich (Dorset, United Kingdom).  
 
66 
 
2.1.4  Other Miscellaneous reagents 
Triton X-100, Tyrode’s salts and Dextran fluorescein isothiocyanate (FITC) 
(Molecular weight:  150,000 ~ 85 Angstroms (8.5nm) were purchased from Sigma-
Aldrich (Dorset, United Kingdom). Ketamine (Ketaset) was from Fort Dodge 
Animal Health Ltd (Southampton, United Kingdom) and Xylazine (Rompun) was 
from Bayer (Newbury, United Kingdom). 
 
2.2  Flow cytometry  
 
Flow cytometry was used to establish the percentage of circulating blood leukocytes 
in WT and ICAM-2 KO mice and expression of ICAM-2 on different leukocyte 
subsets. Blood samples were collected from unstimulated WT and ICAM-2 KO mice 
by cardiac puncture following cervical dislocation. This procedure was carried out by 
cutting through the ribcage to gain access to heart directly. Blood was removed using 
a needle and syringe containing 50μl of 0.5M Ethylenediaminetetraacetic acid 
(EDTA) solution. Approximately 0.5-1 ml blood per animal was withdrawn from the 
right ventricle in each animal. Blood cells were washed by centrifuging the sample at 
300g for 5 mins at 4°C, removing the serum supernant and, resuspending in PBS.  
 
2.2.1  Total leukocyte counts 
Total live cell counts were performed with a Neubauer haemocytometer (Optik 
Labor, Germany) using 0.4% trypan blue (Sigma) and expressed as cells/ml. Trypan 
blue is a dye that enables identification of dead cells, which are permeable to the dye 
and appear blue under light microscopy. Viable cells exclude the dye and appear 
colourless and refractile under phase contrast. A 1:1 dilution of the cell suspension in 
trypan blue was used for cell counts. Approximately 10μl of the mix was loaded onto 
the haemocytometer and the cells were viewed under a microscope (Olympus BH2-
RFCA) at 100 X magnification.  
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2.2.2  Staining of ICAM-2 in different leukocyte subsets 
Unspecific Fc-receptor mediated mAb binding was blocked by incubating 50μl of the 
washed blood cells with 0.5µg Fc block for 15 mins on ice. Each sample was 
labelled with a mixture of fluorescently conjugated antibodies or their specific 
isotype control. Antibody mixture was made up to 50μl using FACs buffer (PBS and 
1% heat inactivated goats serum) and samples were stained for CD115, Gr-1, B220 
and ICAM-2 or CD3, Gr-1, B220 and ICAM-2. Samples were incubated for 30 mins 
at 4°C in the dark with the mAb solution. Blood cells were then pelleted by 
centrifugation at 300g for 5 min at 4°C to remove unbound mAb, and the cell pellet 
was resuspended in 500μl ACK lysis buffer (150mM NH4Cl, 1 mM KHCO3, 0.1 
mM EDTA, pH 7.3.) at room temperature for 5 mins, to lyse the erythrocytes. After 
lysis, cells were spun again under the same conditions, resuspended in 200μl FACS-
PBS buffer (1% goat serum in PBS) to obtain a uniform suspension of single cells. 
Data acquisition was performed using FACS-calibur flow cytometer (Beckson 
Dickinson, Oxford, UK) with CellQuest software (Beckson Dickinson). 20,000 
leukocytes were acquired per sample and analysed using FlowJo 7.6.1. ICAM-2 KO 
blood samples acted as the control for ICAM-2 staining. Unstained and single stained 
samples for all markers were carried out in every experiment to detect background 
staining of leukocytes (auto-fluorescence).  
 
2.2.3  Identification of leukocyte subsets 
Back gating from single stained antibodies confirmed which subsets were leukocytes 
in the forwards and side scatter plots. During data analysis leukocyte populations 
were gated out based on forward scatter (FSC) and side scatter (SSC) (Figure 2.1A). 
Neutrophils and the two monocyte subsets (classical and non-classical) were 
distinguished by Gr-1 labelling intensity versus CD115 intensity after removing 
B220 negative cells to exclude B cells (Figure 2.1D). Neutrophils were identified as 
a Gr-1 high and CD115 negative population, classical monocytes were identified as 
Gr-1 low and CD115 positive cells and non-classical monocytes were Gr-1 and 
CD115 positivity (Figure 2.1D). B cells and T cells were identified by B220 and 
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CD3 expression respectively (Figure 2.1B and C). Total neutrophil, classical and 
non-classical monocyte, B cell, and T cell numbers were calculated by multiplying 
the percentage of leukocytes (derived from flow cytometry) by total leukocyte count 
(derived by trypan blue staining). These different leukocyte subsets were then 
analysed for ICAM-2 expression where the percentage of ICAM-2 positive cells and 
the relative fluorescent intensity (RFI) of each leukocyte subset analysed was 
determined (Figure 2.2). 
 
 
Figure 2.1: Representative flow cytometry plots demonstrating the gating 
strategies for identification of leukocytes subsets.  
(A) Leukocytes were identified based on the FSC/SSC scatter. (B) B220 positive B 
cell population.  (C) CD3 positive T cell population (D) Gr-1 high neutrophils, Gr-1 
high and CD115 positive classical monocytes and Gr-1 low and CD115 positive non- 
classical monocyte populations. Double negative population represent lymphocytes. 
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Figure 2.2: Representative flow cytometry plots demonstrating gating strategies 
for identification of ICAM-2 expression on neutrophils. 
Neutrophils were identified based on the surface expression Gr-1 in both (A) ICAM-
2 Kos and (B) WTs. (C) The percentage of neutrophils which stained positive for 
ICAM-2 was determined in WTs (red line). Gating strategies were based on negative 
control samples taken from ICAM-2 KO mice (black line). The RFI of fluorescently 
labelled ICAM-2 in each leukocyte subset was also determined.  
 
 
2.3  Cremaster muscle 
 
The functional role of ICAM-2 in various vascular responses was predominately 
investigated using a mouse model of cremasteric IVM. This method enables direct 
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visualisation of vascular processes in real time in vivo. Brightfield and confocal IVM 
were used during the course of the study. Brightfield IVM was used to measure 
leukocyte rolling flux, adherent and transmigrated leukocytes. Confocal IVM was 
used to quantitatively analyse EC expression and distribution of adhesion molecules, 
subset of recruited leukocytes (intravascular and extravascular), the dynamics of 
leukocyte-EC interactions, leukocyte TEM dynamics, leukocyte-platelet interactions 
and vascular perfusion. This was carried out using fluorescent immunolabelling of 
specific proteins, in conjunction with genetically modified mice which express 
endogenous eGFP in specific cells. In some studies pre-treatment with functional 
blocking antibodies and/or inflammatory stimuli was carried out. Specific details of 
immunolabelling and pre-treatment are described in the relevant sections. 
 
2.3.1  Cremasteric muscle dissection 
For all IVM studies mice were anesthetized by intraperitoneal (i.p.) injection of 
Ketamine (100 mg/kg) and Xylazine (10 mg/kg) and maintained at 37°C on a 
custom-built, heated microscope stage. The cremaster muscle is a thin layer of 
striated muscle that surrounds the testicle (Figure 2.3). It is commonly used for IVM 
because of the thin translucent nature of this tissue which allows direct visualisation 
of the microvasculature in vivo. To isolate this tissue, a midline incision was made in 
the scrotum making sure not to damage the underlying tissues and testis (Figure 
2.3B). The testicles were gently drawn out by separating the underlying connective 
tissue from the cremaster muscle. The distal end of the cremaster muscle was pinned 
to the viewing column of the microscope stage to keep the cremaster muscle 
exteriorised (Figure 2.3C). An incision was made along the centre of the muscle, 
ensuring that the main artery and venule going into and out of the tissue was kept 
intact (Figure 2.3D). The cremaster muscle was then opened and pinned flat over the 
viewing window. The connective tissue attaching the testis to the cremaster muscle 
was then cut to enable the testes to be laid toward the side so that the entire 
cremasteric microvasculature could be clearly observed (Figure 2.3D). The cremaster 
muscle was kept moist with continous flow of warm Tyrodes buffered solution. Care 
was taken to ensure limited contact between the dissecting instruments and the 
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cremaster muscle throughout surgery. The cremaster muscles were then ready to be 
viewed under a microscope (confocal or brightfield) for detailed analysis of vascular 
responses. 
 
 
 
Figure 2.3: Surgical exteriorisation of the mouse cremaster muscle.  
The cremaster was exteriorized (A,B) and pinned out flat over the optical window 
(C). The mesentary connecting testis and the cremaster muscle was cut and the testis 
moved out of the field of view (D). The microscope stage was kept at a constant 
temperature and was superfused with Tyrode’s solution to keep the tissue moist 
throughout surgery. 
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2.4  Endothelial protein expression and distribution  
 
2.4.1  Whole mount cremasteric immunostaining 
The vascular expression profile of VE-cadherin, PECAM-1 and ICAM-2 was 
initially investigated by immunofluorescent staining and confocal microscopy of 
whole mount murine cremaster muscle and ears. WT mice were injected 
intravenously (i.v.) with a blocking mAb directed against ICAM-2 (3mg/kg). After 
10 min animals were killed by cervical dislocation. Cremaster muscles were 
dissected from the mouse (Figure 2.3) and pinned out on a piece of wax. In some 
experiments the vasculature of the ear was also used. Tissues (cremaster and ear) 
were fixed in 4% PFA for 30 mins at 4°C. Immunofluorescent staining of whole 
mounted tissues was then performed. Tissues were permeabilised after fixation with 
blocking buffer (0.5 % Triton X-100 and 10 % foetal calf serum and 10 % goat 
serum in PBS) for 2 hour, at room temperature on a gentle rotator. Tissues were then 
incubated with appropriate secondary mAb for anti-ICAM-2 mAb for 2 hours in the 
dark. Tissues were washed 3 times with PBS on a shaker and re-blocked in PBS 
containing 20% serum with purified rat IgG2a for 1 hour. The tissues were finally 
incubated with two endothelial markers (anti-PECAM-1 conjugated to Alexa Fluor 
488 mAb and anti-VE-cadherin conjugated to Alexa Fluor 647 mAb) for 24 hours in 
the dark. After a final PBS wash, the tissues were mounted on glass slides and 
viewed under a confocal microscope. Analysis of the distribution of ICAM-2 on 
different parts of the vascular tree was carried out using Imaris (Bitplane, Zurich, 
Switzerland) 3D analysis software.  
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2.5  Intravital microscopy  
 
2.5.1  Pre-treatments and in vivo labelling 
In some studies live confocal IVM was used to analyse EC expression of ICAM-2 in 
unstimulated (saline) or IL-1β-stimulated cremaster muscles. Animals were sedated 
via intramuscular (i.m.) injection of 1 ml/kg anaesthetic (40 mg/kg Ketamine and 2 
mg/kg Xylazine in saline) and were subsequently subjected to intrascrotal (i.s.) 
injection of IL-1β (50 ng/400μl saline) in order to stimulate an inflammatory 
response. Control animals were given saline (i.s.) alone. Saline or IL-1β injections 
were given in conjugation with a non-blocking anti–mouse Alexa Fluor 647–labelled 
PECAM-1 mAb (2μg/mouse) and an anti–mouse Alexa Fluor 488–labelled ICAM-2 
mAb (4μg/mouse) in order to quantitatively analyse the relative distribution patterns 
of PECAM-1 (a well-established EC junctional marker) and ICAM-2. In some 
experiments an anti–mouse Alexa Fluor 555–labelled ICAM-1 mAb (4μg/mouse) 
was also administered. 4 hours after i.s. injections, the cremaster muscles were 
prepared for confocal IVM as described previously.  
 
 
2.6  Confocal microscopy  
 
Tissues were viewed using a Leica SP5 confocal microscope with a 20× water-
dipping objective (NA 1.0) (Figure 2.4). Z-stack images of 3-5 post-capillary venules 
per cremaster, with a diameter of 25–45μm, good blood flow and few branches were 
selected for analysis (3-4 mice per group). Images of half vessels were acquired by 
sequential scanning of the 488 and 633nm channels at a resolution of 1024 × 512 
pixels in the x-y plane and 0.5μm steps in z-direction corresponding to a voxel size of 
0.23 × 0.23 × 0.49μm in x-y-z respectively. Microscope settings were optimised to 
exclude signal from non-specific binding of mAb using isotype control labelled 
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tissues, or tissues from mice genetically deficient for the protein of interest. 
Quantification of the expression and distribution of ICAM-2 on venular ECs was 
carried out using Imaris 3D analysis software. 
 
 
 
Figure 2.4: Leica SP5 confocal microscope incorporating a 20× water-dipping 
objective (NA 1.0) fitted with 561, 488 and 633 nm lasers.  
Mice were placed on a heated stage and the cremaster muscle was exteriorized and 
superfused with Tyrodes buffered solution. Z-stack images of vessels were acquired 
and reconstructed in to 3D models using Imaris software.   
 
2.6.1  Quantifying vascular distribution of proteins 
Vascular distribution of ICAM-2 was deternained through the creation of an 
isosurface using Imaris software. An isosurface is a two dimensional object built on 
the surface of a 3D object (i.e. the vessel) based on it's intensity in the selected 
fluorescent channel. The fluorescent intensity of the selected channel can then be 
specifically quantified within the isosurface. This enables the expression of the 
protein of interest, in this case ICAM-2, within a known structure (PECAM-1 
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expressing endothelial cells) to be quantified. This software module is able to 
identify voxels belonging to an object in a single fluorescent channel. The criterion 
for the identification is the grey value for the voxel hence is able to distinguish 
between high and low intensites. An isosurface of the whole vessel was created (as 
previously described in Proebstl et al., 2012) using the PECAM-1 channel, and the 
fluorescence intensity of Alexa Fluor labelled PECAM-1 and ICAM-2 within this 
surface was quantified (Figure 2.5). This analysis determines the intensity of ICAM-
2 staining within the PECAM-1 positive areas. A differential analysis of the intensity 
of EC junctional and non-junctional expression levels was carried out by creating 
isosurfaces with threshold settings on either high intensity PECAM-1 at the EC 
junctions, or on the low intensity PECAM-1 staining on the EC bodies (Figure 2.6). 
The intensity of both proteins within these regions was determined. The expression 
and distribution of ICAM-1 was also determined using the same method. 
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Figure 2.5: Whole vessel isosurfaces based on the immunostained PECAM-1 
using Imaris software.  
Isosurfaces were constructed using intensity thresholding on PECAM-1 in post-
capillary venules. PECAM-1 (red/yellow) and ICAM-2 (green) labelling intensity 
within these isosurfaces could then be quantified. The background intensity was 
subtracted by creating an isosurface on an area devoid of venules (pink). 
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Figure 2.6: EC junctional and non-junctional isosurfaces based on the intensity 
of immunostained PECAM-1.  
Isosurfaces were constructed using intensity thresholding on PECAM-1 high EC 
junctions, and PECAM-1 low cell bodies in post-capillary venules. The intensity of 
PECAM-1 (red/blue) and ICAM-2 (green/grey) within these isosurfaces could then 
be quantified. 
 
2.6.2  Luminal neutrophil-EC interactions in vivo 
To understand the role of ICAM-2 in neutrophil recruitment luminal leukocyte-EC 
interactions were analysed using confocal IVM. Cremaster muscles of WT or ICAM-
2 KO x Lys-eGFP-ki mice were stimulated with saline or IL-1β, co-administered 
with a non-blocking Alexa Fluor 555–labelled PECAM-1 mAb (2 μg) in order to 
visualize the endothelium. For ICAM-2–, ICAM-1– and MAC-1–blocking 
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experiments the blocking mAb, or rat IgG2a (anti–ICAM-2 isotype) or rat IgG2b 
(anti–ICAM-1/MAC-1 isotype) control mAb, were administered (i.v. 3mg/kg) 15 
minutes before IL-1β stimulation. To analyse the effect of the blocking anti–ICAM-
2, anti–ICAM-1 and anti–MAC-1 mAbs confocal images of 3-5 post-capillary 
venules per cremaster muscle were taken at the end of the experiment (~4 hours after 
i.s. injections), and intravascular and extravascular leukocytes were quantified 
(Figure 2.7). In order to observe firmly adherent neutrophil crawling and neutrophils 
which eventually undergo TEM the cremaster muscles were prepared for confocal 
IVM 2 hours after IL-1β stimulation and observed for a further 2 hours. 
 
Cremaster muscles were viewed using a Leica SP5 confocal microscope 
incorporating a 20× water-dipping objective (NA 1.0). Z-stack images of 1-2 post-
capillary venules per cremaster with a diameter range of 20–45 μm, with good/fast 
blood flow (based on observation of the flow by transmitted light where vessels with 
reduced or slow blood flow have a 'granular' appearance as the individual 
erythrocytes become visible) and few branches, were selected for analysis. Images of 
selected vessels were acquired every 30 seconds for approximately 30-40 minutes 
per vessel for a further 2 hours. This was carried out by sequential scanning of the 
488 and 561 nm channels at a resolution of 1,024 × 350 pixels in the x-y plane and 
0.9 μm steps in z-plane corresponding to a voxel size of 0.41 × 0.41 × 0.99 μm in x-
y-z, respectively. Confocal images were acquired using a resonance scanner of 8,000 
Hz, and acquisition of a single z-stack of ~60 images routinely took ~30 seconds. As 
previously stated Lys-eGFP-ki mice express endogenous eGFP on monocytes as well 
as neutrophils. As the aim of these experiments was to examine neutrophil 
recruitment dynamics confocal settings were optimised to ensure capturing of 
neutrophils only. This was possible due to the high eGFP intensity of neutrophils 
relative to monocytes (Woodfin et al., 2011). Additionally an IL-1β mediated 
response after 4 hours is known to be primarily a neutrophillic response (Thompson 
et al., 2001). 
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2.6.3  Reconstruction of confocal images into four-dimensional confocal IVM 
Post-acquisition sequential z-stacks were analysed using Imaris software. This 
software allows for 3D reconstruction of the vessel with high spatial and temporal 
resolution. As full z-stacks were acquired every 30 seconds 3D video models were 
obtained (4D). For most preparations tissues were stable and movement from the 
heartbeat did not interfere with image acquisition. Slower movements from muscular 
contraction-relaxation occasionally resulted in movement of the vessel of interest in 
x-y-z plane, and a drift-correction algorithm was applied during the 3D 
reconstruction stage by the Imaris software. The resulting 4D confocal IVM video 
models were analyzed offline using Imaris, which renders the optical sections of half 
vessels into 3D video models, thereby enabling the dynamic interactions between 
luminal EC and leukocytes to be observed, tracked and analyzed (Figure 2.8, Movie 
1). All images and videos show half vessels to enable clear visualization from only 
one luminal or abluminal side of the vessel wall. Using this technique luminal 
neutrophil crawling and TEM profile and dynamics were quantified. 
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Figure 2.7: Quantification of intravascular and extravascular neutrophils.  
Confocal image of a cremasteric post-capillary venule (red, endothelial cells, 
PECAM-1 staining) from an IL-1β-stimulated cremaster muscle. Neutrophils (green, 
Lys-eGFP-ki) which were observed in the lumen of the vessel were counted over a 
200µm vessel length. Neutrophils that have transmigrated into the tissue on one side 
of the vessel, in a 50x200μm2 away from the vessel were counted. 
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Figure 2.8: Quantification of luminal neutrophil crawling.  
Confocal image of a cremasteric post-capillary venule (red, endothelial cells, 
PECAM-1 staining) showing individual neutrophil (green, Lys-eGFP-ki) crawling 
tracks (blue) which were clearly observed and tracked for 5 or more frames (>2.5 
minutes). Crawling neutrophils were defined as any neutrophils which had a 
displacement (black arrows) of more than 5µm (approximately half of neutrophil 
diameter).  
 
2.6.4  Analysis of luminal neutrophil crawling dynamics 
For each image sequence neutrophil crawling within the lumen were analysed in 
terms of their location and dynamics. Approximately 70 crawling neutrophils were 
analysed from 3–8 mice per group. Specific parameters were established for 
recording the profile and dynamics of leukocyte luminal crawling on the 
endothelium. Only neutrophils which could be tracked for 5 or more frames (which 
corresponds to >2.5 minutes) were quantified. Stationary neutrophils were defined as 
any neutrophil which had a displacement less than 5µm (approximately half of its 
diameter). Any neutrophils which had a displacement of more than 5µm over the 
period of observation was defined as crawling. On average approximately 10 
neutrophils per venule were tracked. The percentage of stationary and crawling 
neutrophils per venule was determined. Individual luminal neutrophil crawling paths 
were tracked manually using Imaris and the following parameters were quantified: 
(a) observed duration of crawling (minutes), (b) speed of crawling (µm/minute), (c) 
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distance crawled (µm), (d) total displacement (i.e., length in micrometers of the 
shortest distance between the first and last track point), (e) crawling displacement 
direction relative to blood flow, (f) crawling straightness (ratio of crawling 
displacement length to crawling length) and (g) crawling speed variation (ratio of the 
crawling speed standard deviation to the crawling speed mean value).  
 
This imaging system allows neutrophils at various stage of the leukocyte-adhesion 
cascade to be tracked. However as a single z-stack takes 30s only cells which 
remained adherent (for 30s or more) were fully acquired and appeared spherical in 
3D. Rolling neutrophils which move at high speeds appeared as small thin discs and 
so were excluded from crawling analysis. In this model only a small percentage of 
crawling cells were observed to undergo TEM, irrespective of the genotype of the 
mouse. This is due to the technical limitations involved in tracking an individual 
neutrophil from initial adhesion to TEM in a limited time period and in a small field 
of view of each vessel. Only neutrophils that were observed to crawl and were not 
stationary (5µm displacement over the period of observation) were included in the 
analysis of crawling parameters. The crawling behaviour of neutrophils which were 
later observed to undergo transmigration was also analysed in isolation from all other 
crawling cells and various crawling parameters as stated previously were analysed.   
 
2.6.5  Continuity of neutrophil crawling 
Two distinct types of neutrophil crawling behaviour were routinely observed; 
‘continuous crawling’ and ‘discontinuous crawling’. Neutrophils were classified as 
exhibiting continuous crawling if they were mobile for the duration of observation.  
Discontinuous crawling was defined as neutrophils exhibiting crawling behaviour 
with periods of immobility lasting 5 frames or more (i.e.  2.5 minutes or more) 
during the period of observation. Immobility was defined by a cell displacement of 
less than half the diameter of a cell (~5µm). The percentage of ‘continuous’ and 
‘discontinuous’ crawling neutrophils per venule was quantified along with various 
crawling dynamic parameters. 
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2.6.6  Direction of neutrophil crawling relative to blood flow 
Neutrophil crawling directionality in relation to blood flow was analysed. 
Directionality was defined by the overall movement of the neutrophil from the start 
to end position (displacement direction) of a given neutrophil crawling track. Each 
crawling displacement track (Figure 2.8) was categorised as crawling in the direction 
of blood flow or against blood flow within a 45 degree angle either side of the blood 
flow direction, or perpendicular to the blood flow again within a 45 degree angle 
either side of the direction directly (Figure 2.9). 
 
 
 
Figure 2.9: Quantification of neutrophil crawling direction relative to blood 
flow.  
Schematic diagram representing how neutrophil crawling displacement was 
classified into crawling in the direction of blood flow (red), perpendicular to blood 
flow (blue) or against blood flow (purple).   
 
2.6.7  Analysis of leukocyte transendothelial migration dynamics 
In order to investigate the role of ICAM-2 in the migration of neutrophils through the 
EC barrier only neutrophil TEM events clearly visible for the complete duration of 
TEM were analysed. The frequency of neutrophil paracellular TEM events were 
quantified by the occurrence of EC junctional disruption, visualised by the 
occurrence of transient pores in EC layer during a TEM event as previously 
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described (Woodfin et al., 2011). The association of such events with bicellular EC 
contacts or at EC junctions between multicellular (three or more) ECs was noted and 
quantified. Secondly transcellular TEM events were identified as transmigrating cells 
associated with the occurrence of transient pores within the EC body visualised by 
disruption of the diffuse cell body PECAM-1 labelling, but not associated with 
disruption of EC junctions. Lastly the duration for which the neutrophils were in 
contact with an EC junction before commencing paracellular TEM (pre-TEM) and 
the duration of paracellular TEM was analysed (Figure 2.10). It should be noted that 
transcellular events were excluded during the analysis of TEM duration as they were 
infrequently observed. The start of TEM was defined as the time when a leukocyte 
protrusion was inserted into the EC junction and the formation of an EC pore. The 
end of TEM was defined as the time at which the leukocyte was no longer in contact 
with the abluminal side of the endothelium.    
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2.7  Development of a cremasteric Shwartzman Reaction model 
 
The Shwartzman Reaction (SR) is a process which describes the body’s reaction to 
particular toxic reagents and has been likened to, or claimed to manifest in, clinical 
disorders. This includes sepsis, vasculitis and various other conditions which have an 
underlying inflammatory component (Hjort and Rapaport, 1965). Classically it can 
 
 
Figure 2.10: Quantification of neutrophil transendothelial migration dynamics.  
Stages leading up to TEM and TEM were categorized into 3 stages in order to analyse 
the dynamics of leukocyte TEM. (i) Crawling to the site of TEM, (ii) Contact with the 
junction before commencing TEM (pre-TEM), (iii) Paracellular transmigration 
through the EC layer. TEM initiated by the first cell protrusions into the endothelial 
junction and the formation of transient pore in the EC, and transmigration through the 
EC until the cell is no longer in contact with the abluminal side of the junction.  
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be elicited experimentally via two LPS doses 24 hours apart and is characterised by 
leukocyte recruitment, thrombus formation and haemorrhage. SR is commonly 
induced in dermal models. As part of the present project a SR was established for the 
first time in the cremaster model to enable direct visualisation of vascular responses 
in real time.  
 
A classical local SR was elicited by two LPS injections 24 hours apart. 30ug of LPS 
(from E.coil 011:B4) was injected i.s. (Hickey et al., 1998) to prime the endothelial 
cells for a reaction. 24 hours later 150μg of LPS was administered i.v. (Figure 2.11). 
Control animals were treated with saline. 2 hours post-i.v. injection the cremaster 
muscle was exteriorised as previously described (Figure 2.3), and observed using 
brightfield or confocal microscopy. 
 
 
Figure 2.11:  Schematic diagram illustrating the experimental protocol for 
mouse cremasteric Shwartzman Reaction model in vivo.  
Mice were given an i.s. injection of LPS (30µg) to prime the endothelial cells for a 
reaction. 24 hours later they were administered with an i.v. injection of LPS (150µg) 
and the cremaster muscle was exteriorized and vascular responses were analysed by 
brightfield and confocal microscopy. 
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2.7.1  Analysis of leukocyte adhesion and transmigration  
Cremaster muscles were viewed using an upright brightfield microscope (Carl Zeiss, 
Welwyn Garden City, United Kingdom) incorporating a 20×water-dipping objective 
(NA 1.0). A JVC colour video camera was used to acquire the image onto a monitor 
(Figure 2.12A). 3-4 post-capillary venules per cremaster which were 20-40µm in 
diameter with good/fast blood flow (based on observation of the flow by transmitted 
light where vessels with reduced or slow blood flow have a 'granular' appearance as 
the individual erythrocytes become visible) and few branches were selected for 
analysis. Frequency of rolling leukocytes was quantified by counting the number of 
rolling leukocytes that passed a given point in 60 seconds. Firmly adherent 
leukocytes were defined as leukocytes which were stationary for at least 30 seconds, 
and the number of adherent cells was quantified in a 500μm long section of each 
venule. Transmigrated leukocytes in the perivascular region, 50µm each side of the 
500µm length vessel were also analysed. In some experiments using confocal 
microscopy analysis, transmigration 0-50 and 50-100µm into the perivascular tissue 
from one side of the vessel length was also analysed (Figure 2.12B).  
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Figure 2.12: Leukocyte adhesion and transmigration as observed by brightfield 
intravital microscopy.  
(A) Image shows the different components used for brightfield IVM. Mice were 
placed on a heated stage and the cremaster muscle was exteriorized and kept moist 
with Tyrodes buffered solution. A 20 × water-dipping objective connected to a 
camera and projected on monitor where leukocyte responses were analyzed. (B) 
Brightfield image showing an inflamed post-capillary venule. Leukocytes which 
were adherent for more than 30 second in the lumen of the vessel (blue arrows) was 
counted over a 500µm length. Leukocytes that have transmigrated into the tissue, 
50μm either side from the vessel were counted over a length of 500μm. 
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2.7.2  Characterisation of the SR using Lys-eGFP-ki mice and CX3CR1-eGFP-
ki mice 
To characterise the SR response within the cremaster muscle the subtype of 
leukocytes recruited during this reaction was determined through live confocal IVM 
using Lys-eGFP-ki mice (expressing GFP in neutrophils and monocytes) (Faust et 
al., 2000), and CX3CR1-eGFP-ki mice (expressing GFP in monocytes and dendritic 
cells) (Jung et al., 2000). A SR was stimulated in the cremaster muscle and prepared 
for confocal IVM as previously described. Anti–mouse Alexa Fluor 647–labelled 
PECAM-1 mAb (i.s.) was used as a marker for endothelial cells lining the vessel. 3-4 
post-capillary venules were selected and viewed using a Leica SP5 confocal 
microscope as previously described. Live images were acquired through sequential 
scanning of different lasers (488 nm, 561 nm and 633 nm) at a resolution of 512 x 
512 pixels corresponding to a voxel size of approximately 0.7 x 0.7 x 0.9 μm in the 
x-y-z planes, respectively. Acquired z-stack images were reconstructed and analysed 
in 3D using Imaris. The number of intravascular leukocytes in each venule was 
analysed. The number of transmigrated leukocytes in the perivascular region, 0-
50µm and 50-150µm away from the venule was also analysed. 
  
2.7.3  Live immunofluorescent analysis of microthrombi formation 
Platelet-vessel wall interactions in SR-induced inflammation were investigated. 
Platelets were labelled i.v. with anti–mouse phycoerythrin (PE) labelled CD41 mAb 
(0.1μg/g) (Falati et al., 2006). Anti–mouse Alexa Fluor 647–labelled PECAM-1 
mAb was used to label vessels (i.s.). 2 hours after the induction of the SR the 
cremaster muscle was prepared for confocal IVM as previously described and 
imaged, using a Leica SP5 confocal microscope as previously described. Venules of 
300µm in length ranging from 5µm to 60µm in diameter were selected. Live images 
were acquired through sequential scanning of different lasers (488 nm, 561 nm and 
633 nm) at a resolution of 920 x 312 pixels corresponding to a voxel size of 
approximately 0.7 x 0.7 x 0.9 μm in the x-y-z planes. Using Leica LAS AF Lite 
(2.1.1 build) software the mean fluorescent intensity of immunostained stained CD41 
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and PECAM-1within the vessel region was determined by dividing the pixel sum of 
each channel by the area of the whole venule. The ratio of the mean intensity of 
fluorescently labelled CD41 to PECAM-1 was calculated as a measure of 
microthrombi and/or platelet-vessel wall interactions. Vessels which had 
microthrombi would have fluorescently labelled platelets adhering to the 
endothelium and therefore have a higher ratio of CD41 intensity to PECAM-1 
intensity.  
 
2.7.4  Quantification of vascular perfusion in the SR 
Vessel perfusion was investigated using dextran-fluorescein isothiocyanate (FITC) to 
fluorescently label all perfused vessels. 2 hours after the induction of the SR, the 
cremaster muscle was prepared for confocal IVM as previously described. 
Intrascrotal anti–mouse Alexa Fluor 647–labelled PECAM-1 mAb was used to label 
all vessels. 500μg dextran-FITC was administered through the carotid artery in order 
to label only perfused vessels. Five standard regions per cremaster were selected and 
live images were acquired through sequential scanning 488, 561 and 633 nm laser, at 
a resolution of 920 x 312 pixels corresponding to a voxel size of approximately 0.7 x 
0.7 x 0.9 μm in the x-y-z planes, respectively. Using Leica LAS AF Lite software 
mean fluorescent intensity of immunostained stained dextran and PECAM-1 was 
determined by dividing the pixel sum by the area of the whole venule. The ratio of 
the mean intensity of fluorescently labelled dextran to PECAM-1 was calculated as a 
measure of vascular perfusion. Vessels which were perfused would have 
fluorescently labelled dextran and therefore have a higher ratio of fluorescent 
intensity.  
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2.8  Statistics 
All results are presented as mean plus or minus standard error of the mean (SEM). 
Statistical significance was assessed by the unpaired two-tailed Student t test or by 
one-way or two-way analysis of variance (Anova) with the Newman-Keuls multiple 
comparison test. P values below 0.05 were considered significant (GraphPad Prism 4 
software). Further statistical advise from a statiscian was sought with regards to the 
appropreaite minimum n numbers (i.e. number of mice) to be used which will give 
meaanifull data given the ethical implications of using mice.   
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CHAPTER 3: Expression profile of ICAM-2 in vivo 
 
3.1  Introduction 
 
ICAM-2 is an adhesion molecule well known to have a high, constitutive expression 
on vascular ECs. Expression of ICAM-2 on high endothelial venules (lymph node, 
tonsil), sinus lining cells in the spleen, capillary ECs in the lung, Kupffer's cells and 
sinus lining cells in the liver and ECs of the glomerulus and intertubular spindle cells 
in the kidneys has been previously reported (de Fougerolles et al., 1991). In contrast 
to the closely related adhesion molecule ICAM-1, ICAM-2 is not upregulated upon 
stimulation with pro-inflammatory cytokines such as IL-1β and TNF-α. In fact, 
ICAM-2 has be demonstrated to be expressed 10-fold higher than that of ICAM-1 at 
a basal level (de Fougerolles et al., 1991) and for this reason ICAM-2 has been 
considered to be an adhesion molecule involved in homeostatic processes, such as re-
circulation and homing of lymphocytes. More recently, with the development of 
more sensitive techniques, the expression of ICAM-2 has been found to be regulated 
in some inflammatory reactions. Specifically, in IL-1β and TNF-α-stimulated 
HUVECs, ICAM-2 has been reported to be downregulated in both a protein and 
transcriptional level by up to 50% in comparison to basal levels (McLaughlin et al., 
1999; McLaughlin et al., 1998). Subsequent ex vivo studies by the same group 
confirmed ICAM-2 downregulation in ECs from human mammary arteries and 
demonstrated an ERG transcription factor dependent expression (McLaughlin et al., 
1999). In most studies however ICAM-2 expression has been demonstrated to remain 
unchanged on vascular ECs during cytokine induced inflammation (de Fougerolles et 
al., 1991;Hobden, 2003). In vitro studies ICAM-2 has been localized to EC junctions 
(McLaughlin et al., 1998) suggesting a role for this adhesion molecule in leukocyte 
TEM. Indeed ICAM-2 supports leukocyte extravasation into tissues, but the 
expression pattern of EC ICAM-2 in post-capillary venules under basal conditions is 
different to that of other junctional proteins involved in TEM. Most notably ICAM-2 
was observed to have a high heterogenic expression across the vascular lumen as 
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well at EC junctions (Woodfin et al., 2009), an expression profile that was further 
investigated as part of this project.  
 
In addition to ECs, ICAM-2 is also expressed on epithelial cells (Carreno et al., 
2002; Porter and Hall, 2009), neutrophils (Sundd et al., 2012), monocytes (de 
Fougerolles et al., 1991), T cells (de Fougerolles et al., 1991), eosinophils (Gerwin et 
al., 1999), natural killer cells (Helander et al., 1996; Somersalo et al., 1995), platelets 
(Diacovo et al., 1994; Kuijper et al., 1998) and synovial cells (Singh et al., 2006). 
The relative amount of ICAM-2 surface expression on different leukocyte subsets 
seems to be variable and it is well known that a much lower expression is evident on 
leukocytes in comparison to ECs (de Fougerolles et al., 1991; Gerwin et al., 1999; 
Sundd et al., 2012). Some studies have indicated no expression on neutrophils (de 
Fougerolles et al., 1991) whilst other groups have demonstrated clear neutrophil 
ICAM-2 expression (Sundd et al., 2012). It should be noted however, that these two 
latter studies use cells from different species to analyses the expression of ICAM-2 
and this may account for the differences seen. As the focus of the present study is 
related to the role of ICAM-2 in neutrophil transmigration using a murine model, 
ICAM-2 expression on different leukocyte subsets from the mouse blood circulation 
was also investigated. 
 
Although both EC and leukocyte ICAM-2 expression has previously been 
demonstrated, further investigations are required to understand the regulation and 
distribution of these expressions in the context of neutrophil transmigration. This 
chapter aims to investigate the expression profile of ICAM-2 throughout the EC 
vasculature, as well as on specific leukocyte subsets. In order to investigate the 
possibility of EC ICAM-2 redistribution upon inflammation, which may support 
neutrophil transmigration, the sub-cellular localisation of EC ICAM-2 under basal 
conditions was compared with that after IL-1β stimulation. This was carried out in 
comparison with other well-established markers of EC junctions such as PECAM-1 
and VE-cadherin. These objectives were addressed by immunolabelling and confocal 
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microscopic analysis of the mouse cremaster muscle, a tissue that was subsequently 
used for investigations into the role of ICAM-2 in neutrophil trafficking. For 
comparison, key findings in the cremaster muscle were also investigated in the 
dermal (ear) vasculature. The expression profile of ICAM-2 on different leukocyte 
subtypes in the blood circulation of naïve WT mice was also examined using flow 
cytometry as part of this study.  
 
 
3.2  Results 
 
3.2.1  Distribution of ICAM-2 in the vasculature  
 
The expression profile of EC ICAM-2 on the vasculature of the murine cremaster 
muscle was analysed. This tissue was utilised due to its thin and transparent nature, 
rendering it highly amenable for high resolution immunofluorescence staining and 
confocal microscopy. Initially the characteristics of different types of blood vessels 
in the cremasteric vasculature were investigated. As a key aim of this work was to 
analyse the distribution of ICAM-2 in relation to its expression at EC junctional and 
non-junctional regions, well-known EC junctional molecules PECAM-1 and VE-
cadherin  were also stained and their specificity was confirmed using their respective 
isotype control mAb (Figure 3.1). The α-SMA mAb was used to visualise the 
vasculature, and discriminate between arterioles and venules. This staining is 
routinly carried out within our group and the pattern of expression was expected and 
are confident that the expression is specific based on a strain of mice which have 
eGFP expression in the α-SMA gene (see Proebstl al., 2012 for further details). High 
amounts of ICAM-2 were found in ECs surrounding post-capillary venules, arterioles 
and lymphatic’s (Figure 3.2A). Identification of different sections of the vascular tree 
was based on the morphology of vessels and ECs as shown by the well established 
EC junctional markers VE-cadherin and PECAM-1. Specifically, venules commonly 
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displayed multiple meandering vascular branches with rounded cobblestone ECs, 
whereas arterioles displayed fewer branches which were straighter and had elongated 
ECs (Figure 3.2). Lymphatic vessels were blunt ended and had ECs with oak leaf 
morphology. The EC layer within these vessels was thinner and arranged in a more 
irregular fashion than that of venules and arterioles whereby a single EC was not 
clearly visible (Figure 3.2A). In arterioles and post-capillary venules VE-cadherin 
was almost entirely localised at the endothelial junctions, where as PECAM-1 was 
strongly enriched at the junctions but also showed a low homogeneous expression on 
the EC body. In agreement with previous studies, high ICAM-2 expression was seen 
at EC junctions and with high heterogeneous expression on the EC body (Woodfin et 
al., 2009) (Figure 3.2A).  
 
Vascular labelling of PECAM-1 is well established in this tissue, however ICAM-2 
labelling required significant optimisation. In preliminary experiments several 
labelling protocols were carried out in conjunction with tissues from ICAM-2 KO 
mice to confirm specificity of the mAb employed as well as the staining protocols 
(Figure 3.2B). 
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Figure 3.1 : Endothelial junctional expression of PECAM-1 and VE-cadherin in 
the mouse cremasteric vasculature.  
(A) Whole mount tissues were stained with fluorescent secondary mAb directed 
against α-SMA (red) and PECAM-1 (green) or (B) PECAM-1 (red) VE-cadherin 
(blue). Samples were observed using Leica confocal microscope. Representative 
images of half venules were generated using Imaris software. Specificity of anti-
PECAM-1 mAb and anti-VE-cadherin  mAb was confirmed in cremaster muscles 
stained with the respective isotype control. Scale bar represents 30µm. 
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Figure 3.2: Endothelial cell expression of ICAM-2 in the mouse cremasteric 
vasculature.  
(A) Mice were injected with 3mg/kg anti-ICAM-2 (3C4) mAb intravenously. After 
10 mins cremaster muscles were dissected away from mice and fixed in PFA. Whole 
mount tissues were stained with fluorescent secondary mAb directed against ICAM-
2 (red). Tissues were washed, re-blocked and stained for PECAM-1 (green) and VE-
cadherin (blue) using directly conjugated mAbs. Samples were observed using Leica 
confocal microscope. Representative images of half venules were generated using 
Imaris software (n=3). (B) Specificity of the anti-ICAM-2 mAb binding was 
confirmed in immunostainings carried out in cremaster muscles from ICAM-2 KO 
mice. Scale bar represents 20µm. 
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3.2.2  Localisation of ICAM-2 on venular endothelial cells 
 
As the principal aim of the overall study was to understand the role of ICAM-2 in 
neutrophil extravasation, in the present section a detailed analysis and quantification 
of EC ICAM-2 expression on post-capillary venules was conducted. The i.v. method 
of staining previously used (Figure 3.2) required a significant amount of mAb and 
hence the staining method employed for ICAM-2 was further optimised. Taking into 
account that EC PECAM-1 is routinely stained locally in vivo (i.s.) within our group 
(Woodfin et al., 2011), and is very reliable and uses significantly less mAb, it was 
considered that this mode of staining could also be effective for labelling EC ICAM-
2. This method of staining produced results comparable to that noted previously with 
i.v. mAb in terms of distribution within cremasteric vasculature as well as 
localisation on ECs. With this approach, the sub-cellular distribution of venular EC 
ICAM-2 and PECAM-1 was compared in unstimulated and IL-1β-stimulated tissues. 
Image stacks of PECAM-1- and ICAM-2- labelled venules of both small (20-40µm) 
and large (40-70µm) vessels were rendered into 3D models using Imaris (Figure 3.3). 
Intensity thresholding was used to build an isosurface on the whole vessel (Chapter 
2, Figure 2.5). The mean intensity of fluorescently labelled PECAM-1 and ICAM-2 
was determined 4 hours after saline or IL-1β administration. No differences were 
detected in EC PECAM-1 expression between saline and IL-1β pre-treatment or 
between WT and ICAM-2 KO mice (Figures 3.3 and 3.4). Additionally, the size of 
venules had no impact on the fluorescent intensity of PECAM-1. Similarly EC 
expression of ICAM-2 remained unaffected after IL-1β stimulation, and again no 
differences in ICAM-2 expression were detected between small and large venules in 
this tissue (Figures 3.3 and 3.4). It should be noted that the fluorescent intensity 
quantified in these experiments are controlled for between experiments through 
several ways. Firstly confocal microscope settings were kept largely constant and are 
based on control images (i.e. stainings from isotype control tissues or tissues from 
mice lacking that protein). Secondly the fluorescent intensity values given are the 
mean value within the isosurface, therefore are internally controlled for the volume 
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of tissue/vessel wall analysed and most importantly the background fluorescent 
intensity of each channel was substracted from each image (Chapter 2, Figure 2.5). 
 
The sub-cellular distribution of EC PECAM-1 and ICAM-2 on post-capillary venules 
was quantitatively analysed. This was carried out using Imaris software, where again 
the intensity thresholding was used to build an isosurface. This time an isosurface 
was created on the high intensity PECAM-1 corresponding to EC junctions or the 
low intensity PECAM-1 corresponding to EC bodies or EC ‘non-junctional’ regions 
(Chapter 2, Figure 2.6). The mean intensity of PECAM-1 and ICAM-2 within these 
two surfaces in unstimulated and IL-1β-stimulated tissues was determined. PECAM-
1 expression was found to be significantly higher at EC junctions than on the EC 
body, while the mean intensity of fluorescently labelled ICAM-2 was not different in 
these two regions (Figure 3.5). This distribution of EC ICAM-2 was also seen in 
post-capillary venules in the ear dermal microvasculature (Figure 3.7). It should be 
noted that a different method was used for labelling the ear dermal vasculature. 
Specifically the i.v. method of labelling ICAM-2 was carried out within the ear 
(Figure 3.7), a protocol that gave similar results to that previously obtained in the 
cremaster muscle (Figure 3.2). Of note, the i.v. method of labelling ICAM-2 within 
the cremaster muscle showed a comparable distribution of ICAM-2 to that detected 
by the i.s. method of labelling (Figure 3.3). 
 
In the cremaster muscle neither PECAM-1 or ICAM-2 showed differences in their 
respective distribution or fluorescent intensity following IL-1β stimulation (Figures 
3.3, 3.4 and 3.5). Analysis of neutrophil responses (rolling, adhesion and 
transmigration), by brightfield microscopy confirmed a neutrophil response after IL-
1β stimulation in comparison to saline controls (Figure 3.6). Of importance i.s. 
administration of directly labelled anti-PECAM-1 and anti-ICAM-2 mAb did not 
inhibit leukocyte transmigration (Figure 3.6B). As a non-function blocking mAb to 
PECAM-1 and very low doses of anti-ICAM-2 mAb were employed. As a positive 
control ICAM-2 KO mice were also used in thes experiments (Figure 3.6) where no 
difference in leukocyte adhesion is seen after IL-1β stimulation however a significant 
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reduction in leukocyte transmigration is seen in IL-1β stimulation ICAM-2 KO mice 
when compared to WT controls.  
 
Clearly it is not possible to make inferences about the absolute levels of these 
proteins in comparison to each other, due to possible differences in mAb affinity or 
avidity as well as epitope access, but the presence of substantial amounts of ICAM-2 
on the EC body suggests that it may have a function beyond its accepted role in 
leukocyte transmigration. 
 
 
 
Figure 3.3: Distribution of endothelial ICAM-2 on post-capillary venules in IL-
1β-stimulated mouse cremasteric vasculature.  
Mice were injected with IL-1β (50ng/400µl, i.s.) or saline and fluorescently 
conjugated anti-ICAM-2 (3C4) (green) and anti-PECAM-1 (C390) (red) mAbs (i.s.) 
for 4 hours (n=3 mice, 3-5 vessels/cremaster). Cremaster muscles were prepared for 
confocal IVM and live images of samples were observed using a confocal 
microscope. Representative images of half venules were generated using Imaris 
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software. The specificity of binding of anti-ICAM-2 mAb was confirmed in 
cremaster tissues from ICAM-2 KO mice. Scale bar represents 20µm. NB- In these 
experiments tissues were also staining for ICAM-1 results are presented in chapter 6. 
 
Figure 3.4: Quantification of mean fluorescence intensity of total endothelial 
PECAM-1 and ICAM-2 on post-capillary venules in IL-1β-stimulated mouse 
cremaster muscles. 
Isosurfaces were built on the EC layer (Chapter 2, Figure 2.5) and the mean 
fluorescent intensity of total EC (A) PECAM-1 and ICAM-2 was determined in 
saline and IL-1β (50ng/400µl, i.s.) -stimulated tissues from WT and ICAM-2 KO 
mice. (B) Small (20-40µm in diameter) and large (40-70µm in diameter) venules 
from saline and IL-1β-stimulated WT mice were individually grouped. Each bar 
represents the mean fluorescence intensity per mouse (n=3 mice, 3-5 
vessels/cremaster). NB- In these experiments tissues were also staining for ICAM-
1 results are presented in chapter 6. 
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Figure 3.5: Quantification of the distribution of endothelial PECAM-1 and 
ICAM-2 on post-capillary venules in IL-1β-stimulated mouse cremaster 
muscles.  
Isosurfaces were built on the EC non-junctional and junctional regions (Chapter 2, 
Figure 2.6). Using WT and ICAM-2 KO mice the mean fluorescent intensity of 
(A) PECAM-1 and (B) ICAM-2 4 hours after saline and IL-1β (50ng/400µl, i.s.) 
stimulation was determined. Results are presented as mean ± SEM for each mice 
(n=3 mice, 3-5 vessels/cremaster). Significant differences were assessed using one 
way Anova between saline and IL-1β groups indicated by asterisks (***P < 
0.001). NB. ICAM-2 KO treated with IL-1β group n=1 mice. NB- In these 
experiments tissues were also staining for ICAM-1 results are presented in chapter 
6. 
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Figure 3.6: Effect of in vivo labelling of ICAM-2 on leukocyte responses in IL-
1β-stimulated cremaster muscles.  
WT and ICAM-2 KO mice were injected with saline or IL-1β (50ng/400µl, i.s.) 
for 4 hours. Fluorescently conjugated mAbs to PECAM-1 (2μg/mouse) and 
ICAM-2 (4μg/mouse) were co-administered via i.s. injection. Cremaster muscles 
were exteriorised and leukocyte responses were analysed by brightfield IVM. (A) 
The number of rolling leukocytes past a fixed point per minute, adherent 
leukocytes per 500 μm length vessel and (B) transmigrated leukocytes per 
2.5x10
4μm2 were analysed. Results are presented as mean ± SEM for each mice 
(n=3 mice, 3-5 vessels/cremaster). Significant differences were assessed using one 
way Anova between saline and IL-1β groups are indicated by asterisks (***P < 
0.001). Additional statistical comparisons between WT control and ICAM-2 KO 
groups are indicated by hash symbols (###P < 0.001). Comparisons between WT 
+ fluorescent mAb administration and ICAM-2 KOs groups are indicated by 
dollar symbols ($$$P < 0.001).  
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Figure 3.7: The distribution of endothelial PECAM-1 and ICAM-2 on post-
capillary venules in the ear dermal vasculature.  
(A) Mice were injected with 3mg/kg anti-ICAM-2 (3C4) mAb i.v. Ears were 
dissected away from mice and fixed in PFA. Whole mount tissues were stained 
with a fluorescent secondary mAb direct against ICAM-2 (red) and PECAM-1 
(green). Images were captured using a confocal microscope. Representative 
images of half venules were generated using Imaris software. Scale bar represents 
20µm. (B) Region of interest was built on the EC non-junctional and junctional 
regions, and the mean fluorescence intensity of PECAM-1 and ICAM-2 in these 
regions was determined. Results are presented as mean ± SEM for each mice (n=3 
mice, 3-5 vessels/cremaster). Significant differences between groups were 
assessed using an unpaired t-test. 
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3.2.3  Leukocyte ICAM-2 expression 
 
Previous studies have highlighted a role for ICAM-2 during leukocyte extravasation 
and this role was linked to the expression of ICAM-2 on EC. ICAM-2 is however 
also expressed on leukocytes. To date the expression of ICAM-2 on lymphocytes and 
NK cells is well established but the expression of ICAM-2 on neutrophils is currently 
inconsistent. Earlier data has highlighted that ICAM-2 is not expressed on 
neutrophils (de Fougerolles et al., 1991) however more recently using cells from the 
mouse blood and bone marrow, ICAM-2 on neutrophils has been demonstrated 
(Sundd et al., 2012). ICAM-2 has also been shown to undergo homophillic 
interactions (Huang et al., 2005) and therefore it is possible that neutrophil ICAM-2 
may interact with EC ICAM-2 during neutrophil extravasation. Further examination 
of the expression of ICAM-2 on different leukocyte subsets could provide additional 
insights into the mechanism by which ICAM-2 exerts its function during neutrophil 
extravasation.    
 
Peripheral blood leukocytes from WT mice were analysed for surface expression of 
ICAM-2 using flow cytometry. Leukocytes were fluorescently stained for specific 
markers in order to distinguish different leukocyte subsets. For this purpose, 
fluorescent mAbs directed against Gr-1, CD115, B220 and/or CD3 were used. Based 
on current literature, Gr-1 positive and CD115 negative leukocytes corresponds to 
neutrophils. Gr-1 positive and CD115 positive cells corresponds to classical 
monocytes and Gr-1 negative and CD115 positive corresponds to non-classical 
monocytes. Lastly, CD3 and B220 positive leukocytes correspond to T cells and B 
cells respectively. For gating strategies of different leukocyte subsets and ICAM-2 
expression see method section (Chapter 2, Figure 2.1 and 2.2). The results confirmed 
that almost all B and T cells, and 70-80% of all classical and non-classical 
monocytes stained positive for surface ICAM-2 expression (Figure 3.8 and 3.9A). In 
contrast, only 20% of Gr-1 high neutrophils stained positive for ICAM-2. The RFI of 
AlexaFlour-488 labelled anti-ICAM-2 mAb on different leukocyte subsets confirmed 
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that B cells and classical monocytes have the highest expression of ICAM-2 
followed by T cells and non-classical monocytes (Figure 3.9B). Neutrophils however 
displayed the least expression of ICAM-2 with a very low average RFI (Figure 
3.8B). Therefore the data presented here confirms that only a small portion of 
neutrophils express ICAM-2 at relatively low level in comparison to other leukocyte 
subsets. Furthermore, ICAM-2 was not detectable on neutrophils using confocal 
microscopy suggesting that neutrophils express a relatively low levels of ICAM-2 in 
comparison to that observed on ECs.  
 
In initial flow cytometry studies, each stained population was back gated on to the 
forward and side scatter (indicating size and granularity respectively) to ensure 
gating of all leukocyte subsets. These studies also help optimised flow cytometry 
settings and compensation. Antibody specificity was determined by using isotype 
controls. In all experiments unstained and single stained blood samples were used in 
addition to blood samples from ICAM-2 KO mice, confirming anti-ICAM-2 mAb 
specificity. 
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Figure 3.8:  Representative flow cytometry plots demonstrating the expression of 
ICAM-2 in different leukocyte subsets.   
Surface ICAM-2 expression of different mouse blood leukocyte subsets was 
determined by flow cytometry. The percentage of neutrophils, classical and non-
classical monocytes and T and B cells which stained positive for ICAM-2 (red line) 
was determined (see Chapter 2, Figure 2.1 and 2.2 for leukocyte subset gating 
strategies). The RFI of fluorescently labelled ICAM-2 in each leukocyte subset was 
also determined. Gating strategies were based on negative control samples taken from 
ICAM-2 KO mice (black line).  
108 
 
 
 
Figure 3.9: Expression of ICAM-2 in different leukocyte subsets from the mouse 
blood circulation.     
Surface ICAM-2 expression of different mouse blood leukocyte subsets was 
determined by flow cytometry. (A) The percentage of neutrophils, classical and non-
classical monocytes and T and B cells which stained positive for ICAM-2 was 
determined (Chapter 2, Figure 2.1 and 2.2). (B) The RFI of fluorescently labelled 
ICAM-2 in each leukocyte subset was also determined. Gating strategies were based 
on negative control samples taken from ICAM-2 KO mice. Results are presented as 
mean ± SEM for each mice (n=3 mice). 
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3.3  Discussion 
 
In this chapter the expression of ICAM-2 was investigated on mouse ECs in vivo as 
well as on leukocytes. For this purpose the cremaster muscles for EC analysis and 
circulating blood for leukocyte anaylsis were used. The cremaster muscle is a thin, 
translucent and highly vascularised tissue. These characteristics enable 
immunostaining and direct visualisation using confocal microscopy, and thus permit 
detailed analysis of the exact distribution pattern of EC ICAM-2 relative to that of 
more established molecules such as PECAM-1 and VE-cadherin. In previous studies 
the expression pattern of ICAM-2 was reported to be different to that of PECAM-1 
and JAM-A under basal conditions (Woodfin et al., 2009). The present findings 
expand on this observation through detailed quantification of EC ICAM-2 expression 
under control and inflamed conditions. Additionally as there is little information 
regarding the relative expression of ICAM-2 on different leukocyte subsets this was 
also further examined.   
 
To extend our understanding of the expression pattern of EC ICAM-2, cremaster 
muscles were immunostained and analysed by confocal microscopy. In line with 
previous studies ICAM-2 was found to be expressed on ECs of arterioles, post-
capillary venules, large venules and lymphatics in the cremaster muscle under basal 
conditions. The high basal expression of ICAM-2 has been suggested to be involved 
in EC-EC contacts (Huang, 2004), lymphocyte recirculation (Boscacci et al., 2010), 
monocyte patrolling (Schenkel et al., 2004) and in angiogenesis (Huang et al., 2005). 
Although ICAM-2 supports leukocyte extravasation during inflamed conditions the 
expression pattern of EC ICAM-2 on post-capillary venules was found to be distinct 
to other junctional proteins implicated in leukocyte transmigration. In the present 
study quantitative analysis of ICAM-2 localisation within ECs demonstrated a high 
heterogenic expression on the vascular lumen as well as at EC junctions. In contrast 
PECAM-1 was highly localised at EC junctions with a faint and diffuse cell-body 
expression. The distribution pattern of ICAM-2 and PECAM-1 detected in the 
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cremaster muscle under basal conditions was also demonstrated in the ear 
vasculature suggesting that this expression could be applicable to other vascular 
beds. The distinct expression of ICAM-2 compared to that of PECAM-1 further 
suggests that these molecules may have different functional roles. It has been 
demonstrated in prior studies from our group that ICAM-2, PECAM-1 and JAM-A 
have sequential non-redundant roles, and these roles appeared to be dependent on 
direct EC activation (Woodfin et al., 2009). From this study it was suggested that 
ICAM-2 has an early role during TEM whilst JAM-A was involved once the 
leukocyte was within the EC junction and PECAM-1 was involved when the 
leukocyte was on the abluminal side of the vessel. Taking this into account as well as 
the high EC body and junctional expression of ICAM-2, it is possible that ICAM-2 
may have dual roles in leukocyte extravasation, namely luminal leukocyte-EC 
interactions as well as in TEM itself. It is also possible that the distribution of EC 
ICAM-2 may change during inflammation and this was further examined.  
 
ICAM-2 is commonly compared to ICAM-1 as they belong to the same family of 
proteins. Whilst ICAM-1 is highly inducible by a wide range of inflammatory stimuli 
(Sumagin and Sarelius, 2010) ICAM-2 is not. In the present study, using 
immunostaining and confocal microscopy to analyse the mouse cremaster muscle, no 
effect on the total expression of EC ICAM-2 was detected in these vessels after IL-
1β stimulation. This is in line with numerous studies, however using IL-1β 
stimulated HUVECs and human mammary arteries a down regulation in ICAM-2 has 
been reported (McLaughlin et al., 1999;McLaughlin et al., 1998). The differences 
seen between the findings of the present work and the work of McLaughlin et al., 
(1998) may be due to the latter study using ECs lining the arteries. No observable 
differences between venules and arterioles in the mouse cremaster muscle were 
however noted in the present study. Additionally McLaughlin et al., (1998) examined 
ICAM-2 expression using human cells in an in vitro system, suggesting possible 
differences between species (Godwin et al., 2004) and/or experimental conditions 
and this maybe the cause for these inconsistencies. Of interest ICAM-2 expression in 
pigs is similar to that of mice in that it is not downregulated upon stimulation with 
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TNF-α or IL-1β (Godwin et al., 2004). Variation in expression of ICAM-2 in 
different species is understudied and requires further investigation. It is important to 
note that the purpose of ICAM-2 down regulation on human and not in mice ECs is 
unknown, but could be related to the fact that ICAM-1 and ICAM-2, in some 
experimental conditions, have been shown to be functionally redundant (Lehmann et 
al., 2003). 
 
Although total vessel ICAM-2 expression remains unchanged after IL-1β stimulation 
in our model, it is possible that ICAM-2 may undergo redistribution within 
individual ECs to support leukocyte TEM. This hypothesis was postulated in the 
light of recent findings that JAM-C redistributes away from EC junctions in 
inflammation (Scheiermann et al., 2009; Woodfin et al., 2011). In the present model 
no effect on ICAM-2 localisation within individual ECs was found in response to IL-
1β stimulation. Nevertheless, it is possible that using a more complex inflammatory 
stimulus such as a combination of TNF-α and IFNγ, or alternatively I/R injury to 
induce neutrophil recruitment, a redistribution of ICAM-2 away from junctions may 
occur.  
 
In contrast to the general consensus regarding the expression of ICAM-2 in 
inflammatory conditions, in the mucosal layer of the ileum from patients with 
Crohn’s disease, an increase in ICAM-2 expression was detected using 
immunohistochemistry (Bernstein et al., 1998), although a similar study found very 
little change (Vainer and Nielsen, 2000). ICAM-2 expression in whole lung tissue 
from ovalbumin treated mice also demonstrated an up-regulation of ICAM-2 mRNA 
(Gerwin et al., 1999). It is likely that ICAM-2 up-regulation demonstrated in these 
experiments is in fact located on the epithelium rather than on the endothelium. In 
support of this, intraepithelial precursor lesions from patients with pancreatic cancer 
were found to have an upregulated ICAM-2 expression (Hiraoka et al., 2011). In 
human samples of malignant lymph nodes (lymphoma) an increase in ICAM-2 
expression was also evident (Renkonen et al., 1992). It is therefore likely that when 
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lymphocyte infiltration is more dominant or alternately when the epithelium is 
stimulated an up-regulation in ICAM-2 expression occurs. This may reflect a 
different functional role for ICAM-2 under these circumstances. In the current study 
using a relatively simple acute model, no up-regulation or change in distribution of 
ICAM-2 expression on ECs were detected. It still remains to be elucidated whether 
more aggressive inflammatory stimuli would result in alterations in EC ICAM-2 
expression in vivo. Collectively the data on EC ICAM-2 expression reported in the 
current study suggests that ICAM-2 may have dual roles in luminal neutrophil-EC 
interactions as well as in TEM, and this possibility was studied in subsequent 
chapters. 
 
The stimulus used (IL-1β i.s.) in the current study predominately recruits neutrophils 
at a 4 hour time point (Thompson et al., 2001; Woodfin et al., 2011). For this reason 
detailed quantification of leukocyte ICAM-2 expression was carried out in order to 
understand the relative importance of EC versus neutrophil ICAM-2. Neutrophils 
(Sundd et al., 2012), monocytes (de Fougerolles et al., 1991), T cells (de Fougerolles 
et al., 1991), eosinophils (Gerwin et al., 1999) and natural killer cells (Helander et 
al., 1996; Somersalo et al., 1995) have all been previously shown to express ICAM-
2. To date no studies have reported an increase in ICAM-2 expression on leukocytes 
in inflammation or upon activation. It is known that there is high ICAM-2 expression 
on ECs relative to that on leukocytes and the major focus of many previous studies 
investigating ICAM-2 function has been on the role of EC ICAM-2 rather than that 
on leukocytes. In the present study immunostaining of ICAM-2 (via i.v. and i.s. 
administration) and confocal analysis of IL-1β-stimulated cremaster muscles showed 
no evidence of neutrophil ICAM-2. In contrast, using flow cytometry analysis of 
whole mouse blood, neutrophil ICAM-2 expression was detected and this is in line 
with a recent report (Sundd et al., 2012), although a much higher relative fluorescent 
intensity was reported in that study. The current data suggests that ICAM-2 
expression on neutrophils is relatively low in comparison to that of ECs and other 
leukocyte subsets. Flow cytometry analysis of mouse blood leukocytes under basal 
conditions confirmed that almost 100% of T and B cells were ICAM-2 positive. In 
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comparison approximately 80% of classical and non-classical monocytes were 
ICAM-2 positive. In contrast only 20% of all neutrophils expressed ICAM-2 and was 
expressed at relatively very low levels. For this reason homophilic interactions for 
ICAM-2 are also unlikely to occur during neutrophil extravasation. These results 
collectively suggest that the role of ICAM-2 in neutrophil extravasation is due to its 
expression on ECs rather than on neutrophils. The latter is further supported by 
earlier work in which WT bone marrow leukocytes transferred into ICAM-2 KO 
animals did not restore the observed defect in IL-1β-stimulated extravasation 
(Woodfin et al., 2009). Taking this into account, the data suggests that in the mouse 
cremaster muscle the defect in leukocyte extravasation seen after IL-1β stimulation 
when ICAM-2 is not functional, is likely to be a result of the loss of EC ICAM-2 as 
opposed to leukocyte ICAM-2.  
 
Collectively the results from this chapter quantitatively demonstrate the expression 
of ICAM-2 within the mouse vasculature as well as on different leukocyte subsets. 
On post-capillary venules, a high heterogenic ICAM-2 expression was evident on the 
EC body as well at EC junctions. In contrast PECAM-1 was highly localised at EC 
junctions with a faint and diffuse cell-body expression. This expression pattern of EC 
ICAM-2 and PECAM-1 was demonstrated in the mouse cremasteric and ear skin 
vasculature. The total expression and localisation of ICAM-2 was unaffected by IL-
1β stimulation, therefore discounting the possibility of both up-regulation and/or 
redistribution upon IL-1β-induced inflammation. In addition, as EC ICAM-2 
expression is significantly higher than that detected on leukocytes, it is highly likely 
that the deficiency in leukocyte extravasation seen in ICAM-2 KO mice after IL-1β 
stimulation (Huang et al., 2006; Woodfin et al., 2009) is due to loss of EC ICAM-2 
rather than leukocyte ICAM-2. These findings extend previous works on the 
expression profile of ICAM-2 in vivo and suggests a possible role for ICAM-2 in 
neutrophil-EC interactions in addition to its role in TEM. 
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CHAPTER 4: Role of ICAM-2 in luminal neutrophil-
endothelial cell interactions 
 
4.1  Introduction 
 
ICAM-2 is has been shown to support neutrophil extravasation into the tissue, 
however, the mechanism by which it mediates this response is currently unknown. 
The previous chapter focussed on investigating the localisation of ICAM-2 to gain 
further insights into its functions. These studies demonstrated that ICAM-2 has 
relatively high heterogeneous basal EC expression at non-junctional regions in 
comparison to junctional regions between adjacent ECs. This EC ICAM-2 
distribution was in contrast to that observed for PECAM-1, a well-established 
endothelial junctional molecule which is known to support neutrophil migration into 
the extravascular tissue via mediating neutrophil TEM (Privratsky et al., 2010). More 
specifically, PECAM-1 displayed a high EC junctional expression and a relatively 
low homogeneous EC non-junctional expression. The distinct expression of ICAM-2 
compared to PECAM-1 suggests that these molecules may have functionally 
different roles. A role for ICAM-2 at early stages of TEM was suggested (Huang et 
al., 2006; Woodfin et al., 2009) however to date no studies have directly reported the 
mechanism or stage by which EC ICAM-2 is involved in neutrophil extravasation. 
 
The high basal expression of ICAM-2 is likely to be due to its role in EC to cell 
contacts (Huang, 2004), lymphocyte recirculation (Boscacci et al., 2010), monocyte 
patrolling (Schenkel et al., 2004) and its role in angiogenesis (Huang et al., 2005), all 
which have been previously demonstrated. Under inflammatory conditions, ICAM-2 
is likely to have different functions. Trafficking of neutrophils (Hobden, 2003; 
Huang et al., 2006; Issekutz et al., 1999; Woodfin et al., 2009), eosinophils (Gerwin 
et al., 1999), monocytes (Schenkel et al., 2004), T cells (Boscacci et al., 2010; 
Lehmann et al., 2003; Lyck et al., 2003; Reiss et al., 1998; Steiner et al., 2010), 
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dendritic cells (Geijtenbeek et al., 2000; Helander et al., 1996; Wethmar et al., 2006) 
and the activation of natural killer cells (Helander et al., 1996) have all been shown 
to be, at least in part, dependent on the presence of functional ICAM-2. However 
very few studies have investigated the precise stage by which it regulates this 
process. A recent study has confirmed a role for neutrophil ICAM-2 during rolling 
through the formation of ‘slings’ using bone marrow derived neutrophils in in vitro 
microfluidic perfusion assays (Sundd et al., 2012). However they also show that in 
the mouse bone marrow, neutrophils have a higher RFI of immunostained ICAM-2 
than that detected in blood circulation and therefore may reflect differences in the 
role of immature bone marrow neutrophils. The low expression of ICAM-2 on 
neutrophils which was confirmed in Chapter 3 and earlier work showing that WT 
bone marrow leukocytes transferred into ICAM-2 KO animals did not restore the 
observed defect in IL-1β-stimulated neutrophils extravasation (Woodfin et al., 2009), 
together with numerous other reports on the role of EC ICAM-2 in leukocyte 
recruitment (Boscacci et al., 2010; Schenkel et al., 2004; Steiner et al., 2010),  the 
focus of the present study was on EC ICAM-2 function. With the use of real time 
microscopy, previous reports have suggested a role for EC ICAM-2 during T cell 
adhesion, polarisation and possibly TEM (Boscacci et al., 2010; Steiner et al., 2010) 
as well as in monocyte crawling (Schenkel et al., 2004). A study by Phillipson et al 
(2006), reported that a functional blocking mAb to ICAM-2 had no effect on the total 
percentage of adherent neutrophils that crawled, however whether ICAM-2 affected 
the dynamics of crawling was not documented.  
 
Taken together the distinct expression pattern of EC ICAM-2 in comparison to that 
of PECAM-1, and the fact that several different inflammatory models have clearly 
shown a role for ICAM-2 in neutrophil migration into the tissue which seems to be at 
a stage post-adhesion but prior to TEM, it was hypothesised that ICAM-2 may 
mediate luminal neutrophil-EC interactions during crawling. The studies presented in 
the current chapter therefore aimed to investigate the precise function of ICAM-2 in 
mediating neutrophil extravasation by examining its potential role in neutrophil 
crawling. This objective was addressed through the use of the cremasteric confocal 
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IVM model. Using this technique neutrophil migration dynamics were investigated 
in the vasculature from WT and ICAM-2 KO mice. Collectively the results obtained 
provide further insights into the role of ICAM-2 in neutrophil extravasation during 
inflammation.   
 
 
4.2  Results 
 
4.2.1  ICAM-2 contributes to neutrophil extravasation but not initial adhesion 
 
ICAM-2 has been shown to support neutrophil extravasation, and this study aimed to 
elucidate the mechanism by which this occurred. Previous work using transmitted 
light IVM has shown that in the absence of functional ICAM-2, IL-1β stimulation 
elicits normal levels of neutrophil adhesion, but reduced neutrophil extravasation 
(Huang et al., 2006; Woodfin et al., 2009). Initial studies sought to confirm these 
findings using a 4D confocal IVM model.   
 
Mice expressing eGFP under the lysozyme promoter (Lys-eGFP-ki), which exhibit 
endogenous fluorescent neutrophils, and to lesser extent monocytes, were employed 
in this study (Faust et al., 2000). These animals were crossed with mice deficient in 
ICAM-2 to produce a strain of ICAM-2 KO animals with eGFP positive neutrophils 
and monocytes. The vasculature of the cremaster muscle was labelled via an i.s. 
injection of fluorescently tagged anti-PECAM-1 mAb (clone 390, which is a non-
function blocking mAb). This labelling technique has been shown to have no impact 
on normal leukocyte responses (Woodfin et al., 2011). Cremaster muscles were 
subjected to 2 hours stimulation with IL-1β (i.s.) after which the cremaster muscles 
was exteriorised following anaesthesia. Sequential images of venules were captured 
using in vivo confocal microscopy for approximately a further 2 hours. The number 
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of extravasated neutrophils was taken from the final time point of live imaging 
experiments (~ 4 hours after initial IL-1β i.s. injections). Post-acquisition the images 
were analysed using the 4D modelling software Imaris and the numbers of 
intravascular and extravascular cells were quantified (Figure 4.1A).  
 
The leukocyte subtype recruited in this model was neutrophils as the eGFP 
monocytes in Lys-eGFP-ki mice which exhibit lower level of eGFP fluorescence in 
comparison to neutrophils were excluded from the analysis (Woodfin et al., 2011). 
IL-1β stimulation was used as an acute inflammatory stimulus which is primarily 
neutrophil driven at the 4 hour time point (Thompson et al., 2001; Woodfin et al., 
2011), hence the analysis represents acute neutrophillic inflammation.   
 
In both WT and ICAM-2 KO Lys-eGFP-ki mice, IL-1β stimulation elicited a 
significant increase in intravascular neutrophils (Movies 1 and 2), but no difference 
between WT and KO mice were seen (Figure 4.1). In contrast while WT animals 
exhibited a significant increase in extravascular neutrophils following IL-1β 
stimulation (Movie 2), those lacking ICAM-2 showed a substantial reduction in 
extravasation following IL-1β compared to WT, and did not exhibit a response 
significantly different to saline treatment (Figure 4.1). The defect in neutrophil 
recruitment seen in the ICAM-2 KO mice was not due to a reduction in the number 
of circulating leukocytes in the blood. This was illustrated by taking blood samples 
from both mouse strains staining them with trypan blue. Trypan blue enables easy 
identification of dead cells which take up the dye and appear blue with uneven cell 
membranes. In comparison, viable cells repel the dye and appear colourless and 
refractile under phase contrast. Using this technique the total blood leukocytes/ml 
was determined. Both WT and ICAM-2 KO mice had approximately 2.5 x 10
6
 
leukocytes per ml, indicating no differences in bone marrow mobilisation of 
leukocytes between both strains (Figure 4.2A).   
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To further ensure normal percentages of different leukocytes subsets within the blood 
circulation, the percentage of different leukocyte subsets was determined by flow 
cytometry. Leukocyte subsets were identified based on the surface expression of 
specific markers as mentioned previously. All percentages were comparable to that 
detected in published data (Gerwin et al., 1999). Specifically, 25% of leukocytes 
were neutrophils in both WT and ICAM-2 KO mice (Figure 4.2B) and classical 
monocytes and non-classical monocytes represented 4.5% and 5% of leukocytes 
respectively in WT mice with no differences being detected in ICAM-2 KO animals 
(Figure 4.2C). Furthermore, B cell (40%) and T cell (19%) percentages of total 
leukocytes were also comparable in both mouse strains (Figure 4.2D). Together the 
results indicate no defect in the total numbers and the relative percentages of 
circulating blood leukocyte subsets in ICAM-2 KO mice suggesting that the reduced 
number of tissue infiltrated neutrophils was due to a defect in neutrophil 
extravasation. 
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Figure 4.1: IL-1β-induced inflammation in WT and ICAM-2 KO cremasteric 
post-capillary venules. 
Cremasteric confocal IVM of WT or ICAM-2 KO Lys-eGFP-ki mice stimulated with 
i.s. IL-1β (50 ng/mouse) or saline for 2 hours. (A) Representative images of post-
capillary venules where PECAM-1 (i.s. labelling in vivo) are shown in red and 
neutrophils (Lys-eGFP-ki mice) are in green. (B) Quantification of intravascular and 
extravascular neutrophils in WT and ICAM-2 KO mice after saline or IL-1β 
stimulation. N = 3-7 animals per group, 3-5 vessels per cremaster. Error bars show 
SEM.  Statistically significant (Anova) differences between IL-1β or saline 
stimulated tissues are indicated by asterisks, *P<0.05 and ***P<0.001. Differences 
between WT and KO responses are indicated with hash symbols ## P<0.01. 
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Figure 4.2: Circulating blood leukocyte numbers in WT and ICAM-2 KO mice.  
(A) Total blood leukocyte numbers were determined by trypan blue and counted 
using a Neubauer haemocytometer. (B) Neutrophils, (C) monocytes and (D) 
lymphocytes as percentage total of leukocytes present in the blood circulation was 
determined by flow cytometry. Neutrophils were classified by Gr-1 staining. 
Classical monocytes were Gr-1 and CD115 positive where as non-classical 
monocytes were negative for Gr-1 and positive for CD115 staining. T cells 
corresponded to cells which were positive for CD3 staining. B cells corresponded to 
cells which were positive for B220 staining. Results are presented as mean ± SEM 
for each mice (n=3 mice).  
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4.2.2  Luminal crawling of neutrophils under basal conditions 
 
The expression pattern of EC ICAM-2 suggests it may have a role in luminal 
neutrophil-EC interactions. In order to investigate this hypothesis, luminal neutrophil 
crawling dynamics were analysed initially under basal conditions in the mouse 
cremaster muscle using in vivo confocal imaging. The cremasteric vasculature of WT 
or ICAM-2 KO mice expressing eGFP in neutrophils was labelled with fluorescent 
anti-PECAM-1 mAb (i.s.) as described in Chapter 2. Labelled tissues were 
exteriorised after 2 hours, and selected post-capillary venules were imaged at 30 
second intervals for a further 2 hours (approximately 30-40 minutes per vessel).  
Post-acquisition the sequential image stacks were converted into dynamic 3D models 
(an example of uninflamed vs inflamed vessel is shown in Movies 1 and 2 
respectively), and the migratory crawling behaviour of individual cells was tracked 
and quantified using Imaris (Movie 3). Still images of the dynamic movement of an 
individual crawling neutrophil are shown in Figure 4.3.  
 
Using this technique all neutrophils which were able to be tracked for at least 5 
frames (2.5 minutes) was analysed (Figure 4.3). Under basal conditions WT and 
ICAM-2 KO mice had a low average number of quantifiable neutrophil crawling 
events per venule (Figure 4.4A), this is most likely due to the low number of 
adherent neutrophils seen in response to saline treatment (Figure 4.1B) and hence 
fewer cells progressing to the crawling stage. Of the few cells which were tracked 
after saline treatment, various neutrophil crawling dynamics were analysed. In WT 
mice neutrophil crawling speed was 9.4 ± 1.0 µm/min (n=13 cells, from 4 vessels in 
3 mice), duration was 9.8 ± 2.1 min and length covered was 90.5 ± 18.1 µm (Figure 
4.5). In ICAM-2 KO mice these neutrophil crawling dynamics were slightly reduced, 
however this was not significantly different (Figure 4.4) and may reflect the low 
number of cells available to analyse. Overall no conclusions can be made on the role 
of ICAM-2 in mediating neutrophil crawling under basal conditions.  
122 
 
 
 
Figure 4.3: Intraluminal neutrophil crawling on endothelial cells lining post-
capillary venules as analysed by 4D confocal IVM. 
Representative images of cremasteric post-capillary venules from Lys-eGFP-ki mice 
as investigated by confocal IVM. High magnification images acquired at indicated 
time points illustrating the time course of an individual crawling neutrophil which 
could be tracked for at least 5 frames (2.5 minutes) as indicated by the asterisks. The 
blue line shows the entire crawling track and the white arrow shows the track 
displacement of the highlighted neutrophil. Scale bar represents 5 μm. (Movie 3). 
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Figure 4.4: Neutrophil crawling dynamics under basal conditions in WT and 
ICAM-2 KO mice.  
Cremasteric confocal IVM of WT or ICAM-2 KO Lys-eGFP-ki mice stimulated with 
i.s. saline for 2 hours. Various parameters relating to crawling dynamics were 
quantified using Imaris. (A)  The total number of luminal neutrophils which were 
observable for at least 5 frames (2.5 minutes) or more was analysed. The mean total 
(B) speed, (C) duration and (D) track length of luminal crawling cells in WT and 
ICAM-2 KO mice under unstimulated conditions. N=13-16 cells, from 3-4 vessels in 
3 mice per group. Error bars show SEM. (Movie 1). 
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4.2.3  IL-1β stimulates neutrophil luminal crawling in the cremaster muscles 
from WT and ICAM-2 KO mice 
 
Using the technique detailed above, neutrophil crawling dynamics was analysed in 
cremasteric venules post-IL-1β in WT and ICAM-2 KO mice. After IL-1β 
stimulation the total number of clear events analysed per venule increased to 
approximately 10 cells irrespective of genotype (Figure 4.5A). As expected from the 
intravascular data (Figure 4.1), no difference in the number of adherent neutrophils 
was detected between WT and ICAM-2 KO mice after IL-1β stimulation. 
Interestingly, it was found that after IL-1β stimulation, a small subset of neutrophils 
did not exhibit crawling and appeared to undergo only slight movements for the 
duration of the observation period. These cells were classified as ‘stationary 
neutrophils’ and were defined as neutrophils which were able to be tracked and 
displayed immobility of crawling as quantified by a displacement less than 5 μm  
(approximately half of the cell diameter) for the duration of observation (Figure 4.6 
and Movie 3). Crawling cells were defined as neutrophils which were able to be 
tracked for at least 5 frames (2.5 minutes) and displayed a crawling displacement of 
at least 5 μm for the duration of the observation period. These definitions were used 
to quantify the percentage of adherent cells which crawled in WT and ICAM-2 KO 
mice after IL-1β stimulation. In line with published data in both WT and ICAM-2 
KO mice the vast majority of adherent cells exhibited crawling behaviour (Phillipson 
et al., 2006). However as mentioned previously, a small reduction in crawling 
frequency in the ICAM-2 deficient group was seen (95.6 ± 3.4 % WT and 80.4 ± 4.7 
% ICAM-2 KO, n=10 venules, 76-81 cells form 6-7 mice, Figure 4.5B).  
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Figure 4.5: IL-1β-stimulated neutrophil crawling in WT and ICAM-2 KO mice.  
Cremasteric confocal IVM of WT or ICAM-2 KO Lys-eGFP-ki mice stimulated with 
i.s. IL-1β (50 ng/mouse) for 2 hours. Various parameters relating to crawling 
dynamics were quantified using Imaris.  (A)  The total number of luminal neutrophils 
which were observable for 2.5 minutes or more was analysed. (B) The percentage of 
adherent neutrophils which exhibited crawling motility with a displacement of more 
than 5μm was quantified, per venule, in WT and ICAM-2 KO. N = 76-81 cells from 
10 vessels in 6-7 animals per group. Error bars show SEM. Statistically significant 
(T-test) differences between WT and ICAM-2 KO data are indicated by asterisks 
*P< 0.05. (Movie 2). 
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Figure 4.6: Intraluminal stationary neutrophil as analysed by 4D confocal IVM.  
Representative images of cremasteric post-capillary venules from Lys-eGFP-ki mice 
as investigated by confocal IVM. High magnification images acquired at indicated 
time points illustrating the time course of an individual stationary neutrophil 
indicated by the asterisks. Stationary (or immobile) neutrophils as defined by a 
displacement less than 5 μm for the duration of observation. Scale bar represents 5 
μm. (Movie 4). 
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4.2.4  ICAM-2 supports luminal neutrophil crawling dynamics in IL-1β-
stimulated inflammation 
 
Using the detailed in vivo system, individual crawling neutrophils were tracked and a 
number of migratory parameters quantified in WT and ICAM-2 KO cremaster 
muscles post-stimulation with IL-1β. All data presented is the mean of 76-81 cells, 
from 10 venules, from 6-7 mice. A significant reduction (P<0.001) in mean 
neutrophil crawling speed was detected in ICAM-2 KO mice (6.3 ± 0.3 μm/min, n= 
81 cells) in comparison to WT (10.4 ± 0.5 μm/min, n= 76 cells) (Figure 4.7A). 
Interestingly the variability in crawling speed was considerably higher in the ICAM-
2 KO mice as compared to WT (Figure 4.7B). The crawling speed variability of each 
track was calculated by dividing the crawling speed standard deviation by the 
crawling speed mean value. The length and duration of observed neutrophil crawling 
cells was significantly different in these two strains of mice. Whilst the crawling 
length was slightly reduced in the ICAM-2 KO mice (Figure 4.7C), the duration of 
crawling was approximately 4 minutes longer than that detected in WT controls (9.4 
± 0.9 min in WT, 13.1 ± 1.1 min in ICAM-2 KO) (Figure 4.7D). No difference 
between the two strains was detected in neutrophil crawling displacement (the 
distance between the first and the last point) and straightness (displacement/total 
crawling track length) of crawling (Figure 4.8). The net neutrophil crawling 
displacement direction relative to blood flow was also analysed. Each crawling 
displacement vector was classified as crawling in the direction of blood flow, 
perpendicular to or against blood flow and the specific criteria was based on angles 
from the direction of blood flow (Figure 4.9A). In both groups the net crawling 
displacement direction relative to blood flow was predominately in the direction of 
blood flow (52.5 ± 5.6 % in WT, 67.5 ± 4.9 % in ICAM-2 KO), while 34.7 ± 7.0 % 
of neutrophils in WT, 25.7 ± 4.9 % of neutrophils in ICAM-2 KO crawled 
perpendicular to the flow of blood. Approximately 10% of neutrophils crawled 
against the flow of blood in both mouse strains (Figure 4.9). 
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These data indicate that ICAM-2 is essential for supporting efficient luminal 
crawling with respect to speed, duration and distance and this may facilitate the 
identification of sites permissive for TEM thus reducing the total duration of 
crawling time and increasing the crawling speed in WT mice.  
 
 
Figure 4.7: IL-1β-stimulated neutrophil crawling dynamics in WT and ICAM-2 
KO mice. 
Cremasteric confocal IVM of WT or ICAM-2 KO Lys-eGFP-ki mice stimulated with 
i.s. IL-1β (50 ng/mouse) for 2 hours. Various parameters relating to crawling 
dynamics were quantified using Imaris. The mean total (A) speed (B) speed 
variability (C) track length and (D) duration of crawling in WT and ICAM-2 KO 
venules was quantified. N = 76-81 cells from 10 vessels in 6-7 animals per group. 
Error bars show SEM. Statistically significant (T-test) differences between WT and 
ICAM-2 KO data are indicated by asterisks *P< 0.05, ***P< 0.001. 
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Figure 4.8: Neutrophil crawling displacement and straightness after IL-1β 
stimulation in WT and ICAM-2 KO mice.  
Cremasteric confocal IVM of WT or ICAM-2 KO Lys-eGFP-ki mice stimulated with 
i.s. IL-1β (50 ng/mouse) for 2 hours. Various parameters relating to crawling 
dynamics were quantified using Imaris. (A) Diagram showing how neutrophil 
crawling displacement (dashed red line) and straightness was determined. Neutrophil 
crawling straightness is calculated by the track displacement divided by the total 
track length (green line). The mean total (B) displacement and straightness of 
crawling in WT and ICAM-2-KO venules was quantified. N = 76-81 cells from 10 
vessels, in 6-7 animals per group. Error bars show SEM. 
130 
 
 
 
Figure 4.9: Neutrophil crawling displacement direction relative to blood flow in 
IL-1β-stimulated WT and ICAM-2 KO mice.  
Cremasteric confocal IVM of WT or ICAM-2 KO Lys-eGFP-ki mice stimulated with 
i.s. IL-1β (50 ng/mouse) for 2 hours. Various parameters relating to crawling 
dynamics were quantified using Imaris. (A) Diagram showing how neutrophil 
crawling displacement direction relative to blood flow was determined. Dotted lines 
show the regions which were classified as crawling with blood flow, perpendicular to 
blood flow and against blood flow. (B) The percentage of neutrophil crawling 
displacement direction that was in the direction of blood (red), perpendicular to 
blood flow (blue) or against blood flow (purple) was determined. N= 76-81 cells 
from 10 vessels, in 6-7 animals per group. Error bars show SEM. 
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4.2.5  Neutrophils exhibit two distinct types of crawling behaviour 
 
In ICAM-2 KO animals the mean neutrophil crawling speed was reduced, and in 
addition to this there was a greater variability in crawling speed of individual cells. 
The behaviour of individual cells was examined in more detail, and it was observed 
that while some cells exhibited continuous crawling behaviour, in that they were 
mobile for the full duration of tracking, other cells exhibited periods of immobility 
for at least 5 frames (2.5 minutes) during the observation period. These behaviours 
are now referred to as ‘continuous’ (Figure 4.10, Movie 5) and ‘discontinuous’ 
(Figure 4.11, Movie 6) crawling. Neutrophils were classified as exhibiting 
‘continuous’ crawling if they were mobile for the duration of the observation period.  
 
Examples of the speed of different neutrophil crawling behaviours (i.e. continuous or 
discontinuous) throughout their tracks are shown in Figure 4.12A. All crawling 
behaviours were highly variable with respect to speed throughout the duration of 
crawling. Whilst, the continuous crawling cells displayed generally high speeds, 
stationary neutrophils had speeds which remained below 2 μm/min throughout the 
duration of observation (Figure 4.12A). Stationary cells (or immobile cells) did not 
have a speed of 0 μm/min as these cells displayed very slight movements which were 
likely to be a result of shear flow of blood or due to small movements of the 
cremaster muscle itself. In contrast discontinuously crawling neutrophils exhibited 
speeds similar to that of continuously crawling cells however they also exhibited 
periods of immobility which had a speed comparable to that of stationary neutrophils 
(Figure 4.12A). The average duration of the periods of immobility in cells 
categorised as discontinuously crawling was 6.8 minutes, demonstrating that the 
definition of immobility (for 5 frames or 2.5 minutes or more) was a true 
characteristic and the strict categorisation of cells in terms of duration was not a 
restricting factor. On average there was approximately 2 periods of immobility in any 
discontinuously crawling cell, and during this period no evidence of EC junctional 
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disruption (pore formation), or neutrophil protrusions into EC junctions was evident. 
Crawling behaviour at junctional and non-junctional EC regions was determined in 
both continuously and discontinuously crawling neutrophils to understand these 
behaviours in more detail. The results indicated no differences in the crawling speed 
of neutrophils at EC junctional and at non-junctional regions. There was a significant 
reduction in the mean crawling speeds between continuous and discontinuous 
crawling irrespective of its location on EC (Figure 4.12B). The neutrophil crawling 
dynamics between these two behaviours in WT and ICAM-2 KO was subsequently 
analysed in more detail. 
 
 
Figure 4.10: Continuously crawling neutrophil in the venular lumen. 
Time sequence of neutrophil crawling in the cremasteric post-capillary venules from 
Lys-eGFP-ki mice as investigated by confocal IVM. High magnification images 
acquired at indicated time points illustrating the time course of a continuously 
crawling neutrophil as indicated by the asterisks. The blue line shows the entire 
crawling track and the white arrow shows the track displacement of the highlighted 
neutrophil. Scale bar represents 10 μm. (Movie 5). 
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Figure 4.11: Discontinuously crawling neutrophil in the venular lumen.  
Time sequence of neutrophil crawling in the cremasteric post-capillary venules from 
Lys-eGFP-ki mice as investigated by confocal IVM. High magnification images 
acquired at indicated time points illustrating the time course of a discontinuously 
crawling neutrophil as indicated by the asterisks. Time points which are followed by 
hash symbol represents the period of immobility. The blue line shows the entire 
crawling track and the black arrow shows the track displacement of the highlighted 
neutrophil. Scale bar represents 10 μm. (Movie 6). 
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Figure 4.12: Neutrophil crawling speed of individual cells.  
Cremasteric confocal IVM of WT Lys-eGFP-ki mice stimulated with i.s. IL-1β (50 
ng/mouse) for 2 hours. (A) The speed of an individual cell exhibiting continuous, 
discontinuous and stationary crawling behaviours over time. (B) The mean speed of 
continuous and discontinuous crawling cells when in contact with EC junctions and 
non-junctional regions. N = 76-81 cells from 10 vessels, in 6-7 animals per group. 
Error bars show SEM. Statistically significant (Anova) differences between 
respected behaviours continuous and discontinuous data are indicated by asterisks 
***P< 0.001.  
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4.2.6  Dynamic profile of continuously and discontinuously crawling neutrophils 
in WT and ICAM-2 KO mice  
 
Each crawling track from WT and ICAM-2 KO mice, following IL-1β stimulation, 
was classified as showing ‘continuous’ or ‘discontinuous’ crawling, and the 
frequency of each behaviour per venule was determined. In WT mice the majority of 
crawling cells showed continuous crawling (87.2 ± 5.6 %) (Figure 4.13), while in the 
ICAM-2 KO animals there was a shift towards discontinuous crawling (51.5 ± 8.8 
%) (Figure 4.13). This represents a 41.5 % reduction in continuous crawling (P< 
0.01, n=10) in ICAM-2 KO vessels. In order to further understand the differences 
between continuous and discontinuous crawling behaviours in more detail in the two 
mouse strains, the crawling dynamics were determined. Neutrophils exhibiting 
discontinuous crawling phenotype were found to have a significantly reduced 
crawling speed, high speed variation and an increased duration of luminal crawling 
in both WT and ICAM-2 KO animals (Figure 4.14). This group of cells also had a 
tendency towards a lower straightness score than continuously crawling cells in both 
mouse strains (Figure 4.15B). The differences seen are likely to be due to the 
immobile periods in discontinuously crawling cells where small movements within a 
restricted area was seen.  
 
Both groups contained some cells showing discontinuous crawling, and these cells 
had a mean reduction in crawling speed compared to the continuously crawling cells 
(Figure 4.14A). Although this behaviour was more frequently observed in the ICAM-
2 KO animals (Figure 4.13B), this did not however fully account for the overall 
reduction in crawling speed in ICAM-2 KO as compared to WTs (Figure 4.7A). This 
is because when comparing continuously crawling cells between the two mouse 
strains there was still a reduction in crawling speed in the ICAM-2 KO mice and a 
small reduction in crawling length (Figure 4.14A and C). Furthermore, there was also 
a trend towards a reduction in crawling displacement in discontinuous crawling WT 
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mice only, although this difference was not significant (Figure 4.15A) due to the very 
few discontinuously crawling cells noted in WT mice were seen.  
 
 
 
Figure 4.13: The frequency of continuously and discontinuously crawling 
neutrophils in IL-1β-stimulated WT and ICAM-2 KO venules.  
Cremasteric confocal IVM of WT or ICAM-2 KO Lys-eGFP-ki mice stimulated 
with i.s. IL-1β (50 ng/mouse) for 2 hours. The percentage of (A) continuously and 
(B) discontinuously crawling neutrophils per venule was quantified. N = 76-81 cells 
from 10 vessels, in 6-7 animals per group. Error bars show SEM. Statistically 
significant (T-test) differences between WT and ICAM-2 KO data are indicated by 
asterisks **P< 0.01. 
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Figure 4.14: Continuous and discontinuous crawling dynamics in IL-1β-
stimulated WT and ICAM-2 KO mice.  
Cremasteric confocal IVM of WT or ICAM-2 KO Lys-eGFP-ki mice stimulated 
with i.s. IL-1β (50 ng/mouse) for 2 hours. The mean total (A) speed (B) speed 
variability throughout the duration (speed standard deviation divided by the mean 
speed) (C) length (D) duration of crawling in WT and ICAM-2 KO venules was 
quantified. N = 76-81 cells from 10 vessels, in 6-7 animals per group. Error bars 
show SEM. Statistically significant (Anova) differences between continuous and 
discontinuous data are indicated by asterisks *P< 0.05, **P< 0.01, ***P< 0.001. 
Differences between WT and ICAM-2 KO mice are indicated with lines. 
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Figure 4.15: Continuous and discontinuous crawling displacement and 
straightness in IL-1β-stimulated WT and ICAM-2 KO mice.  
Cremasteric confocal IVM of WT or ICAM-2 KO Lys-eGFP-ki mice stimulated 
with i.s. IL-1β (50 ng/mouse) for 2 hours. The mean total (A) displacement (B) 
straightness of crawling in WT and ICAM-2 KO venules was quantified (for 
definitions see Figure 4.8). N = 76-81 cells from 10 vessels, in 6-7 animals per 
group. Error bars show SEM. 
 
4.2.7  Association of periods of immobility during discontinuous crawling with 
EC junctions  
 
To understand discontinuously crawling neutrophils in more detail the site of 
immobility during these periods were examined. As this behaviour was 
predominantly seen in ICAM-2 KO mice, and these mice also had a significant 
reduction in the number of neutrophils in the extravascular tissue, it was 
hypothesised that the periods of immobility seen in this type of crawling could reflect 
failed attempts of neutrophils to initiate TEM. Therefore the possibility that periods 
of immobility were associated with EC junctions was investigated.  
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To investigate this hypothesis the location of all periods of immobility in WT and 
ICAM-2 KO vessels was analysed and identified as being directly on top of a 
junction, partially in contact with a junction or not in contact with a junction (Figure 
4.16B and C). The location of normally adherent/crawling cells was also analysed at 
two time points using the first and last time frame of each confocal image sequences 
acquired (Figure 4.16).  
 
The percentage of immobility located directly on EC junctions, partially on EC 
junctions or at EC non-junction sites were analysed in IL-1β-stimulated venules from 
WT and ICAM-2 KO mice (Figure 4.17). The results showed that almost all 
immobile cells were in contact with a junction and more than 80% of these 
neutrophils were predominately found directly on top of EC junctions (Figure 4.17). 
Crawling/adherent cells within the same vessel were also predominately in contact 
with a junction however only 60% were directly on top of EC junctions (Figure 
4.17). More interestingly there was a significant difference between 
crawling/adherent cells and immobile cells classified as directly on EC junctions 
indicating that immobile cells had a greater association with EC junctions in 
comparison to that of adherent/crawling cells. No difference was seen between WT 
and ICAM-2 KO mice. 
 
In order to determine if these trends were an active association of normally crawling 
cells with junctions rather than a result of the morphology of the vessel wall (or 
distribution of endothelial junctions), in silico experiments were carried out. Using 
the same vessels the distribution of EC junctions were masked, and neutrophil sized 
spots were randomly distributed across the vessel (Figure 4.16D and E). The 
PECAM-1 labelling was then revealed and the location of the randomly placed spots 
was quantified in the same way. Using this system although approximately 90% of 
randomly allocated spots were in contact with the junction, only 32% of the spots 
were directly associated with a junction (Figure 4.17). The results overall showed an 
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increase in adherent/crawling cells and immobile cells associated directly with EC 
junctions compared to that of randomly placed spots suggesting that this association 
was not chance occurrence due to EC morphology. There was an increase in random 
cells which were partially on junctions therefore any association of cells classified as 
‘partially’ on EC junction was due to EC morphology. Together, the data indicates 
that the association of adhesion and to a greater extent the periods of immobility in 
discontinuous crawling neutrophils is associated with neutrophils being positioned 
directly on top of EC junctions regardless of the EC morphology. 
 
Collectively, the data presented in this chapter show that in the absence of functional 
ICAM-2 there is a reduction in both crawling continuity and speed, and an increase 
in speed variation and duration after IL-1β stimulation. Therefore, ICAM-2 supports 
the efficient crawling of neutrophils in IL-1β-induced inflammation. Furthermore 
periods of immobility that occurred during discontinuous crawling appeared to be 
directly associated with EC junctions. It is therefore possible that as discontinuous 
crawling occurs more frequently in stimulated ICAM-2 KO mice, ICAM-2 may also 
have additional roles in the opening of EC junctions.   
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Figure 4.16: Analysing the association of the period of immobility in 
discontinuous crawling behaviour with EC junctions.  
An example confocal image of the cremasteric post-capillary venule from Lys-
eGFP-ki mice. High magnification images illustrate the analysis of association of 
neutrophil adhesion and the periods of immobility in discontinuous crawling with 
EC junctions. (A) Example of an inflamed venule exhibiting PECAM-1 (red) and 
Lys-eGFP/neutrophils (green). The location of the crawling neutrophils in relation 
to EC junctions was quantified at two time points. (B)  Examples of neutrophils 
directly and (C) partially in contact with EC junctions. (D) An isosurface was 
created on the vessel in order to mask the location of EC junctions, and 10 
simulated cells (blue dots) were randomly placed on the vessel. (E) The isosurface 
was removed, and the location of the simulated cells was quantified.  
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Figure 4.17: Association of periods of immobility in discontinuous crawling 
behaviour with EC junctions.  
The percentage of cells and 10 random spots directly and partially associated with 
EC junctions per venule in IL-1β-stimulated WT and ICAM-2 KO mice. The 
location of the crawling/adherent neutrophils in relation to EC junctions was 
quantified at two time points. N = 10 vessels in 6-7 animals per group. Error bars 
show SEM. Statistically significant differences from respective random group is 
indicated by asterisks *P< 0.05, **P< 0.01, ***P< 0.001. Differences between 
crawling/adherent cells and immobile cells are indicated with lines. 
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4.3  Discussion 
 
The role of endothelial proteins in leukocyte extravasation has been the subject of 
intense study for many years, but many details of the molecular mechanisms 
supporting extravasation remain unknown. Whilst the contribution of ICAM-2 is one 
of the more neglected areas in this field, it has been shown to be involved in 
neutrophil extravasation at a stage after the initial adhesion of cells to the vessel wall 
(Huang et al., 2006; Woodfin et al., 2009). Previous studies of fixed tissues have also 
identified sequential and non-redundant roles for ICAM-2, JAM-A and PECAM-1 
during paracellular migration (Woodfin et al., 2009). The work presented in this 
chapter has employed a recently developed in vivo confocal imaging system 
(Woodfin et al., 2011) in order to investigate the role of ICAM-2 in the dynamics of 
neutrophil extravasation in greater detail. As expected in unstimulated conditions 
only a few neutrophils were present in both WT and ICAM-2 KO mice. Under basal 
conditions the very few cells that did adhere and exhibit crawling displayed no 
dynamic differences between WT and ICAM-2 KO mice in terms of crawling speed, 
duration and length. Further analysis into the role of ICAM-2 in crawling dynamics 
was therefore carried out in IL-1β-stimulated tissues. 
 
A significant increase in neutrophil adhesion was detected after IL-1β stimulation, 
hence a higher number of crawling events were able to be tracked and analysed. 
Almost all luminally adherent neutrophils exhibited some crawling, with a small 
reduction in the percentage of crawling cells in ICAM-2 KO mice. This latter 
reduction is in contrast to previously published findings (Phillipson et al., 2006) and 
this difference is likely to be a result of variations in the inflammatory stimuli, 
definition of non-crawling cells and/or imaging system employed. Alternatively it 
could be possible that in the present study the adherent or stationary neutrophils 
observed could be crawling in a discontinuous manner, with long stationary periods 
that lasts the whole period of observation.  
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A number of parameters relating to neutrophil crawling dynamics were quantified in 
WT and ICAM-2 KO animals after IL-1β stimulation. A significant reduction in 
crawling speed was observed in the ICAM-2 KO vessels, while the variability of 
crawling speed of individual cells was increased. The duration of observed crawling 
was also increased in the ICAM-2 KOs, although it is important to remember that 
this value refers to the duration of crawling observed within approximately 30 
minute imaging period, not the absolute duration of crawling between initial 
adhesion and TEM or detachment of neutrophils from the luminal EC back into the 
blood circulation. Furthermore the following parameters relate to a time for which 
each cell was observed during a limited 30-40 minute observation period, and within 
an approximately 300 µm long vessel segment in the field of view. In many cases 
cells which were already adherent at the beginning of observation were still 
exhibiting luminal crawling at the end of the observation period, or simply crawled 
out of the field of view, and as such their ultimate fate was undetermined. 
 
The small increase in the number of stationary neutrophils, the reduction in crawling 
speed and the increased variability in the crawling speed in the ICAM-2 KO vessels 
prompted further investigations of the behaviour of individual cells. It was observed 
that some cells had a discontinuous crawling pattern, with periods of immobility. The 
frequency of continuously and discontinuously crawling cells was quantified in each 
genotype. In WT animals ~90% of crawling cells exhibited a continuous crawling 
behaviour, but in the ICAM-2 KO animals there was a shift towards a more 
discontinuous crawling phenotype (~50%). In both genotypes the continuously 
crawling cells had a shorter duration of crawling. The increased frequency of 
discontinuous crawling only partially accounts for the overall reduction in mean 
crawling speed in the ICAM-2 KOs, as even within the continuously crawling 
populations there was a significant reduction in speed in the ICAM-2 deficient 
animals, indicating that ICAM-2 supports both the speed and continuity of crawling. 
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The mechanisms by which ICAM-2 supports neutrophil crawling speed and 
continuity are currently unknown, although ICAM-2 has also previously been 
implicated in the luminal locomotion of T cells (Steiner et al., 2010) and monocytes 
(Schenkel et al., 2004). With respect to T cells, continuous crawling has been 
demonstrated on primary mouse brain microvascular ECs (pMBMECs), where it was 
found that a majority of cells exhibited continuous crawling with only a small 
proportion showing stationary behaviour (Steiner et al. 2010). This is in line with the 
crawling behaviours noted for neutrophils in the present in vivo study. In the same 
study, discontinuous crawling of T cells which was termed ‘recurrent arrest’ was 
observed. This behaviour was evident only when both ICAM-1 and ICAM-2 were 
genetically deleted, which differs from the current study on neutrophils. This 
highlights that different subsets of leukocytes employ different EC junctional 
proteins during the crawling stage. It should be noted however that no information on 
the dynamics of ‘recurrent arrest’ was documented and so it is not clear as to whether 
‘recurrent arrest’ behaviour is similar to the discontinuous crawling reported in this 
study. 
 
Discontinuous type of crawling occurred for longer time periods at a reduced mean 
speed which was highly variable. There was on average 2 periods of immobility 
which lasted 6.8 minutes. This strengthens the criteria used for defining neutrophil 
discontinuous crawling (immobility for at least 5 frames which represents 2.5 
minutes). The location at which discontinuously crawling cells exhibited periods of 
immobility was investigated, and compared to a random selection of other 
adherent/crawling cells within the same vessels at a fixed time point, and with 
randomly placed simulated cells. The periods of immobility were found to occur 
directly at EC junctions (80%) indicating that these neutrophils may have been trying 
to transmigrate through these sites and when they are unable to do so they resume 
crawling. The high frequency of adherent/crawling cells which were found 
associated with junctions is in line with previous reports (Wojciechowski, 2005), 
although this earlier work did not differentiate between cells which were directly on 
top of a junction from those which had partial contact. It is therefore possible that the 
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immobile cells were at a stage where they were unable to undergo transmigration. 
However no evidence of junctional disruption or neutrophil protrusions was seen and 
as neutrophils undergo TEM quite rapidly once they are at a ‘permissive’ EC 
junction it is possible that a defect in the opening of EC junctions and/or guidance to 
EC junctions may have occurred under these circumstances. 
 
Further studies are required to establish the fate of discontinuously crawling 
neutrophils in our model. It is possible that neutrophils that crawl in a discontinuous 
manner detach from the EC and go back into the blood circulation thereby resulting 
in a reduction in TEM and therefore a reduction in neutrophils in the extravascular 
tissue. There is however an in vitro study that has shown a greater detachment of 
leukocytes on immobilised ICAM-2 (Steiner et al., 2010) although this study was 
carried out with T cells and therefore generalisation of responses from one leukocyte 
subset to another should be avoided due to their different functions (Sumagin et al. 
2010).  It is also possible that when ICAM-2 is not functional, TEM could occur at a 
later time point. 
 
ICAM-2 has the ability to form homophillic interactions in trans (Huang et al., 2005) 
however in Chapter 3 ICAM-2 was shown to be expressed by only a small 
percentage of neutrophils at lower levels in comparison to other leukocyte subsets 
investigated and to a far greater extent the vascular ECs. Whilst not conclusive, the 
data suggests that neutrophil ICAM-2 is unlikely to support the functions reported in 
the present study. The role of EC ICAM-2 is likely to be mediated by ligation of a 
leukocyte ligand, subsequent outside-in signalling, and the activation/stabilisation of 
leukocyte locomotive machinery via pathways involving Rac, Cdc42 and 
WAVE/WASP. The current literature provides evidence for the ability of ICAM-2 to 
bind to key leukocyte integrins LFA-1, MAC-1 and VLA-4 (Li et al., 1993; Seth et 
al., 1991; Staunton et al., 1989; Xie et al., 1995) and some of these integrins are well 
known to be involved in luminal leukocyte crawling (Phillipson et al., 2006; 
Sumagin et al., 2010). Although the involvement of integrins is generally thought to 
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be mediated via their interaction with ICAM-1, it is well documented that ICAM-2 
can interact with β2-integrins and these interactions could also mediate the crawling 
process. Of relevance to the current study, the role of EC ICAM-2 in neutrophil 
migration has been suggested to occur via neutrophil LFA-1 (Issekutz et al., 1999). 
The function of ICAM-2 in this context was however only evident when ICAM-1 
was also blocked, where an additive inhibitory effect on neutrophil migration was 
seen when both proteins were functionally blocked relative to ICAM-1 blockade 
alone. This study was carried out using an in vitro HUVECs model, and any 
differences in the role of ICAM-2 with that presented in the current chapter could be 
a result of different experimental models used.  
 
It is possible that ICAM-2 has two distinct roles in neutrophil extravasation as it is 
expressed on the EC non-junctional and junctional sites. EC non-junctional ICAM-2 
is involved in the ‘efficient’ continuity of crawling whereas EC junctional ICAM-2 
could be associated with the opening of EC junctions. Neutrophil ligands and the 
ability of ICAM-2 to regulate TEM and EC junctional pore opening (which maybe 
occurring during the periods of immobility in discontinuous crawling cells) will be 
further investigated in subsequent chapters. 
 
In summary although ICAM-2 does not have important roles in the frequency of 
initial adhesion and crawling of neutrophils, it has a significant impact on the speed, 
duration and continuity of crawling in IL-1β-stimulated inflammation in the mouse 
cremaster muscle. The high frequency of discontinuous crawling behaviour in 
stimulated ICAM-2 KO mice could be a result of a defect in the opening of EC 
junctions and/or guidance to sites permissive for transmigration. These findings 
extend previous works on the functional role of ICAM-2 by dissecting the precise 
stage at which it mediates neutrophil extravasation in vivo. Further studies are 
required to establish whether ICAM-2 has a role in neutrophil TEM and understand 
the leukocyte ligands with which it interacts. 
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CHAPTER 5: Role of ICAM-2 in neutrophil 
transendothelial migration 
 
5.1  Introduction 
 
Previously presented data has demonstrated a luminal expression of ICAM-2 in post-
capillary venules in two different vascular beds (Chapter 3). This expression pattern 
has been linked to the efficient crawling of neutrophils within the lumen in IL-1β-
stimulated inflammation (Chapter 4). It is therefore believed that efficient crawling 
facilitates effective neutrophil extravasation by enabling cells to locomote to sites 
permissive for TEM. ICAM-2 is also however expressed within EC junctions, and is 
generally considered to be a junctional molecule, so a possible role for this protein in 
supporting TEM directly was investigated as part of the current chapter.  
 
Studies by Steiner et al., (2010) found that the lack of endothelial ICAM-1 and 
ICAM-2 reduced T cell TEM across the mouse BBB (pMBMECs) in vitro to a 
greater extent than conditions where ICAM-1 function alone was inhibited. 
Interestingly no effect on TEM was evident in this model when ICAM-2 function 
alone was impaired, suggesting a synergistic role for these ICAMs in diapedesis of T 
cells. Numerous other studies have however found a role for ICAM-2 in 
extravasation of neutrophils (Hobden, 2003; Huang et al., 2006; Issekutz et al., 1999; 
Woodfin et al., 2009), eosinophils (Gerwin et al., 1999), monocytes (Schenkel et al., 
2004), and dendritic cells (Geijtenbeek et al., 2000; Helander et al., 1996; Wethmar 
et al., 2006) however whether it has a role in TEM directly is unknown. Earlier work 
within our group has shown that in IL-1β-stimulated whole mount cremaster 
muscles, neutrophil TEM occurs through JAM-A interactions at the level of the EC 
and PECAM-1 interactions at the level of the basement membrane (Woodfin et al., 
2009). In relation to this ICAM-2 interactions were suggested to play a role at an 
earlier stage than JAM-A at the level of the EC lumen before entering the EC 
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junction as investigated by fixed tissue confocal analysis. The work presented in the 
current chapter aims to extend these findings by analysing the role of ICAM-2 in the 
dynamics of neutrophil TEM using real time, high resolution confocal IVM imaging.  
 
In Chapter 4 two distinct types of neutrophil crawling behaviour in response to IL-1β 
were quantified. These behaviours were termed continuous crawling which was 
predominantly found in WT mice, and discontinuous crawling which was more 
frequently observed in ICAM-2 KO mice. As the periods of immobility in 
discontinuous crawling were primarily located directly on EC junctions (Chapter 4), 
it was hypothesised that these immobile periods could represent failed attempts to 
initiate neutrophil TEM. Analysis of TEM dynamics in the present chapter may also 
provide further insights into this hypothesis. 
 
 
5.2  Results 
 
5.2.1  IL-1β-stimulated ICAM-2 KO mice display a reduction in neutrophil 
TEM 
 
In addition to the EC non-junctional expression, ICAM-2 is also expressed at EC 
junctions however the role of ICAM-2 at stages prior to TEM and TEM itself has not 
been investigated directly. The dynamics of neutrophil TEM in ICAM-2 KO mice 
was therefore examined to further understand the role of ICAM-2 in neutrophil 
extravasation. In the current study the location and dynamics of TEM was examined 
using 4D confocal IVM of IL-1β-stimulated cremaster muscles from WT and ICAM-
2 KO mice, which expressed endogenous eGFP in their neutrophils. EC junctions 
were labelled with fluorescent non-function blocking anti-PECAM-1 mAb in order 
to visualise neutrophil EC junctional interactions as previously described (Chapter 
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2). Images of venules were captured over a 30-40 minute period and sequences of 
these images were reconstructed into 3D models of half venules using Imaris 
software. This technique allowed direct visualisation of TEM events in real time and 
the number of TEM events per 30 minutes per venule were quantified. TEM events 
were classified as neutrophils migrating through the EC layer from the luminal to the 
abluminal side and in most cases clear neutrophil protrusions into the EC layer and 
formation of EC junctional pores was evident (Movies 3, 7, 8, 9). The results showed 
that ICAM-2 KO mice had a significant reduction in the frequency of TEM (5.5 ± 
2.1 TEM events, per 30 minutes, per venule, n=12 vessels from 6 mice) in 
comparison to WTs (22.18 ± 4.6 events, per 30 minutes, per venule, n=10 vessels 
from 7 mice) (Figure 5.1A). This was in line with results from Chapter 4 (Figure 4.1) 
where neutrophil extravasation was significantly reduced in ICAM-2 KO mice 4 
hours after IL-1β. Furthermore, as several neutrophils were observed to sequentially 
transmigrate through the same EC junctional pore, the frequency of pore formation 
per 30 minutes per venule was also quantified. In WT mice 15.6 ± 3.3 EC junctional 
pores (per 30 min, per venule) was observed, suggesting that a small proportion of 
neutrophils observed do follow other neutrophils and use pre-existing pores to 
transmigrate. Significantly fewer EC junctional pores (4.7 ± 1.8 pores per 30 min, 
per venule) were detected in ICAM-2 KO mice (Figures 5.1B) compared to WTs 
(15.6 ± 3.3 pores). 
 
The route of neutrophil TEM was also quantified and each event was defined as 
following a paracellular (Movies 7 and 8) or transcellular (Movie 9) non-junctional 
route (Figure 5.2). In both WT and ICAM-2 KO mice more than 90% of neutrophil 
TEM events occurred via the paracellular route (Figure 5.3). Of these events there 
was an equal prevalence of bicellular TEM (TEM through the junction between 2 
adjacent ECs, Movie 7) and multicellular TEM (TEM through the junction between 3 
or more ECs, Movie 8) in both groups (Figures 5.4 and 5.5). Collectively ICAM-2 
deficiency reduces the number of neutrophil TEM events whilst the number of 
adherent and crawling cells within the vessel remains normal. However, no 
significant differences were observed in relation to the route of TEM. 
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Figure 5.1: Frequency of IL-1β-stimulated TEM events in ICAM-2 KO and WT 
mice.  
Cremasteric confocal IVM of WT or ICAM-2 KO Lys-eGFP-ki mice stimulated with 
i.s. IL-1β (50 ng/mouse) for 2 hours. (A) The frequency at which cells were seen to 
progress to TEM following IL-1β-stimulation was quantified and is shown as the 
frequency per 30 minutes, the standard period of observation, per venule. (B) The 
frequency at which neutrophils were seen to produce transient EC pores as a 
consequence of TEM was also quantified per 30 minutes (per venule). Bars represent 
mean ± SEM per venule (n = 10 vessels from 6-7 mice per group). Statistically 
significant (T-test) differences between WT and ICAM-2 KO data are indicated by 
asterisks **P< 0.01. (Movies 3, 7, 8, 9). 
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Figure 5.2: Paracellular and transcellular neutrophil TEM as viewed by 4D 
confocal IVM.  
Representative images of cremasteric post-capillary venules from Lys-eGFP-ki mice 
(neutrophils; green). High magnification images illustrating neutrophil (A) 
paracellular (Movies 7 and 8) and (B) transcellular TEM (Movie 9). Individual 
neutrophil TEM events were tracked and classified as paracellular or transcellular 
TEM in relation to the location of EC pores (i.e. junctional or non-junctional) 
(PECAM-1; red). Blue circle indicates the region where the neutrophil breaches the 
endothelium. Lower panels show the PECAM-1 channel only. 
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Figure 5.3: IL-1β-stimulated paracellular and transcellular TEM in ICAM-2 
KO and WT mice. 
Cremasteric confocal IVM of WT or ICAM-2 KO Lys-eGFP-ki mice stimulated with 
i.s. IL-1β (50 ng/mouse) for 2 hours. (A) The frequency at which cells were seen to 
progress to paracellular or transcellular TEM in each venule was quantified per 30 
minutes, the standard period of observation. (B) The percentage of paracellular or 
transcellular TEM events per venule. Bars represent mean ± SEM where n = 10 
vessels from 6-7 mice per group. Statistically significant (Anova) differences 
between paracellular and transcellular data are indicated by asterisks **P< 0.01, 
***P <0.001. Differences between WT and ICAM-2 KO mice are indicated with 
lines. 
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Figure 5.4: Multicellular and bicellular neutrophil TEM as viewed by 4D 
confocal IVM.  
Representative images of cremasteric post-capillary venules from Lys-eGFP-ki mice 
(neutrophils; green). High magnification images illustrating neutrophil (A) 
multicellular (Movie 8) and (B) bicellular (Movie 7) TEM. Individual neutrophil 
TEM events were tracked and classified as multicellular or bicellular TEM  in 
relation to the location of EC pores (i.e. junctional or non-junctional) (PECAM-1; 
red). Blue circle indicates the region where the neutrophil breaches the endothelium. 
Lower panels show the PECAM-1 channel only. 
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Figure 5.5: IL-1β-stimulated multicellular and bicellular TEM in ICAM-2 KO 
and WT mice. 
Cremasteric confocal IVM of WT or ICAM-2 KO Lys-eGFP-ki mice stimulated with 
i.s. IL-1β (50 ng/mouse) for 2 hours. (A) The frequency at which cells were seen to 
progress to multicellular or bicellular TEM in each venule was quantified per 30 
minutes, the standard period of observation. (B) The percentage of multicellular or 
bicellular TEM events per venule. Bars represent mean ± SEM where n = 10 vessels 
from 6-7 mice per group. Statistically significant (Anova) differences between 
multicellular or bicellular data are indicated by asterisks *P< 0.05, **P <0.01. 
Differences between WT and ICAM-2 KO mice are indicated with lines. 
 
5.2.2  Continuously crawling neutrophils support TEM 
 
Previous studies have identified different crawling characteristics depending on the 
presence of functional ICAM-2 (Chapter 4) namely, continuous and discontinuous 
neutrophil crawling. In order to understand the impact of continuous and 
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discontinuous crawling on TEM, the events leading up to neutrophil TEM and TEM 
itself were divided into 3 stages (Figure 5.6A). These stages were, neutrophil 
crawling that was preceded by observed TEM (stage i), the stage at which 
neutrophils were in contact with EC junctions before being breached (pre-TEM, 
stage ii) and TEM through EC junctions (stage iii). While the previous analysis of 
crawling dynamics looked at all luminal crawling cells (Chapter 4), the data here 
looks only at the crawling behaviour of cells which were seen to progress to TEM 
(stage i) in isolation from all other crawling cells. When the crawling behaviour of 
cells which were observed to undergo TEM was examined, 80-90% of this neutrophil 
population crawled in a continuous rather than discontinuous fashion, and this was 
irrespective of ICAM-2 deficiency (Figure 5.6B). This suggests that continuously 
crawling cells, which form the majority in WT vessels, transmigrate more frequently 
than discontinuously crawling cells. The latter crawling behaviour were more 
prevalent in the ICAM-2 KO mice (Chapter 4) where a reduction in TEM events 
were also seen (Figure 5.1). In the KO mice, neutrophil crawling behaviour 
preceding TEM also had a significantly reduced crawling speed (8.2 ± 0.8 µm/mins, 
n=34 for WTs vs 5.2 ± 0.5 µm/mins, n=20 for ICAM-2 KOs) and a longer duration 
of crawling (7.1 ± 1.5 mins, n=34 cells for KOs vs 3.3 ± 0.4 mins, n=20 cells for 
WTs) in comparison to WT mice (Figure 5.6C). This was in line with previous 
crawling dynamics data (Chapter 4, Figure 4.8) which was acquired irrespective of 
the outcome of neutrophil crawling (i.e. whether the neutrophils subsequently de-
adhered and returned back into the circulation or progressed to TEM).  
 
The dynamics of the continuous and discontinuous crawling behaviours were also in 
line with previous data (Chapter 4, Figure 4.15). In WT mice continuously crawling 
neutrophils to EC junctions had an increase in crawling speed and a trend for a 
decrease in speed variability and duration when compared to discontinuously 
crawling cells (Figure 5.7). These characteristics were similar in both WT and 
ICAM-2 KO mice however, as expected (based on data from Chapter 4, Figure 4.15), 
continuous crawling speed was significantly reduced in ICAM-2 KO animals in 
comparison to WTs (Figure 5.7). The duration of crawling was however significantly 
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increased in discontinuous crawling cells in ICAM-2 KO mice when compared to 
WTs (Figure 5.7) which is in contrast to previous data where no difference was 
detected (Chapter 4, Figure 4.15). The reason for this difference is currently unclear 
however the small number of cells which were observed to crawl and undergo TEM 
could account for this variation. In line with previous data in Chapter 4, no 
differences were detected in displacement and straightness parameters between 
continuous or discontinuous crawling cells or between WT and ICAM-2 KOs (Figure 
5.8). Together the results obtained regarding the dynamics of neutrophil crawling 
preceeding TEM, is in general, in line with neutrophil crawling data from Chapter 4, 
where all observable crawling behaviour was analysed regardless of whether they 
progressed to TEM or not. Most importantly continuous crawling neutrophils 
appeared to progress to TEM more efficiently regardless of genotype and as ICAM-2 
KOs have fewer continuously crawling cells this could account for the overall 
reduction in extravasation seen in these mice. 
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Figure 5.6: Neutrophil crawling behaviors preceding TEM in IL-1β-stimulated 
cremaster muscles from ICAM-2 KO and WT mice.  
Cremasteric confocal IVM of WT or ICAM-2 KO Lys-eGFP-ki mice stimulated with 
IL-1β (50 ng/mouse, i.s.) for 2 hours. (A) The sequence of events from neutrophil 
crawling through to completion of TEM was divided into three stages as illustrated. 
(i) Crawling: the period for which a neutrophil is seen to crawl within the lumen prior 
to reaching it’s site of TEM. (ii) Pre-TEM: the period for which a neutrophil is 
interacting with the endothelial junction at it’s TEM location prior to any visible 
disruption of the junctional integrity. (iii) TEM: the period for which the first visible 
disruption of junctional PECAM-1 to the completion of migration to the sub-
endothelial space. (B) The crawling behaviors preceding TEM (stage i) were 
analysed in isolation and neutrophil crawling behavior (C) duration and speed was 
determined (n = 10 vessels from 6-7 mice per group). Data were obtained from 
analysis of 14-34 cells observed at stage i. Bars represent mean ± SEM for all events 
analysed. Statistically significant (T-test) differences between continuous and 
disrupted crawling data are indicated by asterisks **P <0.01, ***P <0.001. 
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Figure 5.7: Neutrophil continuous and discontinuous crawling dynamics 
preceding TEM in IL-1β-stimulated cremaster muscles from ICAM-2 KO and 
WT mice.  
Cremasteric confocal IVM of WT or ICAM-2 KO Lys-eGFP-ki mice stimulated with 
IL-1β (50 ng/mouse, i.s.) for 2 hours. The crawling behavior preceding TEM (stage i) 
were analysed in isolation and the dynamics of neutrophil continuous and 
discontinuous crawling behavior was determined. The mean total speed, speed 
variability, length and duration of crawling in WT and ICAM-2 KO venules was 
quantified. Data were obtained from analysis of 14-34 cells observed at stage i. Bars 
represent mean ± SEM for all events analysed. Statistically significant (Anova) 
differences between continuous and disrupted crawling data are indicated by asterisks 
*P <0.05, **P <0.01. Differences between WT and ICAM-2 KO mice are indicated 
by lines. 
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Figure 5.8: Displacement and straightness of crawling preceding TEM in IL-1β-
stimulated cremaster muscles from ICAM-2 KO and WT mice.  
Cremasteric confocal IVM of WT or ICAM-2 KO Lys-eGFP-ki mice stimulated with 
IL-1β (50 ng/mouse, i.s.) for 2 hours. The crawling behaviors preceding TEM (stage 
i) were analysed in isolation and the dynamics of neutrophil continuous and 
discontinuous crawling behavior was determined. The mean total displacement and 
straightness of crawling in WT and ICAM-2 KO venules was quantified. Data were 
obtained from analysis of 14-34 cells observed at stage i. Bars represent mean ± SEM 
for all events analysed. 
 
5.2.3  ICAM-2 facilitates the initiation of TEM 
 
The results from Chapter 4 suggested that discontinuous neutrophil crawling occurs 
more frequently in ICAM-2 KOs, and the periods of immobility in this type of 
crawling were associated with EC junctions, and this was not due to EC morphology. 
From this data it was hypothesised that the periods of immobility could be due to 
neutrophils failing to undergo TEM. Of note no EC pore formation or neutrophil 
protrusions into the EC junctions were observed during these periods. Taking this 
into account together with the fact that ICAM-2 KO mice stimulated with IL-1β 
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displayed a significant reduction in TEM events, it is possible that ICAM-2 plays a 
key role in TEM directly. However as previous data in this chapter has shown no 
effect of ICAM-2 deficiency on the mode of TEM with respect to transcellular, 
paracellular, multicellular and bicellular TEM, other TEM dynamics were 
investigated using the same technique. 
 
The process of TEM was further categorised into ‘pre-TEM’ and TEM (Figure 
5.9A). In stimulated ICAM-2 KO mice, only a few cells were observed to undergo 
TEM and these cells exhibited a different dynamic profile to that displayed by 
stimulated WTs. This difference was found once neutrophils were in contact with EC 
junctions that were later breached (i.e. pre-TEM). ICAM-2 KO mice exhibited a 
significantly prolonged duration of pre-TEM in comparison to WTs (3.2 ± 0.3 
minutes, n=30 cells for ICAM-2 KO mice and 1.1 ± 0.1 minutes, n=76 cells for WT 
mice) (Figure 5.9B). Interestingly no difference in the duration of TEM was detected, 
which was approximately 6 minutes in both mouse strains (Figure 5.9C). In 
conclusion ICAM-2 was found to have a key role in supporting the initiation of 
TEM, a process which may account for the periods of immobility in discontinuous 
crawling cells, a phenomenon displayed more frequently in stimulated ICAM-2 KO 
mice. 
 
The findings presented in the current chapter demonstrates that ICAM-2 KO mice 
exhibited reduced TEM events in response to IL-1β. Further studies indicated that 
this could be due to the high frequency of discontinuous crawling cells observed in 
ICAM-2 KO mice which are unable to support TEM. ICAM-2 was found to have a 
direct role in the initiation of TEM and this strengthens the possibility that the 
periods of immobility during discontinuous crawling could reflect the inability of 
neutrophils-EC junctional interactions to initiate TEM.  
162 
 
 
Figure 5.9: Neutrophil TEM dynamics in IL-1β-stimulated cremaster muscles 
from ICAM-2 KO and WT mice.  
Cremasteric confocal IVM of WT or ICAM-2 KO Lys-eGFP-ki mice stimulated with 
IL-1β (50 ng/mouse, i.s.) for 2 hours. (A) The sequence of events from neutrophil 
crawling through to completion of TEM was divided into three stages as illustrated. 
Neutrophil crawling preceding TEM (i), Pre-TEM (ii) and TEM (iii). (B) The mean 
duration of pre-TEM (ii) and (C) TEM (iii) was determined in both mouse strains. 
Data were obtained from analysis of 23-76 cells observed at stage ii, and 20-99 cells 
as observed at stage iii. Bars represent mean ± SEM for all events analysed. 
Statistically significant (T-test) differences between WT and ICAM-2 KO data is 
indicated by asterisks ***P <0.001. 
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5.3  Discussion 
 
The expression and role of ICAM-2 has previously been found to be distinct to that 
of well-known EC junctional proteins involved in neutrophil TEM (PECAM-1 and 
JAM-A) (Woodfin et al., 2009). Whist the high luminal ICAM-2 expression was 
found to be involved in mediating neutrophil crawling speed and continuity, the role 
of EC junctional ICAM-2 has been linked to the luminal stages of TEM (Woodfin et 
al., 2009) however the full mechanisms are still unclear. Additionally ICAM-2 KO 
mice stimulated with IL-1β displayed a high frequency of discontinuous crawling 
behaviour which had distinct periods of immobility occurring directly on EC 
junctions (Chapter 4). Based on these findings it was hypothesised that ICAM-2 may 
have a role in supporting the opening of EC junctions during TEM and therefore the 
dynamics of neutrophil TEM was examined in more detail in the present chapter.  
 
The route of neutrophil TEM through the EC layer was initially investigated. The 
frequency at which observed neutrophil TEM events and the formation of EC 
junctional pores was substantially reduced in stimulated ICAM-2 KO mice, and it is 
clear that the comparable numbers of adherent and crawling neutrophils were failing 
to progress to TEM in these mice. In both genotypes the majority (>90%) of TEM 
events followed the paracellular route and there was no preference for TEM events to 
occur at multicellular or at bicellular junctions in straight vessels which was in line 
with previous studies (Sumagin and Sarelius, 2010; Woodfin et al., 2011). These 
TEM sites were shown to be more prone to TEM due to the enrichment of ICAM-1 
which may also increase the likelihood of neutrophil-EC interactions. The TEM 
events observed in the current study were predominately luminal to abluminal 
direction and no evidence of  ‘disrupted’ TEM consisting of reverse (abluminal to 
luminal) migration, or disrupted oscillatory movements within the junction was seen 
(Woodfin et al., 2011).  
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The process of TEM was divided into several stages for further analysis. Neutrophil 
crawling behaviour which preceded TEM was initially examined in isolation from 
other crawling cells in both genotypes. Due to the limitations of this imaging system 
only a small portion of total neutrophil crawling events were observed to undergo 
TEM irrespective of mouse strain. However the majority of cells which were 
observed to successfully progress to TEM had previously crawled in a continuous 
manner, suggesting that efficient crawling is necessary for the migration to, and/or 
identification of, sites permissive for TEM. Various crawling dynamics were also 
analysed in order to fully understand the crawling behaviour prior to TEM, and the 
results were comparable to the crawling events analysed in Chapter 4 where the 
neutrophil fate was unknown (i.e. whether they transmigrated or not). More 
specifically neutrophil crawling that preceded the few cells that transmigrated in 
ICAM-2 KO vessels crawled for a longer time with a reduced speed. Neutrophil 
continuous and discontinuous crawling speed and speed variability was also in line 
with previous data in both mouse strains (Chapter 4). There was however a trend for 
discontinuously crawling neutrophils in ICAM-2 KO mice to crawl longer distances 
over a prolonged time period. The reason for this difference in crawling dynamics of 
all neutrophils (irrespective to fate) with that of neutrophils which were observed to 
undergo transmigration is unknown but this could be due to fewer cells being 
observed to crawl and undergo TEM irrespective of mouse strain. The low 
observable events are likely to be due to the combination of a short time frame and 
the small field of view (i.e. small section of the cremasteric vasculature) used for 
analysing neutrophil migration dynamics in this model. Overall these results do 
however strengthen the data obtained in Chapter 4 where crawling dynamics were 
analysed irrespective of whether they transmigrated through the EC layer.  
 
Although the cause of discontinuous crawling seen in ICAM-2 KO mice is unclear it 
is possible that these events are mediated by the impairment of outside-in integrin 
signalling caused by the lack of ICAM-2 binding. ICAM-2 interactions with LFA-1 
(Staunton et al., 1989) and MAC-1 (Xie et al., 1995) has been reported. Of relevance 
to the current study, the role of EC ICAM-2 in neutrophil migration has been 
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suggested to occur via neutrophil LFA-1 (Issekutz et al., 1999). The role of ICAM-2 
in this context was however only evident when ICAM-1 was also blocked where an 
additional inhibitory effect was seen relative to ICAM-1 blockade alone. This study 
was carried out using an in vitro HUVECs model, and any differences in the role of 
ICAM-2 with that presented in the current chapter could be a result of different 
experimental models used. It is very likely that integrins which are heavily 
implicated in leukocyte polarisation and crawling (Ridley, 2003) are involved in 
facilitating the role of ICAM-2 as demonstrated in the present chapter. Specifically 
integrins are implicated in regulating neutrophil polarity through supporting various 
signalling pathways linked to Rac, Cdc42 and WAVE/WASP which alter leukocyte 
locomotive machinery and thus supporting neutrophil crawling (Ridley, 2003).    
 
Within the ICAM-2 KO vessels those cells which did progress to TEM showed 
significantly prolonged crawling within the lumen before reaching the location of 
TEM, and exhibited almost a fourfold increase in the time spent interacting with the 
EC junctions before initiating TEM (pre-TEM). This data supports previous findings 
from fixed tissue analysis which showed the lack of ICAM-2 leading to arrested cells 
on the luminal surface of ECs (Woodfin et al., 2009). Collectively these findings 
indicate that in addition to a role in supporting luminal crawling efficiency, ICAM-2 
is also important in the identification of TEM sites and/or the initiation of TEM 
(opening of the junction). Interestingly however once TEM had been initiated no 
difference in the duration of TEM itself was detected, indicating that other junctional 
proteins such as JAM-A, PECAM-1, JAM-C, ESAM, CD99 and/or  CD99L2 may 
support later stages of TEM.   
 
A key aspect of the analysis of TEM in the absence of functional ICAM-2 was that 
there was a pronounced reduction in the number of TEM events initiated, identified 
by both observations of transmigrating cells and the formation of a paracellular 
pores. In the ICAM-2 KO mice while there was a delay in the opening of EC 
junctional pores in the small number of neutrophils that proceeded to TEM, there 
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was also a higher number of crawling cells which exhibited periods of immobility 
(during discontinuous crawling) which may represent failed attempts at entering a 
junction. The latter hypothesis is strengthened by the fact that immobility periods 
occurred directly on EC junctions and this was not due to chance (Chapter 4). As 
mentioned previously, once EC junctional disruption occurred TEM was successfully 
completed over a normal duration irrespective of the mouse genotype. Together it 
seems that the greatest defect of the ICAM-2 KO mice in the context of neutrophil 
transmigration was in the identification or initial opening of EC junctions. The 
existence of locations particularly permissive to TEM or ‘transmigratory portals’, 
have been suggested to exist at tricellular junctions (Burns et al., 1997; Sumagin and 
Sarelius, 2010), ICAM-1 enriched regions (Sumagin and Sarelius, 2010), or 
identified by chemotactic gradients (Massena et al., 2010), but there is little 
information regarding a possible role for ICAM-2 in identifying sites of TEM. No 
clear gradients of ICAM-2 which might act as guidance towards junctions were 
observed in studies of EC expression patterns (Chapter 3). 
 
The link between altered crawling characteristics of neutrophils and the formation of 
EC junctional pores in ICAM-2 KO mice is currently unknown. However, the 
mechanism by which ICAM-2 exerts its role in TEM is likely to differ from its role 
in crawling. The C-terminal of ICAM-2 links to the cytoskeleton via binding to α-
actinin and ezrin/radixin/moesin proteins (Heiska et al., 1996; Heiska et al., 1998; 
Helander et al., 1996; Yonemura et al., 1998) so it is possible that ligation of ICAM-
2 at EC junctional regions initiates signalling pathways which facilitates opening of 
the EC junction, similar to that seen with ICAM-1 clustering, VE-PTP activation and 
VE-cadherin disengagement (Alcaide et al., 2009). Alternatively ICAM-2 may play a 
role in the formation of protrusive membrane structures which have been observed, 
primarily in vitro, to form at the site of TEM (Barreiro, 2002; Carman and Springer, 
2004; Phillipson et al., 2008). Additionally neutrophil protrusions into the EC could 
also be supported by EC ICAM-2-induced outside-in integrin signalling within the 
neutrophil which is known to facilitates cytoskeletal rearrangement.  
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PECAM-1 is an important EC junctional molecule which has many similarities to 
ICAM-2 in that they both are members of Ig superfamily which are expressed at EC 
junctions and are both implicated in neutrophil extravasation where they have 
demonstrated stimulus-specific roles (Huang et al., 2006; Thompson et al., 2001; 
Woodfin et al., 2009). Interestingly using PECAM-1 KO mice stimulated with IL-1β 
a delay in neutrophil extravasation was reported rather than a complete inhibition 
(Thompson et al., 2001), indicating a transient role for PECAM-1 in neutrophil 
migration. The genetic deletion of ICAM-2 may also result in a delay in neutrophil 
extravasation rather than a complete inhibition, as demonstrated in an allergic mouse 
model (Gerwin et al., 1999). Further studies into the role of ICAM-2 in neutrophil 
extravasation at later time points are required to fully understand the functions and 
mechanisms of ICAM-2, and to identify other molecules that are capable of 
supporting TEM in the absence of ICAM-2. 
 
In summary the findings presented in this chapter demonstrate that ICAM-2 has a 
role in mediating early stages of TEM and it is tempting to speculate that ICAM-2 
could be involved in the identification of TEM sites and/or the initiation of TEM by 
facilitating the opening of EC junctions in IL-1β-stimulated tissues. The data also 
confirms that once TEM is initiated (i.e. EC junctions opened) neutrophils proceed to 
TEM normally with respect to the route and duration of TEM. These findings extend 
previous works on the functional role ICAM-2 by dissecting the precise stage at 
which ICAM-2 mediates neutrophil TEM in vivo.  
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CHAPTER 6: Potential ligands for ICAM-2 during 
neutrophil-endothelial interactions 
 
6.1  Introduction 
 
ICAM-2 was originally described as a ‘ligand for LFA-1 homologous to ICAM-1’ 
(Staunton et al., 1989). Subsequently numerous other proteins have been 
demonstrated to have binding capabilities to ICAM-2 such as MAC-1 (Li et al., 
1995; Xie et al., 1995), VLA-4 (Seth et al., 1991), DC-SIGN (Geijtenbeek et al., 
2000; Wethmar et al., 2006) and homophilic interactions in trans can occur (Huang 
et al., 2005). The latter interaction is unlikely to occur during neutrophil-EC 
interactions as neutrophil ICAM-2 expression is significantly lower than that on ECs 
(Chapter 3). The role of ICAM-2 in mediating leukocyte extravasation in general has 
previously been attributed to EC ICAM-2 (Boscacci et al., 2010; Lehmann et al., 
2003; Reiss et al., 1998; Schenkel et al., 2004; Steiner et al., 2010; Woodfin et al., 
2009) and for these reasons a possible neutrophil ligand for ICAM-2 was 
investigated. ICAM-2 interactions with the β2-integrins, LFA-1 and MAC-1 are 
widely accepted and have been studied in more detail than its interaction with VLA-
4, which has only been reported in one study and DC-SIGN, which is expressed on 
dendritic cells and macrophages only. Taking all these factors into account as well as 
the key role for β2-integrins in the neutrophil transmigration cascade, it was 
hypothesised that the novel roles of EC ICAM-2 in neutrophil crawling (Chapter 4) 
and the initiation of TEM (Chapter 5) could be governed by its interactions with 
neutrophil integrins. 
 
Only a few studies to date have focused specifically on the ligands that bind to 
ICAM-2 during its role in the recruitment of leukocytes. During dendritic cell 
migration EC ICAM-2 has been shown to bind to DC-SIGN (Geijtenbeek et al., 
2000; Wethmar et al., 2006). In contrast during monocyte crawling EC ICAM-2 has 
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been shown to bind to both LFA-1 and MAC-1 (Schenkel et al., 2004) whereas 
during lymphocyte adhesion EC ICAM-2 binds to LFA-1 or VLA-4 (Seth et al., 
1991). A recent study looking at neutrophil rolling found the formation of neutrophil 
‘slings’ during this process, and this was demonstrated to be supported via ICAM-
2/LFA-1 interactions in trans on neutrophils. Of relevance to the current study, the 
role of EC ICAM-2 in neutrophil migration has been suggested to occur through 
neutrophil LFA-1 (Issekutz et al., 1999). The role of ICAM-2 in this context was 
however only evident when ICAM-1 was also blocked where an additional inhibitory 
effect was seen relative to ICAM-1 blockade alone. This study was carried out using 
HUVECs, and any differences in the role of ICAM-2 with that presented in Chapter 
4 and 5 could be a result of different experimental models used. In line with the latter 
study however various other groups have also highlighted that ICAM-1 and ICAM-2 
have overlapping roles, and can even partially compensate for each other (Boscacci 
et al., 2010; Lehmann et al., 2003; Reiss et al., 1998; Steiner et al., 2010). Taking 
these findings into consideration the distinct roles of ICAM-1 and ICAM-2 in 
neutrophil migration were explored as part of the present chapter. 
 
Integrins are the main leukocyte ligand for ICAMs and have been demonstrated to 
bind to the arginineglycinelaspartic acid (RGD) sequence which is present in various 
extracellular matrix proteins such as fibronectin and fibrinogen. Interestingly ICAM-
2 does not have this motif. LFA-1 and MAC-1 binding sites on ICAM-2 have been 
mapped to the first 22-amino acid sequence (P1) in first Ig domain on the 
extracellular portion (Li et al., 1993; Xie et al., 1995). This sequence is recognised by 
a specific segment called the ‘A’ or ‘I’ domain in the extracellular part of the α-
subunit in integrins. The 2 Ig domains of ICAM-2 have a 35% homology to ICAM-1, 
and as these domains are implicated in ligand binding it is not surprising that these 
two ICAMs have the ability to bind to a similar set of ligands. However as ICAM-2 
has a smaller N-terminal than ICAM-1, it is believed to have restricted accessibility 
for ligands which may limit its roles. For this reason LFA-1 is thought to have much 
lower affinity for ICAM-2 than ICAM-1, and this is also likely to be the case for 
MAC-1, although this has not been directly investigated. Both LFA-1, and to a 
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greater extent MAC-1, have been suggested to be involved in leukocyte polarisation 
and crawling via activation of numerous signalling pathways within leukocytes (Ley 
et al., 2007; Phillipson et al., 2006; Sumagin et al., 2010). As the mechanisms 
underlying these roles are only just beginning to emerge, a potential role for ICAM-2 
in these integrin-mediated events cannot be ruled out. Intracellular proteins such as 
α-actinin (Heiska et al., 1996), ERM (Hamada et al., 2003; Heiska et al., 1998; 
Helander et al., 1996; Yonemura et al., 1998) and PIP2 (Heiska et al., 1998) are also 
known to interact with the cytoplasmic domain of ICAM-2, and are involved in 
intracellular signalling, cell survival (Perez et al., 2002) and ICAM-2 clustering 
(Helander et al., 1996; Perez et al., 2002). Such events could also be involved in the 
downstream mechanisms by which ICAM-2 mediates the initiation of neutrophil 
TEM (Chapter 5).  
 
This chapter focuses on examining the mechanisms underlying the role of ICAM-2 
in neutrophil crawling and the initiation of TEM by investigating the potential 
neutrophil ligands for ICAM-2 in these responses. In general LFA-1 is well accepted 
to be involved in neutrophil adhesion, whereas MAC-1 is considered to be a key 
player of neutrophil crawling (Phillipson et al., 2006; Sumagin et al., 2010). For 
these reasons it was hypothesised that neutrophil MAC-1 interacts with EC ICAM-2 
during neutrophil crawling and the initiation of TEM. MAC-1 can also however 
interact with ICAM-1, and ICAM-1 and ICAM-2 have been shown to have 
overlapping roles in some inflammatory models. As a result the functions of ICAM-
1, ICAM-2 and MAC-1 in neutrophil crawling and the initiation of TEM were 
analysed using functional blocking mAbs to ICAM-1, ICAM-2 and MAC-1 in the 
cremasteric confocal IVM model. Collectively the findings of this chapter provide 
further mechanistic insights into the role of ICAM-2 in neutrophil extravasation.   
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6.2  Results 
 
6.2.1  ICAM-1 and ICAM-2 have overlapping but distinct expression patterns 
on venular endothelial cells 
 
A role for ICAM-2 in mediating neutrophil intraluminal crawling and the initiation 
of TEM has been demonstrated (Chapter 4 and 5), and the identity of the neutrophil 
ligand for ICAM-2 in these processes was subsequently investigated. Initially the 
contribution of ICAM-1 in this model was investigated as this protein shares key 
ligands with ICAM-2 (e.g. LFA-1 and MAC-1), and has been shown to have 
redundant and/or overlapping roles with ICAM-2 in inflammation (Lehmann et al., 
2003; Phillipson et al., 2006; Sumagin et al., 2010). Using in vivo immunostaining 
and confocal analysis of post-capillary venules from the mouse cremaster muscles, 
the expression pattern of EC ICAM-1 was compared to that of EC ICAM-2 in 
unstimulated and IL-1β-stimulated tissues. The expression of ICAM-1 in ICAM-2 
KO mice was also compared to that in WT animals to determine if any compensatory 
expression of ICAM-1 was evident in the ICAM-2 KO mice. ICAM-1 was found to 
be upregulated by IL-1β stimulation in both WT (Figure 6.1 and 6.3) and ICAM-2 
KO mice (Figure 6.2 and 6.3), and this up-regulation was found at EC junctions and 
at EC non-junctional areas (Figure 6.4). No difference in terms of total venular 
expression or in terms of EC junctional and non-junctional distribution was detected 
between WT and ICAM-2 KO mice. The distribution of ICAM-1 within individual 
ECs was distinct from that of PECAM-1. More specifically, whilst PECAM-1 was 
highly localised at EC junctions with a faint diffuse expression at EC bodies, ICAM-
1 was expressed at junctions with a heterogeneous expression at EC bodies (Figure 
6.5). In contrast to EC ICAM-2 expression pattern (Chapter 3), junctional EC ICAM-
1 expression was higher in comparison to non-junctional areas (Figure 6.4). Isotype 
control mAb was also used in the place of anti-ICAM-1 mAb to ascertain potential 
non-specific binding of the anti-ICAM-1 mAb. Tissues treated with this isotype 
control mAb displayed no specific staining on the vasculature (Figure 6.1 and 6.2). 
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WT mice 
 
 
Figure 6.1: PECAM-1 and ICAM-1 expression patterns in WT cremasteric 
post-capillary venules. 
Representative confocal images of venules which were co-injected with saline or IL-
1β (50ng/400ul) and fluorescently conjugated mAbs (4μg/mouse) against PECAM-1 
(shown in green) and ICAM-1 (shown in red) intrascrotally. Tissues were also 
labelled with an isotype control mAb to ascertain potential non-specific binding of 
the anti-ICAM-1 mAb. Scale bar represents 20 μm.  NB- In these experiments tissues 
were also staining for ICAM-1 results are presented in chapter 3. 
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ICAM-2 KO mice 
 
 
Figure 6.2: PECAM-1 and ICAM-1 expression pattern in ICAM-2 KO 
cremasteric post-capillary venules. 
Representative confocal images of venules which were co-injected with saline or IL-
1β (50ng/400ul) and fluorescently conjugated mAbs (4μg/mouse) against PECAM-1 
(shown in green) and ICAM-1 (shown in red) intrascrotally. Tissues were also 
labelled with an isotype control mAb to ascertain potential non-specific binding of 
the anti-ICAM-1 mAb. Scale bar represents 20 μm. NB- In these experiments tissues 
were also staining for ICAM-1 results are presented in chapter 3. 
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Figure 6.3: Post-capillary venule expression of PECAM-1 and ICAM-1 in IL-
1β-stimulated WT and ICAM-2 KO mice.  
Venular expression of PECAM-1 and ICAM-1 was investigated in WT and ICAM-2 
KO mice. Saline or IL-1β-stimulated (50 ng/mouse, i.s) tissues were analysed by 
immunofluorescent staining and confocal microscopy 4 hours post-injection. The 
total post-capillary venule expression of (A) PECAM-1 and (B) ICAM-1 was 
quantified using Imaris software to build isosurfaces on whole venules based on 
PECAM-1 expression (Chapter 2, Figure 2.5). N = 3-5 vessels per mice, 3 mice per 
group, error bars show SEM.  Statistically significant (T-test) differences between 
saline and IL-1β groups are indicated by asterisks, ***P<0.001, not significant (ns). 
NB- In these experiments tissues were also staining for ICAM-1 results are presented 
in chapter 3.  
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Figure 6.4: Endothelial sub-cellular expression of PECAM-1 and ICAM-1 in 
WT and ICAM-2 KO mice. 
Cremasteric post-capillary venules were stimulated with saline or IL-1β-stimulated 
(50 ng/mouse, i.s) and analysed by immunofluorescent staining and confocal 
microscopy 4 hours post-injection. Endothelial junctional and non-junctional 
expression of (A) PECAM-1 and (B) ICAM-1 was quantified using Imaris software 
to build isosurfaces on whole venules based on PECAM-1 expression (Chapter 2, 
Figure 2.6). N = 3-5 vessels per mice, 3 mice per group, error bars show SEM. 
Statistically significant (T-test) differences between junctional or non-junctional 
regions are indicated by asterisks, **P<0.01, ***P<0.001. NB- In these experiments 
tissues were also staining for ICAM-1 results are presented in chapter 3. 
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Figure 6.5: ICAM-2 and ICAM-1 co-localisation in the cremasteric post-
capillary venules. 
Expression of ICAM-1 and ICAM-2 was investigated relative to that of PECAM-1 in 
WT IL-1β-stimulated tissues by immunostaining and confocal microscopy. (A) A 
representative image of a venule which was co-injected with IL-1β (50ng/400ul) and 
the fluorescent mAbs (4μg/mouse) to PECAM-1 (shown in blue), ICAM-1 (shown in 
red) and ICAM-2 (shown in green) intrascrotally. (B) Co-localisation of PECAM-1 
and ICAM-1 can be seen in light blue, co-localisation of PECAM-1 and ICAM-1 can 
be seen in pink and co-localisation of ICAM-1 and ICAM-2 can be seen in 
yellow/orange. Scale bar represents 10 μm. 
177 
 
6.2.2  Low doses of fluorescently conjugated anti-ICAM-1 mAb administered 
for labelling did not alter neutrophil transmigration responses to IL-1β 
 
Analysis of neutrophil adhesion and transmigration by brightfield microscopy 
confirmed that a neutrophil response was elicited after IL-1β stimulation in 
comparison to saline controls (Figure 6.6). Intrascrotal administration of 
fluorescently labelled anti-PECAM-1, anti-ICAM-2 and anti-ICAM-1 mAbs (Figure 
6.5) did not alter leukocyte adhesion or transmigration (Figure 6.6). This was 
because a non-function blocking mAb to PECAM-1 and very low doses of anti-
ICAM-2 and anti-ICAM-1 mAbs were administered. Furthermore ICAM-2 KO mice 
(which had fluorescently labelled mAb administered) also had normal leukocyte 
adhesion responses but as expected had a significant reduction in transmigrated 
leukocytes after IL-1β stimulation in comparison to WT controls.  
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Figure 6.6: Effect of in vivo labelling of ICAM-1 on leukocyte responses in IL-
1β-stimulated cremaster muscles.  
WT and ICAM-2 KO mice were injected with saline or IL-1β (50ng/400µl, i.s.) for 4 
hours. Fluorescently conjugated mAbs to PECAM-1 (2μg/mouse) and ICAM-1 
(4μg/mouse) were co administered with the i.s. injection. Cremaster muscles were 
exteriorised and leukocyte responses were analysed by brightfield IVM. (A) 
Adherent leukocytes per 500 μm vessel segment and (B) transmigrated leukocytes 
per 2.5x10
4μm2 were analysed. Results are presented as mean ± SEM for each mice 
(n=3 mice, 3-5 vessels/cremaster). Significant differences (Anova) between saline 
and IL-1β groups are indicated by asterisks (***P < 0.001). Additional statistical 
comparisons between WT control and ICAM-2 KO groups are indicated by hash 
symbols (###P < 0.001). Lastly, comparisons between WT and fluorescent mAb 
administration and ICAM-2 KO groups are indicated by dollar symbols ($$$P < 
0.001). 
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6.2.3  ICAM-1 and ICAM-2 have distinct roles in regulating intravascular 
neutrophils  
 
To investigate the relative functional roles of ICAM-1 and ICAM-2 in neutrophil 
adhesion and extravasation anti-ICAM-1 and anti-ICAM-2 function blocking mAbs 
were used in the cremaster confocal IVM model. Animals were given 3mg/kg i.v. of 
blocking mAbs, or matched isotype controls, and cremaster muscles were PECAM-1 
labelled and stimulated with IL-1β as previously described. Tissues were exteriorised 
and intravascular and extravasated neutrophil numbers were quantified from images 
taken 4 hours post-i.s. injection (Figure 6.7). Previous data using ICAM-2 KO mice 
could be duplicated using the ICAM-2 blocking mAb administered in WT mice, 
compared to an appropriate isotype control in terms of both intra- and extravascular 
neutrophils. The results showed that animals pre-treated with isotype control mAbs 
had on average 54.6 ± 9.3 intravascular neutrophils in a 500μm vessel segment and 
31.9 ± 9.8 extravascular neutrophils in a 2.5x10
4μm2 segment. Anti-ICAM-2 mAb 
did not significantly reduce the number of intravascular cells (37.4 ± 4.0 cells, n=7 
mice) but there was a significant suppression in extravasation (8.9 ± 3.0 cells, n=7 
mice, P< 0.001) as seen in ICAM-2 KO mice (Chapter 4). In contrast, anti-ICAM-1 
mAb substantially reduced intravascular neutrophils (8.1 ± 1.6 cells, n=6 mice, P< 
0.001) and almost totally abrogated numbers of extravasated cells in comparison to 
controls (Figure 6.7). Anti-ICAM-1 mAb treatment also resulted in a significant (P< 
0.05, n=4-8 mice) decrease in the number of intravascular neutrophils as compared to 
anti-ICAM-2 mAb. This data indicates that whilst ICAM-1 has key roles in 
mediating neutrophil adhesion, ICAM-2 does not and that the reduction in 
extravasation seen in ICAM-2 KOs after IL-1β stimulation (Chapter 4) could be 
replicated using a function blocking mAb to ICAM-2 in IL-1β-stimulated WT 
tissues. 
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Figure 6.7: Effect of ICAM-1 and ICAM-2 inhibition on neutrophil 
extravasation in IL-1β-stimulated venules.   
Cremasteric confocal IVM of WT Lys-eGFP-ki mice stimulated with i.s. IL-1β (50 
ng/mouse). Animals were pre-treated with an i.v. injection of anti-ICAM-1 or anti-
ICAM-2 mAb, or isotype control, at 3 mg/kg. (A) Representative images of post-
capillary venules where PECAM-1 (i.s. labelling in vivo) is shown in red and 
neutrophil (Lys-eGFP-ki mice) are shown in green. (B) The mean total intravascular 
neutrophils per 500μm vessel segment and extravascular neutrophils per 2.5x104μm2 
segment were analysed 4 hours post-stimulation. Data were obtained 4-9 vessels in 4-
8 mice. Bars represent mean ± SEM for all events analysed. Statistically significant 
(Anova) differences between isotype control are represented by asterisks **P< 0.01, 
***P <0.001.  Differences between blocking mAb groups are represented by lines. 
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6.2.4  ICAM-1 and ICAM-2 have overlapping but distinct roles in regulating 
crawling 
 
Neutrophil crawling dynamics were also quantified in IL-1β-stimulated WT mice 
pre-treated with anti-ICAM-1 and anti-ICAM-2 mAbs. The data acquired using 
ICAM-2 KO mice in Chapter 4 could again be duplicated using the anti-ICAM-2 
blocking mAb compared to an appropriate isotype control in terms of neutrophils 
crawling dynamics (Figure 6.8). Both anti-ICAM-2 and anti-ICAM-1 mAb 
significantly reduced neutrophil crawling speed (6.7 ± 0.3 μm/min, n=113 for anti-
ICAM-2 mAb and 5.1 ± 0.2 μm/min, n=46 for anti-ICAM-1 mAb) in comparison to 
their respective isotype control mAbs (10.8 ± 0.6 μm/min, n=53 for IgG2a mAb and 
9.7 ± 0.5 μm/min, n=66 for IgG2b mAb) (Figure 6.8A). Interestingly the reduction in 
crawling speed induced by anti-ICAM-1 mAb was significantly greater than that 
detected after anti-ICAM-2 mAb treatment (P< 0.05), although it should be noted 
that the number of crawling neutrophils analysed per venule after anti-ICAM-1 mAb 
was fewer than that analysed for anti-ICAM-2, as ICAM-1 has a crucial role in initial 
adhesion (Figure 6.8A).  
 
While a reduced number of luminal crawling cells were present following anti-
ICAM-1 mAb treatment, the few cells that were observed to undergo crawling often 
exhibited discontinuous crawling behaviour (70.4 ± 8.7%,  n=6 mice from 6 vessels), 
and this was not significantly different from that seen after anti-ICAM-2 mAb 
treatment (54.9 ± 7.4%, n=8 mice from 9 vessels) (Figure 6.8B). These results were 
comparable to the frequency of discontinuous crawling in ICAM-2 KO mice in 
Chapter 4 (Figure 4.13). After mAb treatment discontinuously crawling cells crawled 
significantly slower than continuously crawling cells (Figure 6.8C). After mAb 
treatment there was also significant reduction in the speed of continuous crawling 
cells in comparison to controls (P<0.001). This suggests that the overall reduction in 
speed was not solely due to the high frequency of slow, discontinuous crawling, as 
continuously crawling cells also crawled significantly slower than in controls (Figure 
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6.8C). This was in line with previous findings using ICAM-2 KO mice (Chapter 4, 
Figure 4.14). Additionally anti-ICAM-1 and anti-ICAM-2 mAb treatment had the 
same level of reduction in the frequency of continuously crawling cells and the speed 
of continuous crawling. Therefore reasons behind the reduction in the overall 
crawling speed after anti-ICAM-1 mAb in comparison to anti-ICAM-2 mAb are 
currently unknown. 
 
The differential effects of blocking ICAM-1 and -2 on the number of intravascular 
crawling neutrophils, and the mean crawling speed suggest that the roles of ICAM-1 
and -2 in this model are not fully overlapping, and maybe a result of differences in 
ligand binding. 
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Figure 6.8: Effect of ICAM-1 and ICAM-2 inhibition on neutrophil crawling 
dynamics in IL-1β-stimulated venules 
Cremasteric confocal IVM of WT Lys-eGFP-ki mice stimulated with i.s. IL-1β (50 
ng/mouse) for 2 hours. Animals were pre-treated with an i.v. injection of anti-ICAM-
1 or anti-ICAM-2 mAb, or isotype control, at 3 mg/kg. (A) The mean crawling speed 
and (B) the percentage of continuously and discontinuously crawling neutrophils was 
determined. (C) The mean crawling speed of continuously and discontinuously 
crawling cells was also determined. Data were obtained from analysis of 46-113 
crawling cells from 4-9 vessels in 4-8 mice. Bars represent mean ± SEM for all 
events analysed. Statistically significant (Anova) differences between isotype control 
are represented by asterisks *P< 0.05, **P< 0.01, ***P <0.001, ns (not significant).  
Differences between blocking mAb groups are represented by lines. 
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6.2.5  Neutrophil MAC-1 does not interact with EC ICAM-2 during neutrophil 
adhesion 
 
As ICAM-2 and ICAM-1 are known to bind LFA-1 and MAC-1 (Issekutz et al., 
1999; Nourshargh et al., 2010; Staunton et al., 1989; Xie et al., 1995), and LFA-1 is 
thought to support initial leukocyte adhesion, whereas MAC-1 is thought to support 
crawling (Phillipson et al., 2006; Sumagin et al., 2010), the possibility that ICAM-
2/MAC-1 interactions were mediating the role of ICAM-2 in neutrophil crawling was 
investigated. It is not possible however to discount the possibility that any observed 
effect of blocking MAC-1 function is related to MAC-1/ICAM-1 interactions, as this 
integrin is also known to be an ICAM-1 ligand, and using an anti-ICAM-1 mAb in 
addition to MAC-1 blockade to exclude any effect of this interaction would reduce 
the number of quantifiable neutrophil crawling events to below viable levels. To this 
end the effect of a MAC-1 blocking mAb in WT and ICAM-2 KO mice was 
examined, on the basis that if there is no cumulative effect of impairing the function 
of ICAM-2 and MAC-1, then the observed inhibition represents the function of these 
two proteins interacting, while a cumulative effect of impairing MAC-1 and ICAM-2 
function would represent a possible MAC-1/ICAM-1 interaction. 
 
Images of IL-1β-stimulated vessels treated with i.v. anti-MAC-1 or an isotype 
control mAb were captured at 4 hours post-IL-1β, and intravascular and extravasated 
cells were quantified (Figure 6.9A). In WT animals that had been pre-treated with 
anti-MAC-1 mAb a significant reduction in intravascular cells was seen in 
comparison to control (56.0 ± 1.0, n=5 mice for control and 22.4 ± 5.4, n=4 mice for 
anti-MAC-1 mAb) (Figure 6.9B). This effect is not seen following ICAM-2 
blockade, indicating that this is a non-ICAM-2 mediated MAC-1 function and is 
likely to be due to ligation with ICAM-1. Of note, the level of inhibition of 
intravascular cells was not as complete as that seen following ICAM-1 blockade, 
suggesting that ICAM-1 has other binding partners that support adhesion namely 
LFA-1. Additionally it is also possible that the efficacy of anti-ICAM-1 mAb is 
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higher than that of anti-MAC-1 mAb and hence resulting in a greater reduction. The 
assertion that this MAC-1 function is not mediated by ICAM-2 is supported by the 
absence of a reduction in intravascular neutrophils in ICAM-2 KO mice (Figure 
6.9B) and in WT mice treated with anti-ICAM-2 mAb (Figure 6.7B). Extravasation 
is almost totally inhibited by either MAC-1 blockade or in the absence of ICAM-2, 
so it is not possible to comment on potential cumulative effect (Figure 6.9B). 
 
 
6.2.6  Neutrophil MAC-1 may interact with EC ICAM-2 during neutrophil 
crawling 
 
Luminal crawling dynamics in IL-1β-stimulated WT and ICAM-2 KO mice pre-
treated with control or anti-MAC-1 mAb were also quantified. WTs treated with 
isotype control mAb had a similar crawling speed to that detected by WTs in Chapter 
4 (9.7 ± 0.7 µm/min, n=66 cells) and as expected this speed was significantly 
reduced in ICAM-2 KO mice treated with isotype control (6.3 ± 0.3 µm/min, n=36). 
The number of crawling/intravascular neutrophils in WT and ICAM-2 KO mice were 
also comparable to that detected previously (Chapter 4). In WT animals the anti-
MAC-1 mAb significantly reduced crawling speeds (7.3 ± 0.3 µm/min, n=63, P< 
0.01) to a level similar to the mean speed seen in ICAM-2 KO mice treated with 
control mAb (Figure 6.10A). When ICAM-2 KO mice were pre-treated with the anti-
MAC-1 mAb no cumulative effect on crawling speed was seen (6.7 ± 0.7 µm/min, 
n=72), indicating that this function could be mediated by ICAM-2/MAC-1 
interactions (Figure 6.10A).  
 
There was a significant reduction in the frequency of continuously crawling cells in 
WT mice pre-treated with anti-MAC-1 mAb (50.4 ± 9.1%, n=6 vessels) in 
comparison to controls and this was in line with that of ICAM-2 KOs treated with 
anti-MAC-1 mAb. However no significant evidence of cumulative inhibition was 
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observed when the functions of both ICAM-2 and MAC-1 were impaired (Figure 
6.10B). The speed of discontinuous crawling across all groups was approximately 6 
μm/min and was in line with previously acquired data (Chapter 4). The speed of 
continuously crawling cells in WT mice treated with control mAb was 11.5 ± 0.5 
μm/min (n=47 cells) and this was significantly reduced after anti-MAC-1 mAb 
treatment (P<0.001), ICAM-2 genetic deficiency (P<0.05) and the joint blockade and 
deletion of MAC-1 and ICAM-2 respectively (P<0.001). No additive effects were 
detected with respect to the speed of continuous crawling cells when MAC-1 and 
ICAM-2 functions were both impaired. This indicates that the overall reduction in 
crawling speed was due to the combination of a high frequency of slow, 
discontinuously crawling cells as well as the reduced crawling speed of continuously 
crawling cells (Figure 6.10C). This finding is comparable to previous data using 
ICAM-2 KO mice (Chapter 4) and WT mice treated with anti-ICAM-2 mAb (Figure 
6.8). 
 
There was a significant reduction in TEM events in stimulated ICAM-2 KO mice (5 
TEM events during a 30 minute period/venule) relative to WT mice as presented in 
Chapter 5. After MAC-1 inhibition there also appeared to be a reduction in TEM 
events in line with the reduced number of extravasated neutrophils at the 4 hour time 
point (Figure 6.7). However only 6 TEM events were observed in animals treated 
with anti-MAC-1 mAb post-stimulation overall across 7 venules in 5 mice. For this 
reason TEM dynamics after anti-MAC-1 mAb could not be analysed in detail and 
hence no comment can be made regarding the potential ligand interactions with 
ICAM-2 during TEM (i.e. pre-TEM).  
 
Collectively the data indicates that ICAM-1 does not compensate for the genetic 
deletion of ICAM-2, suggesting that these molecules have distinct roles in this 
model. Indeed ICAM-1 and ICAM-2 were found to have distinct roles in mediating 
neutrophil adhesion, however they also have overlapping roles in neutrophil crawling 
dynamics after IL-1β stimulation. The lack of an additive effect when ICAM-2 and 
187 
 
MAC-1 functions were impaired suggests that ICAM-2 ligation with neutrophil 
MAC-1 could potentially support the observed roles of ICAM-2 in neutrophil 
luminal crawling speed and continuity.  
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Figure 6.9: Effect of MAC-1 inhibition on neutrophil extravasation in IL-1β-
stimulated WT and ICAM-2 KO venules.  
Cremasteric confocal IVM of WT and ICAM-2 KO Lys-eGFP-ki mice stimulated 
with i.s. IL-1β (50 ng/mouse). Animals were pre-treated with an i.v. injection of anti-
MAC-1 mAb, or isotype control, at 3 mg/kg. (A) Representative images of post-
capillary venules where PECAM-1 (i.s. labelling l) is shown in red and neutrophil 
(Lys-eGFP-ki mice) are shown in green. (B) The mean total intravascular neutrophils 
per 500μm vessel segment and extravascular neutrophils per 2.5x104μm2 segment 
were analysed 4 hours post-stimulation. Data were obtained from 4-7 vessel in 3-5 
mice. Bars represent mean ± SEM for all events analysed. Statistically significant 
(Anova) differences between WT isotype control are represented by asterisks *P< 
0.05, ***P < 0.001, ns (not significant). 
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Figure 6.10: Effect of MAC-1 inhibition on neutrophil crawling dynamics in IL-
1β-stimulated WT and ICAM-2 KO venules. 
Cremasteric confocal IVM of WT and ICAM-2 KO Lys-eGFP-ki mice stimulated 
with i.s. IL-1β (50 ng/mouse) for 2 hours. Animals were pre-treated with an i.v. 
injection of anti-MAC-1 mAb, or isotype control, at 3 mg/kg. (A) The mean crawling 
speed and (B) the percentage of continuously and discontinuously crawling 
neutrophils was determined. (C) The mean crawling speed of continuous and 
discontinuous crawling cells was also determined. Data were obtained from analysis 
of 36-66 crawling cells from 4-7 vessels in 3-5 mice. Bars represent mean ± SEM for 
all events analysed. Statistically significant (Anova) differences between WT isotype 
control are represented by asterisks *P< 0.05, **P< 0.01, ***P < 0.001, ns (not 
significant). 
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6.3  Discussion 
 
In this chapter the molecular mechanisms underlying the role of ICAM-2 in 
neutrophil crawling and the initiation of TEM was investigated by examining the 
ligand interaction for ICAM-2 in this process. ICAM-1 and ICAM-2 share possible 
key ligands, namely LFA-1 and MAC-1, and there is evidence for these ICAMs to 
function in a co-operative and/or redundant manner in various models relating to the 
migration of several leukocyte subsets (Boscacci et al., 2010; Issekutz et al.1999; 
Lehmann et al., 2003; Steiner et al., 2010), which could be associated with their 
leukocyte ligands. The complexity of the relationship between these two endothelial 
proteins, and the overlap between their known ligands and functions, necessitated the 
consideration of a possible ICAM-1 influence in the current model.  
 
The expression profile of EC ICAM-1 was examined using immunofluorescent 
labelling and confocal microscopy of the cremasteric vasculature. Whilst ICAM-1 
was found to be significantly upregulated after IL-1β expression in both WT and 
ICAM-2 KO mice, no difference in expression in terms of localisation and 
fluorescence intensity was found between ICAM-2 KO and WT mice. This suggests 
that no compensatory up-regulation of ICAM-1 is evident on unstimulated or 
stimulated cremasteric ECs when ICAM-2 is genetically deleted. In support of this, 
in ICAM-1 KO ECs, no change in ICAM-2 expression was noted in comparison to 
WTs even after stimulation (Reiss et al., 1998). Although this observation was in 
vitro using a cell line system, the findings are similar to that noted in the current 
study. Taking this into account, it is evident that no compensatory up-regulation in 
ICAM-1 expression was seen in ECs from ICAM-2 KO mice suggesting that they 
have distinct roles and are not fully redundant proteins.   
 
Functional studies confirmed that mAb blockade of ICAM-1 had a highly inhibitory 
effect on IL-1β-stimulated neutrophil adhesion, and almost totally abolished 
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extravasation. These roles are likely to be primarily mediated via its interactions with 
LFA-1 (Phillipson et al., 2006; Sumagin et al., 2010). Quantification of crawling 
dynamics of the few remaining adherent neutrophils showed that the anti-ICAM-1 
mAb significantly reduced crawling speed and discontinuous crawling was more 
frequent, similar to that seen after anti-ICAM-2 mAb treatment. Interestingly the 
reduction in crawling speed after anti-ICAM-1 mAb was significantly more than that 
detected after anti-ICAM-2 mAb, suggesting that these proteins do not have fully 
redundant or overlapping roles within this system. It is also possible that the anti-
ICAM-1 mAb has a higher binding affinity than that of anti-ICAM-2 mAb and hence 
resulting in an increased reduction in speed. It should be noted however that the 
crawling speed detected after anti-ICAM-2 mAb is similar that that detected in the 
ICAM-2 KOs. Determining the neutrophil crawling dynamics in ICAM-1 KO mice 
may provide further clarification in regards to this. 
 
The results presented regarding ICAM-1 and ICAM-2, are in contrast to various 
studies which have reported a co-operative role for ICAM-1 and 2 in the recruitment 
of leukocytes (Reiss et al. 1998; Reiss and Engelhardt 1999; Lehmann et al. 2003; 
Steiner et al. 2010; Boscacci et al. 2010 Issekutz et al., 1999). In one particular study 
when ICAM-1 function was impaired, ICAM-2 was shown to compensate, at least 
partially, for its absence with respect to T lymphocyte adhesion (Boscacci et al. 
2010), however in other models compensation was not evident and a more co-
operative role for ICAM-1 and ICAM-2 was seen (Steiner et al. 2010). The 
compensatory and co-operative roles seem to be largely apparent in the recruitment 
and homing of T lymphocytes and there is data to suggest that this occurs via LFA-1 
interaction (Reiss and Engelhardt, 1999). Studies by Issekutz et al (1999) showed an 
additive effect on the reduction of neutrophil extravasation when ICAM-1 and 
ICAM-2 were both blocked, however in contrast to the current study they found no 
effect on neutrophil extravasation when ICAM-2 alone was inhibited. The 
occurrence of compensation or co-operation therefore seems to be variable, 
depending strongly on the subtype of leukocyte being investigated and in the 
experimental model used. The regulation of ICAM-2 is also dependent on the species 
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investigated (Cowan et al., 2003) and any inconsistencies seen between models using 
HUVECs with that of the current murine studies could be due to this reason. The low 
number of crawling neutrophils per venule analysed could also affect the results 
obtained (e.g. post-administration of anti-ICAM-1 mAb). The results do however 
indicate that in the current model, ICAM-1 and ICAM-2 have distinct roles in 
mediating neutrophil adhesion and have some overlapping functions with respect to 
neutrophil crawling although the latter process is likely to be governed by different 
mechanisms. 
 
Anti-MAC-1 blocking mAb elicited a partial reduction in IL-1β mediated adhesion, 
and this is likely to be a MAC-1/ICAM-1 mediated effect (Smith et al., 1989; 
Sumagin et al., 2010). This inhibition was not as severe as that seen in the presence 
of anti-ICAM-1 mAb, and the incomplete inhibition of neutrophil adhesion after 
anti-MAC-1 mAb administration suggests that ICAM-1/LFA-1 interactions are 
involved in the initial adhesion of neutrophils in this model (Phillipson et al., 2006; 
Smith et al., 1989; Sumagin et al., 2010). Previously published findings from TNF-α 
or MIP-1α stimulated vessels have also found that LFA-1 supports neutrophil 
adhesion, while in contrast to the current study, a lack of functional MAC-1 had little 
effect on numbers of adherent cells (Phillipson et al., 2006; Sumagin et al., 2010). 
The reason for these differences could be a result of the combination of using a 
different inflammatory stimuli and/or different imaging system. Additionally as 
mentioned earlier it is also possible that the efficacy of anti-ICAM-1 mAb is higher 
than that of anti-MAC-1 mAb hence resulting in an incomparable reduction in the 
number intravascular leukocytes. 
 
After MAC-1 blockade a significant reduction in crawling speed and continuity was 
noted, which was comparable to that seen when functional ICAM-2 was impaired. 
There was however no cumulative effect on these parameters when MAC-1 and 
ICAM-2 were both inhibited simultaneously. This lack of additional effect indicates 
that ICAM-2 and MAC-1 may be binding partners, and that this interaction supports 
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efficient leukocyte crawling, which cannot take place without the initial strong 
adhesive bonds between ICAM-1/LFA-1. As there were low numbers of adherent 
neutrophils seen after anti-ICAM-1 mAbs treatment, dual inhibition of ICAM-1 and 
MAC-1 functions to demonstrate ICAM-1 independent roles of MAC-1 was not 
possible. The effects seen in neutrophil crawling dynamics after anti-MAC-1 mAb 
therefore does not directly or completely rule out the possibility of MAC-1/ICAM-1 
interactions. The lack of additive effects after impairing MAC-1 and ICAM-2 
functions does however indirectly indicate that ICAM-2 may potentially be 
interacting with MAC-1. An interaction of MAC-1 with other known ligands such as 
fibrinogen, fibronectin, Factor X or other RGD-containing proteins are highly 
unlikely in this context (Issekutz et al., 1999). 
 
The intracellular mechanism by which MAC-1/ICAM-2 ligation may promote 
neutrophil motility is currently unclear. MAC-1 is homogenously expressed on the 
cell surface and its activity is more pronounced at the leading edge of the cell 
(Hidalgo et al., 2009), suggesting a role in mediating dynamic adhesions and de-
adhesions between leukocytes and ECs during leukocyte crawling. Changes in 
integrin conformation have been linked to inside-out signalling via linkage proteins 
such as talin, which provide communication between the cell membrane and the 
cytoskeleton. These events together with that of outside-in integrin signalling are 
tightly regulated through Rac and Rho signalling pathways as well as through 
WASP/WAVE, PI3K and Cdc42 which are implicated downstream of integrin 
activation during crawling (Ridley, 2003). It is therefore possible that these pathways 
could be impaired when ICAM-2 function is blocked hence resulting in inefficient 
crawling. It is important to note that the mechanism proposed here is that of ICAM-2 
interacting with MAC-1 during neutrophil crawling only. Due to the low frequency 
of observable TEM events after MAC-1 treatment, no comment can be made 
regarding the role of MAC-1/ICAM-2 interactions in the initiation of TEM.  
 
ICAM-2 is also expressed on neutrophils (Chapter 3) and the possibility that ICAM-
2 expressed on neutrophils could be contributing to the effects reported in the current 
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study has not been fully disproved although it does seem unlikely. Neutrophillic 
ICAM-2 has recently been linked to stabilisation of neutrophil rolling through 
intracellular trans interactions with LFA-1 expressed on the same cell (Sundd et al., 
2012). No defects in the progression from rolling to adhesion were observed in this 
model however. The role of EC ICAM-2 (as oppose to neutrophil ICAM-2) as 
suggested in the current study is supported by previous work within our group which 
showed that WT bone marrow leukocytes transferred into ICAM-2 KO animals did 
not restore the observed reduction in IL-1β-stimulated extravasation (Woodfin et al., 
2009). Additionally numerous other studies have also demonstrated a key role of EC 
ICAM-2 in neutrophil (Issekutz et al., 1999), T cell (Boscacci et al., 2010; Lehmann 
et al., 2003; Steiner et al., 2010) and monocyte (Schenkel et al., 2004) recruitment.  
Interestingly lymphocytes and monocytes have significantly more cells that express 
ICAM-2 and at higher levels than that of neutrophils (Chapter 3) and the expression 
of ICAM-2 on the lymphocytes and monocytes are still considered to have minimal 
roles in EC-leukocyte interactions. However these studies still cannot rule out the 
possibility that the effects seen could be due to the impairment of ICAM-2 
homophilic interactions. The relatively low ICAM-2 expression on neutrophils 
strongly indicates that the mechanisms demonstrated here relate to a heterophilic 
binding and homophillic interactions are highly unlikely.   
 
In conclusion results in the present chapter demonstrate that in the absence of ICAM-
2 the expression of ICAM-1 is not altered. This is possibly due to the fact that 
ICAM-1 and ICAM-2 have distinct roles with respect to neutrophil adhesion 
however these ICAMs also have some overlapping functions in neutrophil crawling. 
The role of ICAM-1 in mediating neutrophil crawling speed and continuity is likely 
to be through a distinct mechanism possibly involving LFA-1. The results also show 
that the novel role for ICAM-2 in supporting efficient neutrophil luminal crawling 
could potentially be mediated through the ligation of neutrophil MAC-1. It is not 
currently known if the defects in speed and continuity of crawling, and the 
identification or opening of endothelial junctions reflect several distinct roles for 
ICAM-2. However it is tempting to speculate that crawling is supported by activation 
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of neutrophil locomotive machinery, while EC junctional opening may be facilitated 
by signalling within the ECs leading to junctional and/or cytoskeletal rearrangement. 
Further in vitro and in vivo investigations are required to shed light on these 
questions. 
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CHAPTER 7: Development of a pathological model of 
inflammation 
 
7.1  Introduction 
 
A key role for ICAM-2 in luminal neutrophil crawling and the initiation of TEM has 
been demonstrated in this study using an acute inflammatory reaction induced by IL-
1β. To extend these findings, it would be of value to investigate the role of ICAM-2 
in more complex disease mimicking inflammatory reaction. This chapter describes 
the development of a pathological cremasteric model of inflammation. 
 
Previous data within our group has shown stimulus-specific functions of ICAM-2 in 
neutrophil transmigration, in that it mediates responses by IL-1β but not as induced 
by TNF-α, thioglycolate or LTB4 (Huang et al., 2006; Woodfin et al., 2009). The 
stimulus-specific effects of ICAM-2 in these studies have been linked to the ability 
of the stimulus to predominately activate the ECs directly as in the case for IL-1β 
(Woodfin et al., 2009). These results however question the importance of ICAM-2 in 
pathological inflammatory reactions where several mediators are involved 
simultaneously and thus may bypass the need for ICAM-2 in leukocyte recruitment. 
There have been numerous pathologically relevant studies which do however provide 
evidence for a role of ICAM-2 in leukocyte recruitment. These include a cremasteric 
model of I/R injury (unpublished work by Woodfin et al), a bacterial induced murine 
model of ocular inflammation (Hobden, 2003), and a murine model of allergic 
airway inflammation (Gerwin et al., 1999). Despite the above there exist very few 
studies that have investigated the role of ICAM-2 in neutrophil extravasation in 
inflammatory disease models and therefore a more pathologically relevant reaction in 
the confocal IVM model was established as part of this work. This reaction could be 
used for investigating the role of ICAM-2 and indeed other components of the 
neutrophil adhesion cascade.  
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The Shwartzman reaction (SR) is a phenomena named after Gregory Shwartzman in 
the 1920s. It is a process which describes the body’s reaction to particular toxic 
reagents and has been likened to, and claimed to manifest in, various clinical 
disorders such as septicaemia, acute pancreatitis and hypersensitivity reactions (Hjort 
and Rapaport, 1965). Classically it is elicited experimentally via two LPS doses 24 
hours apart, however other reagents such as TNF-α and zymozan have also shown to 
induce similar characteristics and hence have been termed to stimulate a 
‘Shwartzman-like reaction’ (Movat et al., 1987). A general SR is classed as a 
response affecting the circulation and is evoked by two i.v. injections which 
represents a model of sepsis. A local SR is induced when the initial injection is 
administered into specific areas and is then followed by an i.v. injection (or vice 
versa), or alternatively can be stimulated by two local injections (Brozna, 1990). 
Local SR is commonly known to represent a model of vasculitis. The first 
administration is usually a low dose which prepares the site for a reaction through 
up-regulating various inflammatory mediators. 24 hours later a higher dose is 
injected which then provokes the reaction (Brozna, 1990). The prepared site 
undergoes hemorrhagic necrosis which is fully developed within 24 hours of the 
provoking injection. Key vascular responses noted in the SR include leukocyte 
transmigration peaking at 2 hours (Brozna, 1990), thrombosis of capillaries and veins 
with thrombi consisting of platelets, leukocytes and fibrin, and haemorrhage.  
 
SR is predominately stimulated in dermal models (Argenbright & Barton, 1992; 
Brozna, 1990; Pepys MB, 1982) and to date this reaction has not been established 
and investigated in the mouse cremaster muscle by IVM, a technique that provides 
detailed insight into the dynamics of vascular processes such as leukocyte 
recruitment, thrombosis, hemodynamics, vascular tone and oedema in real time, in 
vivo. Interestingly ICAM-2 is expressed on vascular ECs (de Fougerolles et al., 
1991), neutrophils (Sundd et al., 2012)  and platelets (Diacovo et al., 1994; Kuijper et 
al., 1998), all of which may play a significant role in vascular processes that occur 
during a SR. The cremasteric SR model may therefore provide a valuable tool to gain 
additional insights into the role of ICAM-2 not only in the dynamics of leukocyte 
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extravasation (i.e. neutrophil crawling and initiation of TEM in pathological 
inflammation), but also other vascular processes such as the formation of thrombus 
and haemorrhage in real time. 
 
This chapter describes a series of studies aimed at the development of a cremasteric 
SR model. Although due to lack of time the model was not used for investigations 
into the functional role of ICAM-2, the findings indicate its potential value for such 
future experiments. 
 
 
7.2  Results  
 
7.2.1  Leukocyte responses in the cremasteric Shwartzman Reaction model  
 
A classical local SR was elicited in the cremaster muscle by two LPS injections 24 
hours apart. The initial injection was administered i.s. followed 24 hours later by an 
i.v. dose. 2 hours after the i.v. injection the cremaster muscle was exteriorised and 
analysed by brightfield IVM (Figure 7.1A). Tissues stimulated with this SR protocol 
showed no significant difference in leukocyte adhesion in comparison to controls 
(27.5 ± 4.3 leukocytes, n=5 mice for SR tissues and 21.1 ± 3.4 leukocytes, n=7 mice 
for controls) (Figure 7.1). The reason for this is currently unclear but as the control 
tissues (two saline injections) had a high numbers of adherent leukocytes it is 
possible that the initial i.s. injection of saline 24 hours prior to quantification may 
have induced a leukocyte response. Nevertheless SR stimulation did induce a 
response above that of controls with respect to the number of leukocytes in the 
extravascular tissue (22.1 ± 3.4 leukocytes, n=5 for SR tissues and 10.1 ± 2.2 
leukocytes, n=7) (Figure 7.1B).  
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Live confocal IVM using Lys-eGFP-ki mice, which express eGFP in neutrophils and 
monocytes, and CX3CR1-eGFP-ki mice which express eGFP in monocytes and 
dendritic cells (Jung et al., 2000), confirmed that the SR elicited in the cremaster 
muscle stimulated a neutrophil mediated response as the Lys-eGFP-ki mice had 
significantly higher number of eGFP positive cells in the intravascular and 
extravascular tissue, in comparison to CX3CR1-eGFP mice (Figure 7.2 and 7.3). A 
slightly higher number of neutrophils were detected in the intravascular regions of 
SR-stimulated tissues using this method compared to that noted with brightfield 
IVM, possibly due to the greater resolution of the confocal method. This resulted in a 
significant increase in this parameter in SR tissues compared to controls (Figure 7.2 
and 7.3). After SR stimulation a higher number of neutrophils migrated to the 
extravascular tissue in comparison to both controls and CX3CR1-eGFP mice and this 
was in line with previous data (Figure 7.1). Additionally as neutrophils were 
observed to migrate further into the extravascular tissue, the number of transmigrated 
neutrophils 50-100μm away from the vessel was also quantified. This data also 
showed a high number of neutrophils within the extravascular tissue in comparison 
to both controls and CX3CR1-eGFP mice (Figure 7.2 and 7.3). Overall the high 
number of neutrophil infiltration in SR-stimulated cremaster muscles was in line with 
previous dermal models.  
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Figure 7.1: SR-induced leukocyte recruitment in cremasteric post-capillary 
venules.   
(A) Representative brightfield images of leukocytes responses in control and SR 
(30µg LPS i.s. 24 hours later 150µg LPS i.v.) -stimulated venules. Leukocyte 
adhesion and transmigration was quantified 2 hours later using brightfield IVM. 
Black arrows show adherent leukocytes and red arrows show leukocytes in the 
extravascular region. (B) Adherent leukocytes per 500µm vessel segment (left panel) 
and transmigrated leukocytes in the perivascular tissue 2.5x10
4μm2 segment were 
quantified (right panel) in SR and control tissues. N = 5-7 vessels per cremaster, 5-8 
mice per group, error bars show SEM.  Statistically significant (T-test) differences 
are indicated by asterisks, *P<0.05. 
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Figure 7.2: Confocal images of SR-induced neutrophil and monocyte 
recruitment in cremasteric post-capillary venules.  
Representative images of leukocytes responses in control and SR (30µg LPS i.s. 24 
hours later 150µg LPS i.v.) -stimulated venules from Lys-eGFP-ki mice (neutrophils 
shown in green, left panels) and CX3CR1-eGFP-ki (monocytes shown in green, right 
panels). PECAM-1 (red) was labelled in vivo as a marker for venules. Scale bar 
represents 40-50µm. 
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Figure 7.3: SR-induced neutrophil and monocytes recruitment in cremasteric 
post-capillary venules.  
A SR was induced and vessels were labelled as previously described in Lys-eGFP-ki 
mice (GFP neutrophils and monocytes) and CX3CR1-eGFP-ki (GFP monocytes) 
mice. Tissues were viewed under a confocal microscope where live images of 
venules 20-40µm in diameter was taken and analysed in 3D using Imaris software. 
(A) Quantification of intravascular leukocytes in a 500µm vessel segment and (B) 
extravascular leukocytes in a 2.5x10
4μm2 segment 0-50μm and 50-100μm away from 
the vessel was quantified in both mouse strains in control or SR-stimulated tissues. N 
= 3-5 vessels per mice, 3-7 mice per group, error bars show SEM. Statistically 
significant (Anova) differences between control and SR-stimulated tissues are 
indicated by asterisks (*P<0.05, **P<0.01). Differences between neutrophil and 
monocyte groups are indicated by hash symbols (#P < 0.05, ##P < 0.01, ###P < 
0.001). 
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7.2.2  Hemodynamic responses in the cremasteric Shwartzman Reaction model  
 
Current dermal models of the SR are known to produce sites of haemorrhage and 
microthrombi, and these characteristics were examined in the current cremasteric SR 
model. In brightfield experiments a reduction in vascular perfusion and sites 
corresponding to the formation of microthrombi and haemorrhage were observed in 
SR tissues (Figure 7.4) and some of these events were further quantified using 
immunostaining and confocal IVM. 
  
To quantitatively determine if there was any evidence of microthrombi and/or 
platelet-EC interactions in this model, platelets were fluorescently labelled using 
anti-CD41-PE mAb. Live confocal microscopy analysis of SR-stimulated tissues 
were carried out and the abundance of labelled platelets was examined. SR-
stimulated tissues had higher ratio of anti-CD41-PE to AlexaFluor-647 conjugated 
anti-CD31 fluorescent intensity, indicating that more platelets interacting with the 
ECs were detected in comparison to control tissues (Figure 7.5). This may not reflect 
microthrombi or platelet-EC interaction completely as slower blood flow was also 
observed in SR-induced tissues which would make labelled platelets more visible. In 
conclusion, further investigations are required to establish whether SR-induced in the 
cremaster muscle stimulates microthrombi and/or platelet-EC interactions. 
  
Having directly visualised SR-induced tissues in real time, there appeared to be a 
distinct decrease in the number of perfused vessels (Figure 7.4). These findings were 
extended by fluorescently labelling perfused vessels with dextran-FITC and 
analysing tissues using live confocal microscopy. SR-induced tissues showed a trend 
towards lower ratio of dextran-FITC to AlexaFluor-647 conjugated anti-CD31 
fluorescent intensity in comparison to control tissues (Figure 7.6).  Future studies are 
however required to explore the loss of vascular perfusion post-induction of SR in 
terms of magnitude. 
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Taken together, the established model of the SR in the cremaster muscle is 
characterised by neutrophil extravasation, a possible increase in platelet-EC 
interaction and a trend towards reduced vascular perfusion. Further work is required 
to fully characterise and quantify these vascular responses.  
 
 
Figure 7.4: Brightfield images of SR-induced vascular responses in cremasteric 
post-capillary venules.  
Representative images of vascular perfusion, microthrombi and haemorrhage in the 
cremaster muscle SR (30µg LPS (i.s.) 24 hours later 150µg LPS (i.v.)). Black arrows 
show perfused vessels, blue arrows show non-perfused vessels and red arrows show 
microthrombi. 
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Figure 7.5: SR-induced platelet-endothelial interaction in cremasteric post-
capillary venules.   
A SR was induced in the cremaster muscle and vessels were labelled (PECAM-1, 
green) in vivo as previously described (Chapter 2). Platelets were labelled using anti-
CD41-PE i.v. (red) and the cremaster muscle was viewed under a confocal 
microscope where live images of venules were taken. (A) Representative confocal 
images of venules from control and SR-stimulated tissues where platelets and 
endothelial cell interactions can be seen. (B) Anti-CD41-PE to AlexaFluor-647 
conjugated anti-PECAM-1 ratio intensity in control and SR-induced tissues was 
analysed using Leica LAS AF Lite (2.1.1 build) software. N = 3-4 mice, 4-8 vessels 
per cremaster, error bars show SEM.  Statistically significant (T-test) differences are 
indicated by asterisks, *P<0.05. 
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Figure 7.6: Vascular perfusion in SR-stimulated post-capillary venules.  
A SR was induced and vessels were labelled (PECAM-1, blue) in vivo as previously 
described (Chapter 2). Perfused vessels were labelled using FITC-dextran (green) 
and the cremaster muscle was viewed under a confocal microscope where live 
images of venules were taken. (A) Representative confocal images of specific 
regions from control and SR-stimulated tissues where perfused vessels (green and 
blue) and all vessels (blue) can be seen. Scale bar represents 50µm. (B) FITC-
dextran to AlexaFluor-647 conjugated anti-anti-PECAM-1 ratio intensity in control 
and SR-induced tissues was analysed using Leica LAS AF Lite (2.1.1 build) 
software. N = 3-4 mice, 5 regions per cremaster, error bars show SEM.  
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7.3  Discussion 
 
In this chapter a cremasteric SR IVM model was developed that could be used for 
investigations into the functional role of ICAM-2 and other adhesion molecules in a 
vascular injury model of inflammation. The SR was selected due to the hemorrhagic 
and microthrombotic characteristics that occur in conjunction with leukocyte 
recruitment and hence represents features often noted in severe pathological 
inflammatory scenarios. As the SR is predominately stimulated in dermal models 
(Argenbright and Barton, 1992; Brozna, 1990; Pepys MB, 1982) and had not 
previously been studied in the cremasteric model of IVM, the latter was established 
as a technique that could provide detailed insights into numerous vascular responses 
in real time in vivo.  
 
For the present project a classical SR-stimulated by an initial local LPS dose (i.s.) 
followed by an i.v. dose 24 hours after was used. The results demonstrated that a SR-
stimulated in the cremaster muscle resulted in neutrophil extravasation, low 
frequency of haemorrhage and a possible increase in platelet-EC interactions. 
Current literature suggests that these vascular processes occur in the SR due to the 
first dose of LPS priming the EC by up-regulating various inflammatory mediators 
(e.g. IL-1β and TNF-α) and adhesion molecules (e.g. E-selectin and ICAM-1) 
(Brozna, 1990). The second dose of LPS primarily induces a thrombohemorrhagic 
response (Brozna, 1990). SR-stimulated in the cremaster muscle did not completely 
reflect responses as observed in dermal models in terms of the severity of thrombus 
and haemorrhage formation, however leukocyte extravasation was clearly evident.  
 
A high number of neutrophils were found in the intra and extravascular tissue of SR-
stimulated cremaster muscles although no differences in the number of adherent 
leukocytes was detected by brightfield IVM. The reason for the lack of difference in 
neutrophil adhesion between control and SR tissues in this model is currently 
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unknown however using confocal IVM a significant increase in intravascular and 
extravascular neutrophils was seen. This could be due to the fact that confocal IVM 
enables analysis of tissue sections deeper within the muscle therefore a more 
complete representation of the recruitment of leukocytes in that vessel can be 
acquired. It is also likely that as the leukocytes were fluorescently tagged in confocal 
IVM experiments they were seen with greater clarity and hence higher numbers of 
intravascular neutrophils could be quantified.   
 
As the SR is known to incorporate thrombosis, platelets were also fluorescently 
labelled using anti-CD41-PE mAb, in order to analyse EC-platelet interactions in this 
model. A high fluorescent intensity of anti-CD41-PE mAb was detected in SR tissues 
implying that there could be an increase in platelet-EC interactions. In the present 
study the blood velocity of SR-induced tissues also appeared to be reduced, and this 
would have influenced the high fluorescent intensity of anti-CD41-PE mAb detected. 
Therefore no conclusions on this parameter in the cremasteric SR model can be made 
using the current data. Interestingly the reduction in blood pressure is a characteristic 
of sepsis and as LPS was administered i.v. this could have led to various systemic 
effects which were not analysed in these experiments. Local vascular perfusion was 
however analysed and the results indicated that the SR-induced a trend towards 
reduced vascular perfusion. It is also possible that the local systemic effects observed 
could be a result of leukocyte plugs and/or EC-platelet interactions. 
 
The characteristics displayed in the cremasteric SR model is in agreement with 
numerous literature reports using dermal models of the SR although dermal models 
have shown a much higher frequency of microthrombi and haemorrhage formation 
(Brozna, 1990; Pepys MB, 1982). The differences between cremasteric and dermal 
models could be due to the reactivity of the two tissues to local inflammatory 
mediators, in line with their different physiological roles. The cremaster muscle is 
located deep within the body relative to that of the skin vasculature and is therefore 
less susceptible to thrombus and haemorrhage formation in response to local trauma 
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in comparison to the dermis. The skin is a tissue on the outer surface and acts as a 
protective barrier and hence maybe more sensitive to locally applied stimuli making 
it more prone to thrombus and haemorrhage formation. In contrast the cremaster 
muscles primary function is to regulate the temperature of the testis and it may 
therefore not be highly responsive to locally applied LPS.   
 
In summary a SR-stimulated in the cremaster muscle produced neutrophil 
transmigration, low frequency of haemorrhage formation, a possible increase in EC-
platelet interactions and reduced vascular perfusion. Further studies are however 
required to fully characterise these parameters and this response in more detail before 
extending it to investigations of the functional roles of molecules such as ICAM-2.  
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CHAPTER 8: General discussion 
 
8.1  Project overview  
 
The recruitment of leukocytes from the circulation to the site of inflammation is 
crucial for physiological and pathological processes involving the innate and 
adaptive immune system. Although a lot of progress has been made in identifying the 
molecular mechanisms involved during leukocyte extravasation there are still many 
unanswered questions particularly with respect to specific functions of individual 
adhesion molecules. This study aimed to investigate the role of the largely neglected 
adhesion molecule ICAM-2 at specific stages of the leukocyte transmigration 
cascade. In order to address this, the expression profile, functional role and the 
possible ligand interactions of ICAM-2 were examined in an acute IL-1β-induced 
inflammatory model. To extend these findings to a more complex pathological 
scenario, a cremasteric SR was also developed as part of this project.   
 
Using immunostaining and confocal microscopy of the mouse cremasteric 
vasculature, the expression profile of EC ICAM-2 was examined under basal and IL-
1β-stimulated conditions. Detailed analysis of the distribution of EC ICAM-2 
expression within post-capillary venules showed that this molecule is expressed at 
non-junctional regions of ECs in addition to junctional sites, under both basal and IL-
1β-stimulated conditions. As a result of this finding it was hypothesised that ICAM-2 
could be involved in luminal neutrophil-EC interactions post-adhesion, in addition to 
TEM, and these possible roles of ICAM-2 were investigated.  
 
Using the cremasteric confocal IVM model neutrophil-EC interactions were 
examined in IL-1β-stimulated tissues. A functional blocking mAb to ICAM-2 as well 
as an ICAM-2 KO mouse strain, which also exhibited Lys-eGFP-ki, were utilised. 
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The results indicated that neutrophil adhesion was unaffected by the impairment of 
ICAM-2 function in inflamed tissues, however a reduced number of neutrophils were 
detected in the extravascular tissue, confirming previous work (Huang et al., 2006; 
Woodfin et al., 2009). The precise mechanisms by which ICAM-2 mediates 
extravasation is currently unknown, and the present study focused on investigating 
the role of ICAM-2-mediated mechanisms at specific stages of the neutrophil 
transmigration cascade. Detailed analysis of IL-1β-induced neutrophil crawling and 
TEM dynamics were carried out using confocal IVM. Overall the results indicated a 
role for ICAM-2 in facilitating efficient neutrophil crawling, as well as supporting 
the initiation of TEM. The former role, at least in part, was found to be potentially 
mediated by EC ICAM-2 interacting with neutrophil MAC-1.  
 
This study provides the first direct in vivo evidence that ICAM-2 can support 
neutrophil intraluminal crawling and the initiation of TEM in IL-1β-induced 
neutrophil extravasation. This discussion gives a critical overview of the functions 
attributed to ICAM-2 during neutrophil extravasation in the present study, and 
suggests potential mechanisms that may underlie these roles. 
 
 
8.2  The distribution of EC ICAM-2 during neutrophil recruitment 
 
Initial experiments focused on examining the expression pattern of ICAM-2 in order 
to gain further insights into it’s functions during neutrophil extravasation. These 
studies expanded on previous observations that ICAM-2 is heterogeneously 
distributed on the surface of venular ECs (Woodfin et al., 2009). More specifically 
ICAM-2 was found to be expressed at both EC non-junctional and junctional areas as 
shown by immunofluorescent staining and confocal microscopy. This expression 
pattern was seen in venules of the mouse cremaster muscle as well as venules of the 
ear dermis, suggesting that the distribution of EC ICAM-2 expression found in the 
cremaster muscle was not tissue-specific.  
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The overall venular EC ICAM-2 expression, in terms of total levels, was found to be 
unaffected by IL-1β-stimulation which is in line with the majority of previous reports 
(de Fougerolles et al., 1991; Hobden, 2003). Studies using IL-1β-stimulated 
HUVECs and human mammary arteries have however reported a down regulation in 
ICAM-2 (McLaughlin et al., 1999; McLaughlin et al., 1998). The differences seen 
between the findings of the present work and the work of Mc Laughlin and 
colleagues maybe due to the latter study being carried out with human cells in in 
vitro and ex vivo contexts, suggesting possible differences between species and/or 
influences of the experimental conditions used. The reason why ICAM-2 is down 
regulated on human and not mouse ECs is currently unknown. Although human 
ICAM-2 expression in ECs has been linked to the binding of Sp1 and GATA-2 
transcription factors (Cowan et al., 1998), there is currently little information with 
respect to the transcriptional regulation of ICAM-2 in mice. For these reasons further 
studies are required to understand the regulation of ICAM-2 expression on a 
transcriptional level in a range of different species.   
 
While the total venular EC expression of ICAM-2 remained unchanged under 
inflamed conditions, it is possible that ICAM-2 may redistribute within ECs in order 
to support neutrophil extravasation. For this reason the EC non-junctional and 
junctional expression of ICAM-2 was determined in control and in IL-1β stimulated 
conditions. The results however indicated no significant re-distribution of ICAM-2 
following IL-1β stimulation. Interestingly a previous study found that on NK cells 
ICAM-2 was localised at uropods where its function was linked to cytoskeletal 
redistribution via erzin binding to the C-terminal of ICAM-2 (Helander et al., 1996). 
The differences in the ability of ICAM-2 to re-distribute on NK cells and not on ECs, 
is most likely to be a direct consequence of the individual function of ICAM-2 in the 
two cell types. It must be noted that other stimuli or processes such as angiogenesis, 
which ICAM-2 has been linked to, may induce redistribution. 
 
213 
 
ICAM-2 is known to have a role in neutrophil extravasation into the tissue but no 
roles in earlier stages of adhesion have been described, similar to that reported for 
PECAM-1 and JAM-A (Woodfin et al., 2009). The expression pattern of EC ICAM-
2 on post-capillary venules was however found to be distinct to these junctional 
proteins (PECAM-1 and JAM-A) implicated in leukocyte transmigration. Whilst 
PECAM-1 was found to be highly localised at EC junctions with a faint and diffuse 
cell-body expression, ICAM-2 was expressed equally at these areas as previously 
described. The distinct expression of ICAM-2 compared to that of PECAM-1 
suggests that these molecules may have different functional roles. It was therefore 
hypothesised that ICAM-2 may have a role in luminal leukocyte-EC interactions 
post-adhesion, as well as in TEM during neutrophil recruitment and this hypothesis 
was examined.  
 
8.3  The role of ICAM-2 in IL-1β-induced neutrophil crawling 
 
The present study confirmed that ICAM-2 supports neutrophil extravasation and not 
initial adhesion using 4D confocal IVM of IL-1β-stimulated cremaster muscles from 
WT and ICAM-2 KO mice. The mechanism by which ICAM-2 mediates 
extravasation was subsequently investigated by analysing luminal neutrophil-EC 
interactions post-adhesion using the same high resolution imaging system. Using this 
technique various neutrophil crawling dynamics were analysed. It was found that in 
ICAM-2 KO mice, neutrophils crawled slower, for longer time periods and in a 
discontinuous manner, where distinct periods of immobility were seen (Figure 8.1). 
Discontinuous crawling behaviour was more frequently observed in stimulated 
ICAM-2 KO mice and further analysis into the dynamics of discontinuous crawling 
revealed that this behaviour had a slower crawling speed in comparison to 
continuously crawling cells in both mouse strains. The high frequency of 
discontinuously crawling cells in ICAM-2 KO mice however only partially 
accounted for the overall reduction in crawling speed as continuously crawling cells, 
in this mouse strain, also crawled more slowly (Figure 8.1). This indicates that 
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ICAM-2 supports both speed and continuity of crawling. Neutrophils crawling 
dynamics observed in IL-1β-induced tissues from ICAM-2 KO mice were 
comparable to that observed in stimulated WT mice treated with an anti-ICAM-2 
mAb. This confirms the affinity and efficacy of the anti-ICAM-2 mAb used and 
more importantly discounts the possibility of any compensatory mechanisms 
occurring in the ICAM-2 KO mice as a result of the genetic deletion of ICAM-2 with 
respect to neutrophil recruitment. Collectively these results indicate that neutrophil 
crawling is supported by ICAM-2. This process maybe regulated through its 
interactions with its neutrophil ligand thus inducing various signalling pathways 
within the neutrophil which is associated with crawling and polarisation.  
 
215 
 
 
 
Figure 8.1: IL-1β-induced neutrophil recruitment dynamics in WT and KOs.  
A summary diagram depicting neutrophil crawling and TEM dynamics in response to 
IL1-β in the presence (blue) and absence (red) of ICAM-2 in the mouse cremaster 
muscles. In ICAM-2 KO mice changes occur in the dynamics of neutrophil 
recruitment in comparison to WT mice. More specifically in ICAM-2 KOs the 
efficiency of neutrophil crawling and the initiation of TEM are impaired, leading to a 
reduction in the number of extravascular neutrophils. Arrows indicate an increase or 
decrease in each parameter in the KO mice in comparison to WTs. 
 
The neutrophil ligand for EC ICAM-2 during neutrophil crawling was investigated in 
order to gain some insights into the mechanisms involved. MAC-1 has been shown 
to interact with ICAM-2 (Xie et al., 1995) and it has also been implicated in 
neutrophil crawling, but not adhesion (Phillipson et al., 2006; Sumagin et al., 2010). 
These findings collectively suggest a role for MAC-1/ICAM-2 pathway in neutrophil 
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crawling. To test this hypothesis a MAC-1 blocking mAb was administered in WT 
and ICAM-2 KO mice, and the dynamics of neutrophil-EC interactions were 
examined. If there was no evidence of a cumulative effect of deletion/inhibition of 
ICAM-2 and MAC-1 respectively, then the findings could suggest an interaction 
between these two proteins. Alternatively a cumulative effect could suggest a MAC-
1 function independent of ICAM-2, and hence may indicate a role for MAC-1 
interacting with other ligands, possibly ICAM-1. ICAM-1 mediated influences in the 
current model were also investigated for this reason. Distinct differences between the 
role of MAC-1 and ICAM-1 in neutrophil adhesion and crawling dynamics were 
noted suggesting some ICAM-1-independent MAC-1 functions (some of which 
could be mediated via ICAM-2). Neutrophil crawling dynamics in ICAM-2 KO mice 
after anti-MAC-1 mAb inhibition were therefore investigated. The results were 
comparable to that detected in ICAM-2 KO mice without mAb treatment, showing 
no cumulative effect. The lack of additive effects when both molecules were 
functionally impaired suggests that these two molecules could potentially be 
interacting during neutrophil crawling. It should be noted that although this was not 
directly confirmed, it is possible that this interaction would induce intracellular 
signalling within neutrophils resulting in polarisation and cytoskeletal contraction 
required for efficient crawling of neutrophils (Ridley, 2003).  
 
The specific intracellular mechanism by which MAC-1/ICAM-2 ligation may 
promote neutrophil crawling is currently unclear, however there is a lot of 
information available regarding the signalling mechanisms downstream of integrins. 
The interaction of ICAM-2 with MAC-1 is known to occur via the first Ig domain of 
ICAM-2, located on the extracellular N-terminal (Staunton et al., 1989) with the β 
subunit on the extracellular N-terminal of MAC-1 (Xie et al., 1995). This could 
stimulate neutrophil MAC-1 outside-in integrin signalling which is known to cause 
structural rearrangement of the actin cytoskeleton and cell polarisation (Figure 8.2) 
(Ridley, 2003). Cell polarisation is required for crawling, and occurs when the front 
of the cell nearest to the chemokine gradient forms a leading edge, and the opposite 
side forms a trailing edge. Rapid, transient and adhesive interaction of protrusions to 
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the EC is followed by de-adhesion (Rottner and Stradal, 2011). The differential 
distribution of proteins at either end of the cell regulates adhesion. When adhesion 
occurs at the leading edge de-adhesion occurs at the trailing edge which induces a 
millipede-like motion facilitating neutrophil crawling (Ridley, 2003; Rohlena, 2009; 
Rottner and Stradal, 2011).  
 
MAC-1 is known to be homogenously expressed on the cell surface, and its activity 
is more pronounced at the leading edge of the cell (Hidalgo et al., 2009), and could 
have a role in mediating dynamic adhesions and de-adhesions between neutrophil 
and ECs during crawling. Integrin conformational changes have been linked to 
inside-out signalling via proteins such as talin, which provide communication 
between the cell membrane and the cytoskeleton (Figure 8.2). These events are 
tightly regulated through Rac and Rho signalling pathways as well as through VAV-
1, WASP/WAVE, PI3K and Cdc42 (Ridley, 2003). In ICAM-2 KO mice neutrophils 
crawled more slowly than neutrophils in WT mice therefore de-adhesion maybe 
partially impaired, hence reducing the mobility of the neutrophil resulting in slower 
neutrophil crawling. ICAM-2 induced outside-in MAC-1 signalling within 
neutrophils may therefore specifically support transient de-adhesion required for 
efficient crawling.  
 
The possibility of ICAM-2/LFA-1 and/or ICAM-2/ICAM-2 interactions occurring 
during crawling are not fully discounted, however analysis of ICAM-2 expression on 
whole mouse blood indicated that this protein is expressed on a small percentage of 
neutrophils at very low levels. Additionally earlier studies in which WT bone 
marrow leukocytes were transferred into ICAM-2 KO animals did not restore the 
observed defect in IL-1β-stimulated extravasation (Woodfin et al., 2009). These 
facts, coupled with the absence of the CD18 integrins, which are the primary ICAM-
2 ligands, on the endothelium, strongly indicate that mechanisms demonstrated here 
relate to EC expressed ICAM-2. Collectively these findings, along with previously 
published studies, suggest that in this model both ICAM-1/LFA-1 and ICAM-
218 
 
1/MAC-1 binding (Phillipson et al., 2006; Smith et al., 1989) supports initial 
adhesion, while MAC-1 interactions with ICAM-2 contributes to the speed and 
continuity of luminal crawling. Further studies are required in order to fully conclude 
that the observed roles for ICAM-2 are mediated largely by MAC-1. 
 
 
 
 
Figure 8.2: Suggested mechanisms associated with EC ICAM-2 during 
neutrophil crawling. 
A summary diagram depicting possible mechanisms for the role of EC ICAM-2 in 
neutrophil crawling. EC ICAM-2 is suggested to interact with neutrophil MAC-1 
during neutrophil crawling. Inside-out MAC-1 signalling induces conformational 
change in the structure of MAC-1 allowing this protein to interact with ICAM-2 and 
support neutrophil adhesion. Signalling events within the neutrophil as a result of 
ICAM-2 ligation to MAC-1 could stimulate outside-in integrin signalling collectively 
resulting in neutrophil cytoskeletal rearrangement, neutrophil polarity and the 
formation of protrusions facilitating neutrophil crawling.  
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8.4  The role of ICAM-2 in IL-1β-induced neutrophil TEM 
 
The periods of immobility during discontinuous crawling were associated with EC 
junctions, suggesting that these periods may be a result of failed attempts to initiate 
TEM. The role of ICAM-2 in mediating crawling speed and continuity of crawling 
may therefore be a result of two distinct mechanisms. For this reason togather with 
the finding that ICAM-2 is expressed at EC junctions the dynamics of neutrophil 
TEM was analysed in more detail. Neutrophil TEM through the EC layer was 
investigated in IL-1β-stimulated WT and ICAM-2 KO mice. The frequency at which 
TEM was observed to occur was substantially reduced in the ICAM-2 KO mice, and 
WT mice treated with anti-ICAM-2 mAb, and it is clear that the comparable numbers 
of adherent and crawling neutrophils were failing to progress to TEM (Figure 8.1). In 
both these groups TEM primarily followed the paracellular route. The crawling 
behaviour which preceded TEM was analysed, and in both genotypes the majority of 
cells which successfully progressed to TEM had previously crawled in a continuous 
manner (Figure 8.1), suggesting that efficient crawling is necessary for the migration 
to, and/or identification of, sites permissive for TEM.  
 
The process of TEM was divided into two stages, pre-TEM (neutrophil-EC 
junctional interactions preceding TEM) and TEM (classified by neutrophil 
protrusions into EC junctions) for further analysis. In the ICAM-2 KO vessel the few 
cells which did progress to TEM spent significantly longer time periods migrating 
within the lumen before reaching the location of TEM. These cells also displayed a 
fourfold increase in the time spent interacting with the junction before initiating 
TEM (pre-TEM). These findings are in line with previous data from our group using 
fixed tissue analysis of inflamed vessels from ICAM-2 KO mice (Woodfin et al., 
2009). These studies collectively suggest that ICAM-2 deficiency leads to 
prolonged/arrested luminal neutrophil junctional interactions and that discontinuous 
crawling may also represent failed attempts of neutrophils to undergo TEM. These 
data indicate that in addition to a role in supporting luminal crawling efficiency, 
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ICAM-2 is also important in the identification of TEM sites and/or the initiation of 
TEM (opening of the junction) (Figure 8.3).  
 
A striking feature of the analysis of TEM in the absence of functional ICAM-2 was 
once any disruption of the junction had been achieved the TEM was successfully 
completed over a normal time frame. It therefore seems that the greatest defect lies in 
the identification or initial opening of the junctions and that other junctional proteins 
such as JAM-A, PECAM-1 and JAM-C may support the latter stages of TEM 
(Dangerfield et al., 2002; Woodfin et al., 2009; Woodfin et al., 2011).  No comment 
can be made in regards to the ligand interaction of EC junctional ICAM-2 during the 
initiation of TEM in this study as very few events were observed after anti-MAC-1 
mAb treatment in comparison to TEM events following anti-ICAM-2 mAb 
treatment.  
 
ICAM-2 was found to support the migration of neutrophils to specific sites to 
undergo TEM and/or support the opening of the EC junctions, however the precise 
mechanism is currently unclear. The existence of locations particularly permissive to 
neutrophil TEM have previously been suggested to be at EC tricellular junctions 
(Burns et al., 1997; Sumagin and Sarelius, 2010), ICAM-1 enriched regions 
(Sumagin and Sarelius, 2010) and determined by chemotactic gradients (Massena et 
al., 2010). There is little information however, regarding a possible role for ICAM-2 
in identifying sites of TEM, and no gradients of ICAM-2 which might act as 
haptotactic guidance towards junctions have been reported. As TEM occurs at 
multiple sites even around an individual EC it seems highly unlikely that the 
inefficient crawling seen in ICAM-2 KO mice resulted in neutrophils being unable to 
find sites permissive for TEM. It seems more plausible that the biggest defect in 
stimulated ICAM-2 KO mice was the failed attempts to initiate TEM. This may also 
be the underlying reason for the high frequency of discontinuously crawling cells 
observed in the in the ICAM-2 KO mice. More specifically, the periods of 
immobility displayed during discontinuous crawling could reflect failed attempts to 
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initiate TEM. This is supported by the fact that the periods of immobility were 
associated to occur directly on EC junctions. Additionally crawling cells which were 
observed to undergo TEM were found to crawl in a continuous fashion confirming 
that discontinuous crawling is less able to support TEM in this reaction, at this time 
point. The impaired ability to initiate TEM in the KOs could be a result of the lack of 
strong adhesive interactions with the EC junctions in the ICAM-2 KOs however 
further studies are required to fully understand this process in more depth.  
 
Interestingly, the C-terminal of ICAM-2 links to the cytoskeleton via α-actinin and 
ezrin/radixin/moesin proteins (Heiska et al., 1996; Heiska et al., 1998; Helander et 
al., 1996; Yonemura et al., 1998), so it is possible that ligation of ICAM-2 at 
junctional regions initiates signalling pathways which facilitate opening of the EC 
junctions, similar to that seen with ICAM-1 clustering, VE-PTP activation and VE-
cadherin disengagement (Figure 8.3) (Alcaide et al., 2009). ICAM-2 has also been 
shown to mediate downstream Rac signalling which is known to regulate the 
phosphorylation status of VE-cadherin and thus cause EC-EC junctional disruption 
(Figure 8.3). A lack of neutrophil protrusions into the EC was also observed in 
ICAM-2 KO mice and therefore the impairment of ICAM-2/integrin interaction may 
also cause defects in the formation of protrusion within the neutrophil into the EC 
junction which occurs during TEM through outside-in integrin signalling (Figure 
8.3). Alternatively ICAM-2 may play a role in the formation of docking structures 
within the EC layer which has been observed, primarily in vitro, to form at the site of 
TEM (Barreiro et al., 2002; Carman and Springer, 2004; Phillipson et al., 2008). 
Other molecules such as ICAM-1 and VCAM-1 have also been previously 
demonstrated to have key roles in supporting TEM at preferred sites via the 
formation of docking structures and could also be involved in opening EC junctions 
together with numerous other molecules (Barreiro et al., 2002) in conjunction with 
ICAM-2.  
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Collectively the current study demonstrates that ICAM-2 is directly involved in 
neutrophil crawling and the initiation of TEM in vivo. It is likely that these roles 
represent two distinct mechanisms associated with EC ICAM-2 binding to its 
neutrophil ligand. Firstly, efficient neutrophil crawling may potentially be mediated 
by neutrophil MAC-1, and hence induce outside-in MAC-1 signalling within the 
neutrophil to support crawling. Secondly EC ICAM-2 signalling may strengthen 
neutrophil-EC junctional interactions and/or activate EC signalling pathways to open 
junctions and hence initiate EC junctional pore formation. Together this provides 
further insights into the role of ICAM-2 in neutrophil extravasation during IL-1β-
stimulated inflammation. 
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Figure 8.3: Suggested mechanisms associated with EC ICAM-2 during 
neutrophil TEM. 
A summary diagram depicting possible mechanisms for the role of EC ICAM-2 in 
the initiation of neutrophil TEM. EC ICAM-2 is suggested to interact with neutrophil 
integrins during the neutrophil transmigration cascade. Inside-out integrin signalling 
induces conformational change in the structure of integrins allowing this protein to 
interact with ICAM-2 and support neutrophil adhesion. Signalling events within the 
EC as a result of ICAM-2 ligation with integrins could stimulate the interaction of 
the C-terminal of ICAM-2 with intracellular proteins (e.g. ERM, α-actinin) which are 
linked to the EC cytoskeleton. This may consequently induce Rac mediated 
phosphorylation of VE-cadherin. Thus EC-EC junctional contacts are dissociated 
resulting in the opening of EC junctions allowing the neutrophil to transmigrate 
through it. Outside-in and/or inside-out integrin signalling within the neutrophil may 
collectively result in cytoskeletal rearrangement, neutrophil polarity and thus support 
the formation of neutrophil protrusions into EC junctions which is required during 
TEM.  
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8.5  Development of a cremasteric SR model 
 
To extend the findings for role of key molecules in neutrophil extravasation a more 
complex, disease mimicking inflammatory reaction was developed as part of this 
project. Although due to lack of time the model was not used for investigations into 
the functional role of key molecules (i.e. ICAM-2), the findings indicate its potential 
value for such future experiments. SR stimulated in the cremaster muscle produced 
neutrophil transmigration, low frequency of haemorrhage formation, a possible 
increase in EC-platelet interactions and reduced vascular perfusion. Further studies 
are however required to fully characterise these parameters and this response in more 
detail before extending it to investigations of the functional roles of molecules such 
as ICAM-2. 
 
 
8.6  Future directions and unanswered questions 
 
8.6.1  Does ICAM-2 bind to ligands other than MAC-1 during its role in 
neutrophil extravasation?  
MAC-1 and LFA-1 both exhibit binding affinity to ICAM-2 and have been shown to 
have distinct and overlapping functions. During monocyte crawling EC ICAM-2 has 
been shown to bind to both LFA-1 and MAC-1 (Schenkel et al., 2004) whereas 
during lymphocyte adhesion EC ICAM-2 binds to LFA-1 or VLA-4 (Seth et al., 
1991). Whether ICAM-2 binds to LFA-1 during neutrophil crawling and/or the 
initiation of TEM during extravasation in the current model, as well as MAC-1 is 
unknown. Although the present study provides evidence for the potential interaction 
of ICAM-2/MAC-1 during neutrophil crawling, it does not exclude a possible 
interaction of ICAM-2 with LFA-1. Investigating the contribution of ICAM-2/LFA-1 
interaction in this model using anti-LFA-1 mAb was not conducted as LFA-1 has a 
profound role in supporting neutrophil adhesion. Based on the results obtained using 
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anti-ICAM-1 mAb which is the key ligand for LFA-1 in adhesion, inhibiting LFA-1 
would result in more than 90% reduction in neutrophil adhesion, and hence a very 
low frequency of crawling events. Additionally the ligand for ICAM-2 during the 
initiation of TEM has not been determined in the present study again due to the low 
frequency of events following anti-MAC-1 mAb treatment. Further studies are 
therefore required to understand these concepts in more detail. 
 
Administering anti-LFA-1, anti-MAC-1, anti-ICAM-1 or anti-ICAM-2 mAbs post-
adhesion during the crawling stage in the cremasteric confocal IVM model could 
provide further details in regards to this. After anti-LFA-1 and anti-ICAM-1 mAb 
treatment post-adhesion, neutrophils could however deattach from the EC and go 
back into the circulation as ICAM-1/LFA-1 interactions could be crucial to the 
maintenance of adhesion. It is however also possible that other interactions involving 
ICAM-2 are sufficient to keep the neutrophils in contact with the ECs during 
crawling, in which case various crawling dynamics could be analysed post-adhesion 
and the contribution of LFA-1/ICAM-1, LFA-1/ICAM-2, MAC-1/ICAM-1 and 
MAC-1/ICAM-2 interactions could be determined. Depending on the frequency of 
TEM events, various TEM parameters could then be analysed in order to further 
understand ICAM-2 ligand interactions during its role in the initiation of TEM.  
 
Another technique such as fluorescence resonance energy transfer (FRET) may be 
required to understand the contribution of these interactions at specific stages of the 
neutrophil transmigration cascade. Using this technique the function of ICAM-1 
interactions with LFA-1 or MAC-1, and ICAM-2 interactions with LFA-1 or MAC-1 
during neutrophil crawling and the initiation of TEM could be determined in more 
detail. Of note this technique could also be used to examine the downstream 
signalling events that occur within ECs upon ICAM-2 ligation which could provide 
further detail into the mechanisms underlying the role of ICAM-2 as suggested in the 
current study (Section 8.2 and 8.3). This latter area of investigation is also currently 
understudied and further information regarding the intracellular signalling pathways 
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involved is required to fully appreciate the role of ICAM-2 in neutrophil crawling 
and the initiation of TEM.   
 
8.6.2  Is there a delay or a total inhibition in neutrophil TEM in the absence of 
functional ICAM-2? 
In the absence of functional ICAM-2 a reduction in neutrophil extravasation is seen 
at 4 hours post IL-1β stimulation. This effect was attributed to the involvement of 
ICAM-2 in supporting neutrophil crawling speed, continuity of crawling and the 
initiation of TEM. Whether these effects persist at later time points (> 4 hours) after 
IL-1β stimulation is currently unknown. It is possible that the slow, discontinuously 
crawling cells in IL-1β-stimulated ICAM-2 KO vessels do undergo TEM at a later 
point, thus resulting in a delay in neutrophil extravasation as opposed to a complete 
inhibition. Analysis of neutrophil dynamics for longer and/or at later time periods 
would provide further insights into the role of ICAM-2 in supporting neutrophil 
extravasation. More specifically its key functions in mediating crawling speed, 
continuity and the initiation of TEM can be further examined to understand the fate 
of discontinuously crawling cells. Of note a delayed response in ICAM-2 KO mice 
has been reported in the recruitment of eosinophils to the lungs in a hyperresponsive 
allergic model (Gerwin et al., 1999) and thus requires further studies with respect to 
neutrophil recruitment.  
 
8.6.3  Does ICAM-2 support crawling and the initiation of TEM in a stimulus-
specific manner? 
Previous data within our group has shown stimulus-specific functions of ICAM-2, 
indicating a role for ICAM-2 in IL-1β-stimulated responses but not in response to 
TNF-α or thioglycolate (Huang et al., 2006). This was demonstrated in both the 
cremasteric IVM model as well as in the peritonitis model (Huang et al., 2006), 
findings that were subsequently linked to the ability of the stimulus to predominately 
activate ECs directly (Woodfin et al., 2009). It would therefore be of interest to 
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investigate the role of ICAM-2 in the dynamics of neutrophil recruitment in several 
inflammatory models in order to gain further insights into the factors that influence 
ICAM-2 functions. 
 
8.6.4  Does ICAM-2 support crawling and the initiation of TEM in disease 
models? 
The stimulus-specific roles of ICAM-2 as described previously, also questions the 
pathological relevance of ICAM-2 in the recruitment of neutrophils in inflammation. 
A number of studies have used disease models to demonstrate the role of ICAM-2. 
This includes a murine bacterial induced inflammatory model (Hobden, 2003), a 
murine allergic hypperresponsive airway model (Gerwin et al., 1999), a human 
pancreatic carcinogenesis model (Hiraoka et al., 2011) and a study using tissue 
samples from patients with Crohn’s disease (Bernstein et al., 1998) although the 
latter three are likely to be due to ICAM-2 expression on epithelium rather than on 
EC and therefore the function of ICAM-2 may differ. Collectively there are very few 
studies published which have investigated the role of EC ICAM-2 in neutrophil 
extravasation in pathological inflammation where a more complex reaction takes 
place. Previous work in our group has however indicated a role for ICAM-2 in a 
cremasteric ischemia-reperfusion (I-R) injury model (unpublished work by Woodfin 
et al) and the results were in line with inflammatory responses induced by IL-1β, 
where a role for ICAM-2 in neutrophil extravasation, but not adhesion was 
demonstrated. Further examination of the dynamics of neutrophil crawling and TEM 
in a cremasteric I-R injury model would be valuable to understand the roles of 
ICAM-2 in more pathologically relevant models. 
 
The present study describes a series of studies aimed at the development of a 
cremasteric SR model. This model was developed in order to extend our current 
understanding of endothelial junctional molecules in a more complex disease 
mimicking reaction (Chapter 7). However, due to time restrictions this reaction was 
not used for investigations into the role of endothelial junctional molecules. This 
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model could therefore be used in order to gain further insights into the role of ICAM-
2 in numerous vascular processes such as thrombosis and vascular damage 
simultaneously alongside neutrophil recruitment in real time which is more clinically 
relevant to conditions such as vacuities. The cremasteric SR response induced 
neutrophil extravasation, few sites of thrombi and haemorrhage formation. Further 
studies are now required to fully characterise the later two processes in more detail 
before investigating the role of ICAM-2 in this model. Understanding the role of this 
molecule as well as other junctional molecules such as PECAM-1 and JAM-A would 
be of great interest due to the key role of platelets in this model together with the fact 
that these molecules are also expressed on platelets where there function is currently 
unknown.    
 
8.6.5  Do different leukocyte subtypes use different mechanisms to undergo 
crawling and initiation of TEM during leukocyte extravasation? 
In this study the role of ICAM-2 in leukocyte migration dynamics was restricted to 
neutrophils. A key function for ICAM-2 in monocyte crawling in vitro has been 
demonstrated however dynamics of this response in relation to ICAM-2 expression 
was not investigated (Schenkel et al., 2004). Understanding whether ICAM-2 is 
involved in the regulation of monocyte crawling speed, continuity and the initiation 
of TEM, as reported for neutrophils, would provide further insight into the role of 
ICAM-2 in the recruitment of leukocytes as a whole and may shed further light into 
the general mechanisms associated with this process. Using the Lys-eGFP-ki mice 
monocytes can be distinguished from neutrophils due to their lower GFP intensity 
and hence provides a model to investigate monocyte responses. Alternatively cross 
breeding the ICAM-2 KO mice with CX3CR-1-eGFP mice (mice which 
endogenously express GFP in monocytes and dendritic cells) would also provide a 
key tool to investigate the role of ICAM-2 in the dynamics of monocyte recruitment. 
Anti-ICAM-2 mAb administration in the CX3CR-1-eGFP mice would also be useful 
in conjunction with the ICAM-2 KO mice studies to eliminate the possibility of 
compensatory mechanisms occurring as a result of the genetic deficiency of ICAM-
2. These experiments could be carried out by using a monocytic stimulus such as 
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CCL2 where various monocyte-EC dynamics can be determined using confocal 
IVM. This will be based on the assumption that ICAM-2 is involved in CCL2 
induced monocyte recruitment which is currently unknown. The stimulus-specific 
roles of ICAM-2 previously demonstrated (Woodfin et al., 2009) however suggest 
that CCL2 may bypass the need for EC ICAM-2 in this reaction as it can directly 
activate monocytes. Alternatively IL-1β- or LPS-induced inflammation could be 
examined at time points when monocyte recruitment is at its peak.   
 
8.6.6  What is the function of ICAM-2 on platelets in inflammation? 
ICAM-2 is known to be expressed on platelets (Diacovo et al., 1994) and to date its 
function in this cell type is largely unknown. Since platelets are involved in the 
recruitment of leukocytes (Gawaz et al., 2005) it is possible that platelet ICAM-2 
could mediate adhesive interactions with integrins found on leukocytes. ICAM-2 
expressed on platelets could also interact homophillically with ECs and/or platelets 
and/or leukocytes. Additionally it is also possible that these cellular interactions 
could occur through a ligand which is yet to be discovered. It would therefore also be 
interesting to see if ICAM-2 has a role in leukocyte-platelet and/or platelet-EC 
interactions during leukocyte extravasation. This could be carried out using confocal 
IVM in WT and ICAM-2 KO Lys-eGFP-ki mice under conditions where platelets 
and ECs have also been labelled by appropriate fluorescently labelled mAbs.   
 
8.6.7  Does ICAM-2 support vascular integrity? 
ICAM-2 has been previously found to support EC-EC interactions via homophilic 
interactions (Huang et al., 2005). Taking this into account together with the fact that 
ICAM-2 is highly expressed on ECs under basal conditions, it is possible that ICAM-
2 could be involved in supporting junctional integrity. Numerous other related 
molecules such as JAMs (Dejana, 2004) and PECAM-1 (Privratsky et al., 2011) have 
also being studied in this respect and have demonstrated to have key roles in 
regulating the permeability of the EC layer. To date there exist no information on the 
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potential role of ICAM-2 in vascular permeability during inflammation, an issue that 
requires further investigation. A simple and direct way of investigating this would be 
through experiments addressing vascular leakage of i.v. Evans blue in the mouse 
dorsal skin inflammatory model in WT and ICAM-2 KO mice. Alternatively using 
small fluorescent dextran or microspheres in the confocal IVM model as described in 
the present study can also be used to answer this question.     
 
8.6.8  What are the translational implictaions of the findings? 
Leukocyte migration from the blood into in the site of infection or injury is a crucial 
component of both physiological and pathological inflammation. Uncontrollable and 
excessive recruitment of leukocytes contribute to the progression of many pathogical 
disorders such as atherosclerosis and ischemia-reperfusion injury. Further 
understanding of the mechanisms of leukocyte recruitment would facilitate 
identification of potential therapeutic targets. Through the use of rigorous in vivo 
imaging methods this study has provided significant insight into the role of a key EC 
adhesion molecule ICAM-2 in leukocyte recruitment. Future translational benefits to 
healthcare may take in the form of novel therapeutics that specifically target ICAM-
2. ICAM-2 blocking therapies may be able to specifically target pathological 
neutrophil accumulation, without causing more widespread immunosupression. This 
of course requires futher comprehensive understanding of the role of ICAM-2 
specifically in disease models to see the therapeutic value in individual inflammatory 
reactions. The strong emphasis of this work on understanding of fundamental cellular 
mechanisms of inflammation could lead to novel drug targets but the time-scale of 
this will not be easy to predict.  
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8.7  Concluding remarks 
 
This study has demonstrated for the first time a role for ICAM-2 in neutrophil 
crawling and the initiation of TEM during IL-1β-induced extravasation in vivo. It 
was found that ICAM-2 facilitates neutrophil crawling speed and continuity, as well 
as neutrophil-EC junctional interactions preceding TEM. The results also suggest 
that some of these roles maybe mediated through the ligation of EC ICAM-2 with 
neutrophil MAC-1, adding an additional molecular interaction to the neutrophil 
transmigration cascade. It is not currently known if the defects in speed and 
continuity of crawling and the identification and/or opening of endothelial junctions 
reflect several distinct roles for ICAM-2, although it is tempting to speculate that 
crawling is supported by activation of neutrophil locomotive machinery, while 
junctional opening may be facilitated by signalling within the ECs leading to 
junctional and/or cytoskeletal rearrangement. ICAM-2 is therefore a molecule that 
should be added to the list of proteins crucial for neutrophil crawling and the 
initiation of TEM. Collectively the findings of the present study provide further 
insights into the biological mechanisms of neutrophil extravasation in vivo.  
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